{"id":{"repo_id":"whiterose","oai_identifier":"oai:etheses.whiterose.ac.uk:36645"},"canonical_url":"https://search.ndltd.org/etd/whiterose/oai:etheses.whiterose.ac.uk:36645","repository":{"repo_id":"whiterose","name":"White Rose University Consortium","base_url":"https://etheses.whiterose.ac.uk/cgi/oai2"},"display":{"title":"Epicardial adipose tissue remodelling in type 2 diabetes and the potential therapeutic role of ketosis in diabetic heart disease","abstract":null,"abstract_html":null,"abstract_has_math":false,"creators":["Kotha, Sindhoora"],"institution":"University of Leeds","degree_name":"Ph.D","degree_level":"doctoral","degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":["Levelt, Eylem","Greenwood, John P","Plein, Sven"],"committee_chairs":[],"committee_members":[],"year":2024,"date_issued":"2024-10","date_published":"2024-10","updated_at":"2026-11-18T23:29:21Z","subjects":[],"languages":["eng"],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[{"key":"person:identifier.orcid","label":"ORCID","values":["0000000168533231"],"render_values":[{"text":"0000-0001-6853-3231","href":"https://orcid.org/0000-0001-6853-3231","code":true}]}]},"links":{"outbound_url":null,"outbound_label":null,"outbound_source":null,"record_url":null,"record_label":null,"record_kind":null,"record_source":null,"download_url":"https://etheses.whiterose.ac.uk/id/eprint/36645/1/S%20Kotha%20thesis%20updated%20with%20corrections.pdf","download_label":"Download PDF","download_source":"dc:identifier.uri","access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://etheses.whiterose.ac.uk/cgi/oai2?verb=GetRecord&metadataPrefix=uketd_dc&identifier=oai%3Aetheses.whiterose.ac.uk%3A36645","prefix":"uketd_dc"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Levelt, Eylem","Greenwood, John P","Plein, Sven"]},{"key":"dc:creator","label":"Author","values":["Kotha, Sindhoora"]},{"key":"person:identifier.orcid","label":"ORCID","values":["0000000168533231"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2024-10"]},{"key":"dc:date.issued","label":"Date","values":["2024-10"]},{"key":"dc:publisher.department","label":"Dc Publisher Department","values":["School of Medicine (Leeds)"]},{"key":"dc:publisher.institution","label":"Dc Publisher Institution","values":["University of Leeds"]},{"key":"dc:relation.isreferencedby","label":"Dc Relation Isreferencedby","values":["https://etheses.whiterose.ac.uk/id/eprint/36645/"]},{"key":"dc:relation.references","label":"Dc Relation References","values":["1. Levelt E, Rodgers CT, Clarke WT, Mahmod M, Ariga R, Francis JM, Liu A, Wijesurendra RS, Dass S, Sabharwal N, et al. Cardiac energetics, oxygenation, and perfusion during increased workload in patients with type 2 diabetes mellitus. Eur Heart J. 2016;37:3461-3469. doi: 10.1093/eurheartj/ehv442 2. Lopaschuk GD, Karwi QG, Tian R, Wende AR, Abel ED. Cardiac Energy Metabolism in Heart Failure. Circ Res. 2021;128:1487-1513. doi: 10.1161/circresaha.121.318241 3. Nowakowska M, Zghebi SS, Ashcroft DM, Buchan I, Chew-Graham C, Holt T, Mallen C, Van Marwijk H, Peek N, Perera-Salazar R, et al. The comorbidity burden of type 2 diabetes mellitus: patterns, clusters and predictions from a large English primary care cohort. BMC Med. 2019;17:145. doi: 10.1186/s12916-019-1373-y 4. Whicher CA, O’Neill S, Holt RIG. Diabetes in the UK: 2019. Diabetic Medicine. 2020;37:242-247. doi: 10.1111/dme.14225 5. Nichols GA, Gullion CM, Koro CE, Ephross SA, Brown JB. The Incidence of Congestive Heart Failure in Type 2 Diabetes. An update. 2004;27:1879-1884. doi: 10.2337/diacare.27.8.1879 6. Maack C, Lehrke M, Backs J, Heinzel FR, Hulot J-S, Marx N, Paulus WJ, Rossignol P, Taegtmeyer H, Bauersachs J, et al. Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association–European Society of Cardiology. European Heart Journal. 2018;39:4243-4254. doi: 10.1093/eurheartj/ehy596 7. Jia G, Hill MA, Sowers JR. Diabetic Cardiomyopathy: An Update of Mechanisms Contributing to This Clinical Entity. Circ Res. 2018;122:624-638. doi: 10.1161/circresaha.117.311586 8. Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, Grishman A. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol. 1972;30:595-602. doi: 10.1016/0002-9149(72)90595-4 9. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol. 1974;34:29-34. doi: 10.1016/0002-9149(74)90089-7 10. Norhammar A, Bodegard J, Nystrom T, Thuresson M, Eriksson JW, Nathanson D. Incidence, prevalence and mortality of type 2 diabetes requiring glucose-lowering treatment, and associated risks of cardiovascular complications: a nationwide study in Sweden, 2006-2013. Diabetologia. 2016;59:1692-1701. doi: 10.1007/s00125-016-3971-y 11. Rawshani A, Rawshani A, Franzén S, Eliasson B, Svensson A-M, Miftaraj M, McGuire DK, Sattar N, Rosengren A, Gudbjörnsdottir S. Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes. New England Journal of Medicine. 2017;376:1407-1418. doi: 10.1056/NEJMoa1608664 12. Hippisley-Cox J, Coupland C. Diabetes treatments and risk of heart failure, cardiovascular disease, and all cause mortality: cohort study in primary care. BMJ. 2016;354. doi: 10.1136/bmj.i3477 13. Jia G, DeMarco VG, Sowers JR. Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy. Nat Rev Endocrinol. 2016;12:144-153. doi: 10.1038/nrendo.2015.216 14. Zarich SW, Arbuckle BE, Cohen LR, Roberts M, Nesto RW. Diastolic abnormalities in young asymptomatic diabetic patients assessed by pulsed Doppler echocardiography. J Am Coll Cardiol. 1988;12:114-120. doi: 10.1016/0735-1097(88)90364-6 15. Levelt E, Mahmod M, Piechnik SK, Ariga R, Francis JM, Rodgers CT, Clarke WT, Sabharwal N, Schneider JE, Karamitsos TD, et al. Relationship Between Left Ventricular Structural and Metabolic Remodeling in Type 2 Diabetes. Diabetes. 2016;65:44-52. doi: 10.2337/db15-0627 16. Galderisi M, Anderson KM, Wilson PW, Levy D. Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (the Framingham Heart Study). Am J Cardiol. 1991;68:85-89. doi: 10.1016/0002-9149(91)90716-x 17. de Simone G, Devereux RB, Roman MJ, Ganau A, Saba PS, Alderman MH, Laragh JH. Assessment of left ventricular function by the midwall fractional shortening/end-systolic stress relation in human hypertension. J Am Coll Cardiol. 1994;23:1444-1451. doi: 10.1016/0735-1097(94)90390-5 18. Negishi K. Echocardiographic feature of diabetic cardiomyopathy: where are we now? Cardiovasc Diagn Ther. 2018;8:47-56. doi: 10.21037/cdt.2018.01.03 19. Levelt E, Mahmod M, Piechnik SK, Ariga R, Francis JM, Rodgers CT, Clarke WT, Sabharwal N, Schneider JE, Karamitsos TD, et al. Relationship Between Left Ventricular Structural and Metabolic Remodeling in Type 2 Diabetes. Diabetes. 2015;65:44-52. doi: 10.2337/db15-0627 20. Ernande L, Bergerot C, Rietzschel ER, De Buyzere ML, Thibault H, PignonBlanc PG, Croisille P, Ovize M, Groisne L, Moulin P, et al. Diastolic Dysfunction in Patients with Type 2 Diabetes Mellitus: Is It Really the First Marker of Diabetic Cardiomyopathy? Journal of the American Society of Echocardiography. 2011;24:1268-1275.e1261. doi: https://doi.org/10.1016/j.echo.2011.07.017 21. Taegtmeyer H, McNulty P, Young ME. Adaptation and maladaptation of the heart in diabetes: Part I: general concepts. Circulation. 2002;105:1727-1733. doi: 10.1161/01.cir.0000012466.50373.e8 22. Scheuermann-Freestone M, Madsen PL, Manners D, Blamire AM, Buckingham RE, Styles P, Radda GK, Neubauer S, Clarke K. Abnormal cardiac and skeletal muscle energy metabolism in patients with type 2 diabetes. Circulation. 2003;107:3040-3046. doi: 10.1161/01.Cir.0000072789.89096.10 23. McGavock JM, Lingvay I, Zib I, Tillery T, Salas N, Unger R, Levine BD, Raskin P, Victor RG, Szczepaniak LS. Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study. Circulation. 2007;116:1170-1175. doi: 10.1161/CIRCULATIONAHA.106.645614 24. Chowdhary A, Javed W, Thirunavukarasu S, Jex N, Kotha S, Kellman P, Swoboda P, Greenwood JP, Plein S, Levelt E. Cardiac Adaptations to Acute Hemodynamic Stress in Function, Perfusion, and Energetics in Type 2 Diabetes With Overweight and Obesity. Diabetes Care. 2022;45:e176-e178. doi: 10.2337/dc22-0887 25. Thirunavukarasu S, Jex N, Chowdhary A, Hassan IU, Straw S, Craven TP, Gorecka M, Broadbent D, Swoboda P, Witte KK, et al. Empagliflozin Treatment Is Associated With Improvements in Cardiac Energetics and Function and Reductions in Myocardial Cellular Volume in Patients With Type 2 Diabetes. Diabetes. 2021;70:2810-2822. doi: 10.2337/db21-0270 26. Young ME, McNulty P, Taegtmeyer H. Adaptation and Maladaptation of the Heart in Diabetes: Part II. Circulation. 2002;105:1861-1870. doi: 10.1161/01.cir.0000012467.61045.87 27. Poornima IG, Parikh P, Shannon RP. Diabetic Cardiomyopathy. Circulation Research. 2006;98:596-605. doi: 10.1161/01.res.0000207406.94146.c2 28. Dhalla NS, Liu X, Panagia V, Takeda N. Subcellular remodeling and heart dysfunction in chronic diabetes. 1998. 29. Hardin NJ. The myocardial and vascular pathology of diabetic cardiomyopathy. Coronary Artery Disease. 1996;7:99-108. 30. McGarry JD, Brown NF. The Mitochondrial Carnitine Palmitoyltransferase System — From Concept to Molecular Analysis. European Journal of Biochemistry. 1997;244:1-14. doi: 10.1111/j.1432-1033.1997.00001.x 31. Finck BN, Lehman JJ, Leone TC, Welch MJ, Bennett MJ, Kovacs A, Han X, Gross RW, Kozak R, Lopaschuk GD, Kelly DP. The cardiac phenotype induced by PPARα overexpression mimics that caused by diabetes mellitus. J Clin Invest. 2002;109:121-130. doi: 10.1172/jci0214080 32. Gulick T, Cresci S, Caira T, Moore DD, Kelly DP. The peroxisome proliferator-activated receptor regulates mitochondrial fatty acid oxidative enzyme gene expression. Proc Natl Acad Sci U S A. 1994;91:11012-11016. doi: 10.1073/pnas.91.23.11012 33. Mather KJ, Hutchins GD, Perry K, Territo W, Chisholm R, Acton A, Glick-Wilson B, Considine RV, Moberly S, DeGrado TR. Assessment of myocardial metabolic flexibility and work efficiency in human type 2 diabetes using 16-[<sup>18</sup>F]fluoro-4-thiapalmitate, a novel PET fatty acid tracer. American Journal of Physiology - Endocrinology And Metabolism. 2016;310:E452. 34. Peterson LR, Herrero P, Schechtman KB, Racette SB, Waggoner AD, Kisrieva-Ware Z, Dence C, Klein S, Marsala J, Meyer T, Gropler RJ. Effect of Obesity and Insulin Resistance on Myocardial Substrate Metabolism and Efficiency in Young Women. Circulation. 2004;109:2191. 35. Taegtmeyer H, McNulty P, Young ME. Adaptation and Maladaptation of the Heart in Diabetes: Part I: General Concepts. Circulation. 2002;105:1727-1733. doi: 10.1161/01.cir.0000012466.50373.e8 36. Park T-S, Yamashita H, Blaner WS, Goldberg IJ. Lipids in the heart: a source of fuel and a source of toxins. Current Opinion in Lipidology. 2007;18:277-282. doi: 10.1097/MOL.0b013e32814a57db 37. Finck BN, Han X, Courtois M, Aimond F, Nerbonne JM, Kovacs A, Gross RW, Kelly DP. A critical role for PPARα-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: Modulation by dietary fat content. Proceedings of the National Academy of Sciences. 2003;100:1226-1231. doi: 10.1073/pnas.0336724100 38. Unger RH. The Physiology of Cellular Liporegulation. Annual Review of Physiology. 2003;65:333-347. doi: 10.1146/annurev.physiol.65.092101.142622 39. Unger RH. Lipotoxic Diseases. Annual Review of Medicine. 2002;53:319-336. doi: 10.1146/annurev.med.53.082901.104057 40. Finck BN, Lehman JJ, Leone TC, Welch MJ, Bennett MJ, Kovacs A, Han X, Gross RW, Kozak R, Lopaschuk GD, Kelly DP. The cardiac phenotype induced by PPARα overexpression mimics that caused by diabetes mellitus. The Journal of Clinical Investigation. 2002;109:121-130. doi: 10.1172/JCI14080 41. Chiu H-C, Kovacs A, Ford DA, Hsu F-F, Garcia R, Herrero P, Saffitz JE, Schaffer JE. A novel mouse model of lipotoxic cardiomyopathy. The Journal of Clinical Investigation. 2001;107:813-822. doi: 10.1172/JCI10947 42. Bielawska AE, Shapiro JP, Jiang L, Melkonyan HS, Piot C, Wolfe CL, Tomei LD, Hannun YA, Umansky SR. Ceramide is involved in triggering of cardiomyocyte apoptosis induced by ischemia and reperfusion. The American Journal of Pathology. 1997;151:1257-1263. 43. Poornima IG, Parikh P, Shannon RP. Diabetic cardiomyopathy: the search for a unifying hypothesis. Circulation research. 2006;98:596-605. doi: 10.1161/01.RES.0000207406.94146.c2 44. Murthy VK, Shipp JC. Accumulation of Myocardial Triglycerides in Ketotic Diabetes: Evidence for Increased Biosynthesis. Diabetes. 1977;26:222-229. 45. Paulson DJ, Crass MF. Endogenous triacylglycerol metabolism in diabetic heart. American Journal of Physiology - Heart and Circulatory Physiology. 1982;242:H1084-H1094. 46. Glenn DJ, Cardema MC, Ni W, Zhang Y, Yeghiazarians Y, Grapov D, Fiehn O, Gardner DG. Cardiac steatosis potentiates angiotensin II effects in the heart. American Journal of Physiology - Heart and Circulatory Physiology. 2015;308:H339-H350. 47. Levelt E, Mahmod M, Piechnik SK, Ariga R, Francis JM, Rodgers CT, Clarke WT, Sabharwal N, Schneider JE, Karamitsos TD, et al. Relationship between Left Ventricular Structural and Metabolic Remodelling in Type 2 Diabetes Mellitus. Diabetes. 2015. doi: 10.2337/db15-0627 48. Ritchie RH, Abel ED. Basic Mechanisms of Diabetic Heart Disease. Circ Res. 2020;126:1501-1525. doi: 10.1161/circresaha.120.315913 49. Neubauer S, Horn M, Cramer M, Harre K, Newell JB, Peters W, Pabst T, Ertl G, Hahn D, Ingwall JS, Kochsiek K. Myocardial Phosphocreatine-to-ATP Ratio Is a Predictor of Mortality in Patients With Dilated Cardiomyopathy. Circulation. 1997;96:2190-2196. doi: 10.1161/01.CIR.96.7.2190 50. Bluemke DA, Kronmal RA, Lima JAC, Liu K, Olson J, Burke GL, Folsom AR. The Relationship of Left Ventricular Mass and Geometry to Incident Cardiovascular Events: The MESA Study. Journal of the American College of Cardiology. 2008;52:2148-2155. doi: 10.1016/j.jacc.2008.09.014 51. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic Implications of Echocardiographically Determined Left Ventricular Mass in the Framingham Heart Study. New England Journal of Medicine. 1990;322:1561-1566. doi: 10.1056/NEJM199005313222203 52. Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovascular Diabetology. 2018;17. doi: 10.1186/s12933-018-0728-6 53. Sethi SS, Akl EG, Farkouh ME. Diabetes Mellitus and Acute Coronary Syndrome: Lessons From Randomized Clinical Trials. Current Diabetes Reports. 2012;12:294-304. doi: 10.1007/s11892-012-0272-9 54. Cavender MA, Steg PG, Smith SC, Eagle K, Ohman EM, Goto S, Kuder J, Im K, Wilson PWF, Bhatt DL. Impact of Diabetes Mellitus on Hospitalization for Heart Failure, Cardiovascular Events, and Death. Circulation. 2015;132:923-931. doi: 10.1161/circulationaha.114.014796 55. Søren Christensen Kjærgaard H-H. In-hospital Outcome for Diabetic Patients with Acute Myocardial Infarction in the Thrombolytic Era. Scandinavian Cardiovascular Journal. 1999;33:166-170. doi: 10.1080/14017439950141803 56. Malmberg K, Yusuf S, Gerstein HC, Brown J, Zhao F, Hunt D, Piegas L, Calvin J, Keltai M, Budaj A, Investigators FTOR. Impact of Diabetes on Long-Term Prognosis in Patients With Unstable Angina and Non–Q-Wave Myocardial Infarction. Circulation. 2000;102:1014-1019. doi: 10.1161/01.cir.102.9.1014 57. Newman JD, Anthopolos R, Mancini GBJ, Bangalore S, Reynolds HR, Kunichoff DF, Senior R, Peteiro J, Bhargava B, Garg P, et al. Outcomes of Participants With Diabetes in the ISCHEMIA Trials. Circulation. 2021;144:1380-1395. doi: 10.1161/circulationaha.121.054439 58. Martín-Timón I, Sevillano-Collantes C, Segura-Galindo A, Del Cañizo-Gómez FJ. Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength? World J Diabetes. 2014;5:444-470. doi: 10.4239/wjd.v5.i4.444 59. Kolwicz SC, Jr., Purohit S, Tian R. Cardiac metabolism and its interactions with contraction, growth, and survival of cardiomyocytes. Circ Res. 2013;113:603-616. doi: 10.1161/circresaha.113.302095 60. Shivu GN, Phan TT, Abozguia K, Ahmed I, Wagenmakers A, Henning A, Narendran P, Stevens M, Frenneaux M. Relationship Between Coronary Microvascular Dysfunction and Cardiac Energetics Impairment in Type 1 Diabetes Mellitus. Circulation. 2010;121:1209-1215. doi: 10.1161/circulationaha.109.873273 61. Scheuermann-Freestone M, Madsen PL, Manners D, Blamire AM, Buckingham RE, Styles P, Radda GK, Neubauer S, Clarke K. Abnormal Cardiac and Skeletal Muscle Energy Metabolism in Patients With Type 2 Diabetes. Circulation. 2003;107:3040-3046. doi: 10.1161/01.cir.0000072789.89096.10 62. Crilley JG, Boehm EA, Blair E, Rajagopalan B, Blamire AM, Styles P, McKenna WJ, Ostman-Smith I, Clarke K, Watkins H. Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy. J Am Coll Cardiol. 2003;41:1776-1782. doi: S0735109702030097 [pii] 63. Jung WI, Sieverding L, Breuer J, Schmidt O, Widmaier S, Bunse M, van Erckelens F, Apitz J, Dietze GJ, Lutz O. Detection of phosphomonoester signals in proton-decoupled 31P NMR spectra of the myocardium of patients with myocardial hypertrophy. J Magn Reson. 1998;133:232-235. doi: S1090-7807(98)91454-9 [pii] 10.1006/jmre.1998.1454 64. Jung WI, Hoess T, Bunse M, Widmaier S, Sieverding L, Breuer J, Apitz J, Schmidt O, van Erckelens F, Dietze GJ, Lutz O. Differences in cardiac energetics between patients with familial and nonfamilial hypertrophic cardiomyopathy. Circulation. 2000;101:E121. 65. Shivu GN, Abozguia K, Phan TT, Ahmed I, Henning A, Frenneaux M. (31)P magnetic resonance spectroscopy to measure in vivo cardiac energetics in normal myocardium and hypertrophic cardiomyopathy: Experiences at 3T. Eur J Radiol. 2008. doi: S0720-048X(08)00574-3 [pii] 10.1016/j.ejrad.2008.10.018 66. Neubauer S, Krahe T, Schindler R, Horn M, Hillenbrand H, Entzeroth C, Mader H, Kromer EP, Riegger GA, Lackner K, et al. 31P magnetic resonance spectroscopy in dilated cardiomyopathy and coronary artery disease. Altered cardiac high-energy phosphate metabolism in heart failure. Circulation. 1992;86:1810-1818. 67. Neubauer S, Horn M, Pabst T, Godde M, Lubke D, Jilling B, Hahn D, Ertl G. Contributions of 31P-magnetic resonance spectroscopy to the understanding of dilated heart muscle disease. Eur Heart J. 1995;16 Suppl O:115-118. 68. Neubauer S, Horn M, Cramer M, Harre K, Newell JB, Peters W, Pabst T, Ertl G, Hahn D, Ingwall JS, Kochsiek K. Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation. 1997;96:2190-2196. 69. Neubauer S, Horn M, Pabst T, Harre K, Stromer H, Bertsch G, Sandstede J, Ertl G, Hahn D, Kochsiek K. Cardiac high-energy phosphate metabolism in patients with aortic valve disease assessed by 31P-magnetic resonance spectroscopy. J Investig Med. 1997;45:453-462. 70. Sardanelli F, Zandrino F, Molinari G, Cordone S, Delfino L, Levrero F. Magnetic resonance spectroscopy of ischemic heart disease. Rays. 1999;24:149-164. 71. Okada M, K. M, Inubushi T, Kinoshita M. Influence of aging or left ventricular hypertrophy on the human heart: Contents of phosphorus metabolites measured by 31P MRS. MRM. 1998;39:772-782. 72. Beer M, Sandstede J, Landschütz W, Seyfarth T, Lipke C, Köstler H, Pabst T, Kenn W, Meininger M, von Kienlin M, et al. Absolute concentrations of myocardial high-energy phosphate metabolites in normal, hypertrophied and failing human myocardium, measured non-invasively with 31P-SLOOP-magnetic resonance spectroscopy. J Am Coll Cardiol. 2002;40:1267-1274. 73. Conway MA, Allis J, Ouwerkerk R, Niioka T, Rajagopalan B, Radda GK. Detection of low phosphocreatine to ATP ratio in failing hypertrophied human myocardium by 31P magnetic resonance spectroscopy. Lancet. 1991;338:973-976. doi: 0140-6736(91)91838-L [pii] 74. Taegtmeyer H, Lam T, Davogustto G. Cardiac Metabolism in Perspective. Compr Physiol. 2016;6:1675-1699. doi: 10.1002/cphy.c150056 75. Taegtmeyer H. Metabolism—the lost child of cardiology∗. Journal of the American College of Cardiology. 2000;36:1386-1388. doi: 10.1016/S0735-1097(00)00870-6 76. Obrzut S, Jamshidi N, Karimi A, Birgersdotter-Green U, Hoh C. Imaging and modeling of myocardial metabolism. J Cardiovasc Transl Res. 2010;3:384-396. doi: 10.1007/s12265-010-9170-1 77. Hudsmith LE, Neubauer S. Detection of myocardial disorders by magnetic resonance spectroscopy. Nature Clinical Practice Cardiovascular Medicine. 2008;5:S49-S56. doi: 10.1038/ncpcardio1158 78. Neubauer S. The failing heart--an engine out of fuel. N Engl J Med. 2007;356:1140-1151. doi: 10.1056/NEJMra063052 79. Young ME, McNulty P, Taegtmeyer H. Adaptation and Maladaptation of the Heart in Diabetes: Part II: Potential Mechanisms. Circulation. 2002;105:1861-1870. doi: 10.1161/01.cir.0000012467.61045.87 80. Levelt E, Rodgers CT, Clarke WT, Mahmod M, Ariga R, Francis JM, Liu A, Wijesurendra RS, Dass S, Sabharwal N, et al. Cardiac energetics, oxygenation, and perfusion during increased workload in patients with type 2 diabetes mellitus. European Heart Journal. 2015. 81. Bratis K, Child N, Terrovitis J, Nanas J, Felekos I, Aggeli C, Stefanadis C, Mastorakos G, Chiribiri A, Nagel E, Mavrogeni S. Coronary microvascular dysfunction in overt diabetic cardiomyopathy. IJC Metabolic & Endocrine. 2014;5:19-23. doi: http://dx.doi.org/10.1016/j.ijcme.2014.08.007 82. Ungar I, Gilbert M, Siegel A, Blain JM, Bing RJ. Studies on myocardial metabolism: IV. Myocardial metabolism in diabetes. The American Journal of Medicine. 1955;18:385-396. doi: http://dx.doi.org/10.1016/0002-9343(55)90218-7 83. Anderson EJ, Kypson AP, Rodriguez E, Anderson CA, Lehr EJ, Neufer PD. Substrate-Specific Derangements in Mitochondrial Metabolism and Redox Balance in Atrium of Type 2 Diabetic Human Heart. Journal of the American College of Cardiology. 2009;54:1891-1898. doi: 10.1016/j.jacc.2009.07.031 84. Heather LC, Clarke K. Metabolism, hypoxia and the diabetic heart. Journal of Molecular and Cellular Cardiology. 2011;50:598-605. doi: http://dx.doi.org/10.1016/j.yjmcc.2011.01.007 85. Taegtmeyer H. Cardiac Metabolism as a Target for the Treatment of Heart Failure. Circulation. 2004;110:894-896. doi: 10.1161/01.cir.0000139340.88769.d5 86. Evans RD CK. Myocardial substrate metabolism in heart disease. Front Biosci (Schol Ed). 2012;4:556-580. 87. Stanley WC, Chandler MP. Energy Metabolism in the Normal and Failing Heart: Potential for Therapeutic Interventions. Heart failure reviews. 2002;7:115-130. doi: 10.1023/A:1015320423577 88. Veech RL. The therapeutic implications of ketone bodies: the effects of ketone bodies in pathological conditions: ketosis, ketogenic diet, redox states, insulin resistance, and mitochondrial metabolism. Prostaglandins, leukotrienes, and essential fatty acids. 2004;70:309-319. doi: 10.1016/j.plefa.2003.09.007 89. Nagoshi T, Yoshimura M, Rosano GMC, Lopaschuk GD, Mochizuki S. Optimization of Cardiac Metabolism in Heart Failure. Current Pharmaceutical Design. 2011;17:3846-3853. doi: 10.2174/138161211798357773 90. Mjøs OD. Effect of Free Fatty Acids on Myocardial Function and Oxygen Consumption in Intact Dogs. The Journal of Clinical Investigation. 1971;50:1386-1389. doi: 10.1172/JCI106621 91. Veech RL. The therapeutic implications of ketone bodies: the effects of ketone bodies in pathological conditions: ketosis, ketogenic diet, redox states, insulin resistance, and mitochondrial metabolism. Prostaglandins, Leukotrienes and Essential Fatty Acids. 2004;70:309-319. doi: 10.1016/j.plefa.2003.09.007 92. Sato K, Kashiwaya Y, Keon C, Tsuchiya N, King M, Radda G, Chance B, Clarke K, Veech R. Insulin, ketone bodies, and mitochondrial energy transduction. The FASEB journal. 1995;9:651-658. 93. Nielsen R, Møller N, Gormsen Lars C, Tolbod Lars P, Hansson Nils H, Sorensen J, Harms Hendrik J, Frøkiær J, Eiskjaer H, Jespersen Nichlas R, et al. Cardiovascular Effects of Treatment With the Ketone Body 3-Hydroxybutyrate in Chronic Heart Failure Patients. Circulation. 2019;139:2129-2141. doi: 10.1161/CIRCULATIONAHA.118.036459 94. Aubert G, Martin OJ, Horton JL, Lai L, Vega RB, Leone TC, Koves T, Gardell SJ, Krüger M, Hoppel CL, et al. The Failing Heart Relies on Ketone Bodies as a Fuel. Circulation. 2016;133:698-705. doi: 10.1161/CIRCULATIONAHA.115.017355 95. Robinson AM, Williamson DH. Physiological Roles of Ketone-Bodies as Substrates and Signals in Mammalian-Tissues. Physiol Rev. 1980;60:143-187. 96. McGarry JD, Foster DW. Hormonal control of ketogenesis. Advances in experimental medicine and biology. 1979;111:79. 97. McGarry JD, Foster DW. Hormonal control of ketogenesis: Biochemical considerations. Archives of internal medicine. 1977;137:495. 98. Lopaschuk GD, Ussher JR. Evolving Concepts of Myocardial Energy Metabolism. Circulation Research. 2016;119:1173-1176. doi: 10.1161/CIRCRESAHA.116.310078 99. Ferrannini E, Mark M, Mayoux E. CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis. Diabetes Care. 2016;39:1108-1114. doi: 10.2337/dc16-0330 100. Weiss RG, Bottomley PA, Hardy CJ, Gerstenblith G. Regional Myocardial Metabolism of High-Energy Phosphates during Isometric Exercise in Patients with Coronary Artery Disease. New England Journal of Medicine. 1990;323:1593-1600. doi: 10.1056/nejm199012063232304 101. Yabe T, Mitsunami K, Okada M, Morikawa S, Inubushi T, Kinoshita M. Detection of myocardial ischemia by 31P magnetic resonance spectroscopy during handgrip exercise. Circulation. 1994;89:1709-1716. doi: 10.1161/01.cir.89.4.1709 102. Zhang Z, Li J, Wu S, Liu Y, Fan Z, Zhou X, Zhao H, Li D, Huan Y. Cine-MRI and (31)P-MRS for evaluation of myocardial energy metabolism and function following coronary artery bypass graft. Magn Reson Imaging. 2010;28:936-942. doi: 10.1016/j.mri.2010.03.040 103. Schaefer S, Camacho SA, Gober J, Obregon RG, DeGroot MA, Botvinick EH, Massie B, Weiner MW. Response of myocardial metabolites to graded regional ischemia: 31P NMR spectroscopy of porcine myocardium in vivo. Circ Res. 1989;64:968-976. doi: 10.1161/01.res.64.5.968 104. Sourdon J, Lewsey SC, Schär M, Weiss RG. Measuring Myocardial Energetics with Cardiovascular Magnetic Resonance Spectroscopy. Heart Failure Clinics. 2021;17:149-156. doi: 10.1016/j.hfc.2020.08.011 105. Buchthal SD, den Hollander JA, Merz CN, Rogers WJ, Pepine CJ, Reichek N, Sharaf BL, Reis S, Kelsey SF, Pohost GM. Abnormal myocardial phosphorus-31 nuclear magnetic resonance spectroscopy in women with chest pain but normal coronary angiograms. N Engl J Med. 2000;342:829-835. doi: 10.1056/nejm200003233421201 106. Shomanova Z, Florian A, Bietenbeck M, Waltenberger J, Sechtem U, Yilmaz A. Diagnostic value of global myocardial perfusion reserve assessment based on coronary sinus flow measurements using cardiovascular magnetic resonance in addition to myocardial stress perfusion imaging. Eur Heart J Cardiovasc Imaging. 2017;18:851-859. doi: 10.1093/ehjci/jew315 107. Sørensen MH, Bojer AS, Broadbent DA, Plein S, Madsen PL, Gæde P. Cardiac perfusion, structure, and function in type 2 diabetes mellitus with and without diabetic complications. European Heart Journal - Cardiovascular Imaging. 2020;21:887-895. doi: 10.1093/ehjci/jez266 108. Liu X, Yang Z-G, Gao Y, Xie L-J, Jiang L, Hu B-Y, Diao K-Y, Shi K, Xu H-Y, Shen M-T, et al. Left ventricular subclinical myocardial dysfunction in uncomplicated type 2 diabetes mellitus is associated with impaired myocardial perfusion: a contrast-enhanced cardiovascular magnetic resonance study. Cardiovascular Diabetology. 2018;17. doi: 10.1186/s12933-018-0782-0 109. Levelt E, Piechnik SK, Liu A, Wijesurendra RS, Mahmod M, Ariga R, Francis JM, Greiser A, Clarke K, Neubauer S, et al. Adenosine stress CMR T1-mapping detects early microvascular dysfunction in patients with type 2 diabetes mellitus without obstructive coronary artery disease. Journal of Cardiovascular Magnetic Resonance. 2017;19. doi: 10.1186/s12968-017-0397-8 110. Heydari B, Juan Y-H, Liu H, Abbasi S, Shah R, Blankstein R, Steigner M, Jerosch-Herold M, Kwong RY. Stress Perfusion Cardiac Magnetic Resonance Imaging Effectively Risk Stratifies Diabetic Patients With Suspected Myocardial Ischemia. Circulation: Cardiovascular Imaging. 2016;9. doi: 10.1161/circimaging.115.004136 111. Shi Y, Vanhoutte PM. Macro- and microvascular endothelial dysfunction in diabetes. Journal of Diabetes. 2017;9:434-449. doi: 10.1111/1753-0407.12521 112. Levy BI, Schiffrin EL, Mourad J-J, Agostini D, Vicaut E, Safar ME, Struijker-Boudier HAJ. Impaired Tissue Perfusion. Circulation. 2008;118:968-976. doi: 10.1161/circulationaha.107.763730 113. Quiñones MJ, Nicholas SB, Lyon CJ. Insulin resistance and the endothelium. Current Diabetes Reports. 2005;5:246-253. doi: 10.1007/s11892-005-0018-z 114. Kruljac I, Cacic M, Cacic P, Ostojic V, Stefanovic M, Sikic A, Vrkljan M. Diabetic ketosis during hyperglycemic crisis is associated with decreased all-cause mortality in patients with type 2 diabetes mellitus. Endocrine. 2016. doi: 10.1007/s12020-016-1082-7 115. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine. 2015;373:2117-2128. doi: 10.1056/nejmoa1504720 116. Tahara A, Kurosaki E, Yokono M, Yamajuku D, Kihara R, Hayashizaki Y, Takasu T, Imamura M, Li Q, Tomiyama H, et al. Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats. Journal of Pharmacy and Pharmacology. 2014;66:975-987. doi: 10.1111/jphp.12223 117. Ferrannini E, Baldi S, Frascerra S, Astiarraga B, Heise T, Bizzotto R, Mari A, Pieber TR, Muscelli E. Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes. Diabetes. 2016;65:1190-1195. doi: 10.2337/db15-1356 118. Mudaliar S, Alloju S, Henry RR. Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis. Diabetes Care. 2016;39:1115-1122. doi: 10.2337/dc16-0542 119. Ferrannini E, Mark M, Mayoux E. CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis. Diabetes Care. 2016;39:1108. 120. Mudaliar S, Alloju S, Henry RR. Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis. Diabetes Care. 2016;39:1115. 121. Sato K, Kashiwaya Y, Keon CA, Tsuchiya N, King MT, Radda GK, Chance B, Clarke K, Veech RL. Insulin, ketone bodies, and mitochondrial energy transduction. Faseb j. 1995;9:651-658. doi: 10.1096/fasebj.9.8.7768357 122. Selvaraj S, Kelly Daniel P, Margulies Kenneth B. Implications of Altered Ketone Metabolism and Therapeutic Ketosis in Heart Failure. Circulation. 2020;141:1800-1812. doi: 10.1161/CIRCULATIONAHA.119.045033 123. Medium Chain Acyl Coa Dehydrogenase-Deficiency. Lancet. 1991;338:544-545. 124. Van Hove JLK, Grunewald S, Jaeken J, Demaerel P, Declercq PE, Bourdoux P, Niezen-Koning K, Deanfeld JE, Leonard JV. D,L-3-hydroxybutyrate treatment of multiple acyl-CoA dehydrogenase deficiency (MADD). Lancet. 2003;361:1433-1435. 125. Balietti M, Casoli T, Di Stefano G, Giorgetti B, Aicardi G, Fattoretti P. Ketogenic diets: An historical antiepileptic therapy with promising potentialities for the aging brain. Ageing Res Rev. 2010;9:273-279. doi: DOI 10.1016/j.arr.2010.02.003 126. Kossoff EH, Rho JM. Ketogenic Diets: Evidence for Short- and Long-term Efficacy. Neurotherapeutics. 2009;6:406-414. 127. Westman EC, Mavropoulos J, Yancy WS, Volek JS. A review of low-carbohydrate ketogenic diets. Current atherosclerosis reports. 2003;5:476-483. 128. Amari A, Grace NC, Fisher WW. Achieving and maintaining compliance with the ketogenic diet. Journal of applied behavior analysis. 1995;28:341. 129. Rider OJ, Francis JM, Tyler D, Byrne J, Clarke K, Neubauer S. Effects of weight loss on myocardial energetics and diastolic function in obesity. Int J Cardiovasc Imaging. 2013;29:1043-1050. doi: 10.1007/s10554-012-0174-6 130. Fox CS, Massaro JM, Hoffmann U, Pou KM, Maurovich-Horvat P, Liu C-Y, Vasan RS, Murabito JM, Meigs JB, Cupples LA, et al. Abdominal Visceral and Subcutaneous Adipose Tissue Compartments: Association With Metabolic Risk Factors in the Framingham Heart Study. Circulation. 2007;116:39-48. doi: 10.1161/circulationaha.106.675355 131. Okura T, Nakata Y, Yamabuki K, Tanaka K. Regional Body Composition Changes Exhibit Opposing Effects on Coronary Heart Disease Risk Factors. Arteriosclerosis, Thrombosis, and Vascular Biology. 2004;24:923-929. doi: 10.1161/01.ATV.0000125702.26272.f6 132. Fantuzzi G, Mazzone T. Adipose Tissue and Atherosclerosis: Exploring the Connection. Arteriosclerosis, Thrombosis, and Vascular Biology. 2007;27:996-1003. doi: 10.1161/atvbaha.106.131755 133. Montani JP, Carroll JF, Dwyer TM, Antic V, Yang Z, Dulloo AG. Ectopic fat storage in heart, blood vessels and kidneys in the pathogenesis of cardiovascular diseases. Int J Obes Relat Metab Disord. 0000;28:S58-S65. 134. Rabinowitz D, Zierler KL. FOREARM METABOLISM IN OBESITY AND ITS RESPONSE TO INTRA-ARTERIAL INSULIN. CHARACTERIZATION OF INSULIN RESISTANCE AND EVIDENCE FOR ADAPTIVE HYPERINSULINISM. Journal of Clinical Investigation. 1962;41:2173-2181. 135. Felig P, Wahren J, Hendler R, Brundin T. Splanchnic glucose and amino acid metabolism in obesity. Journal of Clinical Investigation. 1974;53:582-590. 136. Caro JF, Dohm LG, Pories WJ, Sinha MK. Cellular alterations in liver, skeletal muscle, and adipose tissue responsible for insulin resistance in obesity and type II diabetes. Diabetes/Metabolism Reviews. 1989;5:665-689. doi: 10.1002/dmr.5610050804 137. RAVUSSIN E, SMITH SR. Increased Fat Intake, Impaired Fat Oxidation, and Failure of Fat Cell Proliferation Result in Ectopic Fat Storage, Insulin Resistance, and Type 2 Diabetes Mellitus. Annals of the New York Academy of Sciences. 2002;967:363-378. doi: https://doi.org/10.1111/j.1749-6632.2002.tb04292.x 138. Fox CS, Gona P, Hoffmann U, Porter SA, Salton CJ, Massaro JM, Levy D, Larson MG, D'Agostino RB, O'Donnell CJ, Manning WJ. Pericardial Fat, Intrathoracic Fat, and Measures of Left Ventricular Structure and Function: The Framingham Heart Study. Circulation. 2009;119:1586-1591. doi: 10.1161/circulationaha.108.828970 139. Fox CS, Massaro JM, Schlett CL, Lehman SJ, Meigs JB, O'Donnell CJ, Hoffmann U, Murabito JM. Periaortic Fat Deposition Is Associated With Peripheral Arterial Disease: The Framingham Heart Study. Circulation: Cardiovascular Imaging. 2010;3:515-519. doi: 10.1161/circimaging.110.958884 140. Rijzewijk LJ, van der Meer RW, Smit JWA, Diamant M, Bax JJ, Hammer S, Romijn JA, de Roos A, Lamb HJ. Myocardial Steatosis Is an Independent Predictor of Diastolic Dysfunction in Type 2 Diabetes Mellitus. Journal of the American College of Cardiology. 2008;52:1793-1799. doi: http://dx.doi.org/10.1016/j.jacc.2008.07.062 141. Rijzewijk LJ, Jonker JT, van der Meer RW, Lubberink M, de Jong HW, Romijn JA, Bax JJ, de Roos A, Heine RJ, Twisk JW, et al. Effects of Hepatic Triglyceride Content on Myocardial Metabolism in Type 2 Diabetes. Journal of the American College of Cardiology. 2010;56:225-233. doi: http://dx.doi.org/10.1016/j.jacc.2010.02.049 142. Greenstein AS, Khavandi K, Withers SB, Sonoyama K, Clancy O, Jeziorska M, Laing I, Yates AP, Pemberton PW, Malik RA, Heagerty AM. Local Inflammation and Hypoxia Abolish the Protective Anticontractile Properties of Perivascular Fat in Obese Patients. Circulation. 2009;119:1661-1670. doi: 10.1161/circulationaha.108.821181 143. Lee Y-C, Chang H-H, Chiang C-L, Liu C-H, Yeh J-I, Chen M-F, Chen P-Y, Kuo J-S, Lee TJF. Role of Perivascular Adipose Tissue–Derived Methyl Palmitate in Vascular Tone Regulation and Pathogenesis of Hypertension. Circulation. 2011;124:1160-1171. doi: 10.1161/circulationaha.111.027375 144. Visceral and Ectopic Fat : Risk Factors for Type 2 Diabetes, Atherosclerosis, and Cardiovascular Disease. United States: Elsevier Science Publishing Co Inc; 2022. 145. Antonopoulos AS, Antoniades C. The role of epicardial adipose tissue in cardiac biology: classic concepts and emerging roles. The Journal of Physiology. 2017;595:3907-3917. doi: 10.1113/jp273049 146. Iacobellis G, Corradi D, Sharma AM. Epicardial adipose tissue: anatomic, biomolecular and clinical relationships with the heart. Nature Clinical Practice Cardiovascular Medicine. 2005;2:536-543. doi: 10.1038/ncpcardio0319 147. Iacobellis G. Epicardial adipose tissue in contemporary cardiology. Nature Reviews Cardiology. 2022;19:593-606. doi: 10.1038/s41569-022-00679-9 148. Aldiss P, Davies G, Woods R, Budge H, Sacks HS, Symonds ME. ‘Browning’ the cardiac and peri-vascular adipose tissues to modulate cardiovascular risk. International Journal of Cardiology. 2017;228:265-274. doi: 10.1016/j.ijcard.2016.11.074 149. Sacks HS, Fain JN, Holman B, Cheema P, Chary A, Parks F, Karas J, Optican R, Bahouth SW, Garrett E, et al. Uncoupling protein-1 and related messenger ribonucleic acids in human epicardial and other adipose tissues: epicardial fat functioning as brown fat. J Clin Endocrinol Metab. 2009;94:3611-3615. doi: 10.1210/jc.2009-0571 150. Frontini A, Cinti S. Distribution and Development of Brown Adipocytes in the Murine and Human Adipose Organ. Cell Metabolism. 2010;11:253-256. doi: 10.1016/j.cmet.2010.03.004 151. Golozoubova V, Cannon B, Nedergaard J. UCP1 is essential for adaptive adrenergic nonshivering thermogenesis. Am J Physiol Endocrinol Metab. 2006;291:E350-357. doi: 10.1152/ajpendo.00387.2005 152. Betz MJ, Enerback S. Human Brown Adipose Tissue: What We Have Learned So Far. Diabetes. 2015;64:2352-2360. doi: 10.2337/db15-0146 153. Ouellet V, Routhier-Labadie A, Bellemare W, Lakhal-Chaieb L, Turcotte E, Carpentier AC, Richard D. Outdoor Temperature, Age, Sex, Body Mass Index, and Diabetic Status Determine the Prevalence, Mass, and Glucose-Uptake Activity of 18F-FDG-Detected BAT in Humans. The Journal of Clinical Endocrinology & Metabolism. 2011;96:192-199. doi: 10.1210/jc.2010-0989 154. Moreno-Santos I, Pérez-Belmonte LM, Macías-González M, Mataró MJ, Castellano D, López-Garrido M, Porras-Martín C, Sánchez-Fernández PL, Gómez-Doblas JJ, Cardona F, et al. Type 2 diabetes is associated with decreased PGC1α expression in epicardial adipose tissue of patients with coronary artery disease. J Transl Med. 2016;14:243. doi: 10.1186/s12967-016-0999-1 155. Oikonomou EK, Antoniades C. The role of adipose tissue in cardiovascular health and disease. Nature Reviews Cardiology. 2019;16:83-99. doi: 10.1038/s41569-018-0097-6 156. Lodewijks F, McKinsey TA, Robinson EL. Fat-to-heart crosstalk in health and disease. Front Genet. 2023;14:990155. doi: 10.3389/fgene.2023.990155 157. Yang H, Xiong B, Xiong T, Wang D, Yu W, Liu B, She Q. Identification of key genes and mechanisms of epicardial adipose tissue in patients with diabetes through bioinformatic analysis. Front Cardiovasc Med. 2022;9:927397. doi: 10.3389/fcvm.2022.927397 158. Iacobellis G, Leonetti F. Epicardial Adipose Tissue and Insulin Resistance in Obese Subjects. The Journal of Clinical Endocrinology & Metabolism. 2005;90:6300-6302. doi: doi:10.1210/jc.2005-1087 159. Mazurek T, Zhang L, Zalewski A, Mannion JD, Diehl JT, Arafat H, Sarov-Blat L, O’Brien S, Keiper EA, Johnson AG, et al. Human Epicardial Adipose Tissue Is a Source of Inflammatory Mediators. Circulation. 2003;108:2460-2466. doi: 10.1161/01.cir.0000099542.57313.c5 160. Levelt E, Pavlides M, Banerjee R, Mahmod M, Kelly C, Sellwood J, Ariga R, Thomas S, Francis J, Rodgers C, et al. Ectopic and Visceral Fat Deposition in Lean and Obese Patients With Type 2 Diabetes. Journal of the American College of Cardiology. 2016;68:53-63. doi: 10.1016/j.jacc.2016.03.597 161. Cherian S, Lopaschuk GD, Carvalho E. Cellular cross-talk between epicardial adipose tissue and myocardium in relation to the pathogenesis of cardiovascular disease. American Journal of Physiology-Endocrinology and Metabolism. 2012;303:E937-E949. doi: 10.1152/ajpendo.00061.2012 162. Ansaldo AM, Montecucco F, Sahebkar A, Dallegri F, Carbone F. Epicardial adipose tissue and cardiovascular diseases. Int J Cardiol. 2019;278:254-260. doi: 10.1016/j.ijcard.2018.09.089 163. Nerlekar N, Brown AJ, Muthalaly RG, Talman A, Hettige T, Cameron JD, Wong DTL. Association of Epicardial Adipose Tissue and High-Risk Plaque Characteristics: A Systematic Review and Meta-Analysis. J Am Heart Assoc. 2017;6. doi: 10.1161/jaha.117.006379 164. Mancio J, Azevedo D, Saraiva F, Azevedo AI, Pires-Morais G, Leite-Moreira A, Falcao-Pires I, Lunet N, Bettencourt N. Epicardial adipose tissue volume assessed by computed tomography and coronary artery disease: a systematic review and meta-analysis. European Heart Journal - Cardiovascular Imaging. 2018;19:490-497. doi: 10.1093/ehjci/jex314 165. Gaeta M, Bandera F, Tassinari F, Capasso L, Cargnelutti M, Pelissero G, Malavazos AE, Ricci C. Is epicardial fat depot associated with atrial fibrillation? A systematic review and meta-analysis. EP Europace. 2017;19:747-752. doi: 10.1093/europace/euw398 166. Chen J, Mei Z, Yang Y, Dai C, Wang Y, Zeng R, Liu Q. Epicardial adipose tissue is associated with higher recurrence risk after catheter ablation in atrial fibrillation patients: a systematic review and meta-analysis. BMC Cardiovasc Disord. 2022;22:264. doi: 10.1186/s12872-022-02703-9 167. Wu A, Yang Z, Zhang X, Lin Z, Lu H. Association between epicardial adipose tissue and left atrial and ventricular function in patients with heart failure-a systematic review and meta-analysis. Curr Probl Cardiol. 2023:101979. doi: 10.1016/j.cpcardiol.2023.101979 168. Dozio E, Vianello E, Briganti S, Fink B, Malavazos AE, Scognamiglio ET, Dogliotti G, Sigrüener A, Schmitz G, Corsi Romanelli MM. Increased reactive oxygen species production in epicardial adipose tissues from coronary artery disease patients is associated with brown-to-white adipocyte trans-differentiation. Int J Cardiol. 2014;174:413-414. doi: 10.1016/j.ijcard.2014.04.045 169. Li C, Li S, Zhang F, Wu M, Liang H, Song J, Lee C, Chen H. Endothelial microparticles-mediated transfer of microRNA-19b promotes atherosclerosis via activating perivascular adipose tissue inflammation in apoE−/− mice. Biochemical and Biophysical Research Communications. 2018;495:1922-1929. doi: https://doi.org/10.1016/j.bbrc.2017.11.195 170. Cabaro S, Conte M, Moschetta D, Petraglia L, Valerio V, Romano S, Di Tolla MF, Campana P, Comentale G, Pilato E, et al. Epicardial Adipose Tissue-Derived IL-1β Triggers Postoperative Atrial Fibrillation. Front Cell Dev Biol. 2022;10:893729. doi: 10.3389/fcell.2022.893729 171. Ernault AC, Meijborg VMF, Coronel R. Modulation of Cardiac Arrhythmogenesis by Epicardial Adipose Tissue: JACC State-of-the-Art Review. Journal of the American College of Cardiology. 2021;78:1730-1745. doi: https://doi.org/10.1016/j.jacc.2021.08.037 172. Levelt E, Gulsin G, Neubauer S, McCann GP. MECHANISMS IN ENDOCRINOLOGY: Diabetic cardiomyopathy: pathophysiology and potential metabolic interventions state of the art review. Eur J Endocrinol. 2018;178:R127-r139. doi: 10.1530/eje-17-0724 173. Dillmann WH. Diabetic Cardiomyopathy. Circ Res. 2019;124:1160-1162. doi: 10.1161/circresaha.118.314665 174. Chowdhary A, Thirunavukarasu S, Jex N, Coles L, Bowers C, Sengupta A, Swoboda P, Witte K, Cubbon R, Xue H, et al. Coronary microvascular function and visceral adiposity in patients with normal body weight and type 2 diabetes. Obesity. 2022;30:1079-1090. doi: https://doi.org/10.1002/oby.23413 175. Al-Talabany S, Mordi I, Graeme Houston J, Colhoun HM, Weir-McCall JR, Matthew SZ, Looker HC, Levin D, Belch JJF, Dove F, et al. Epicardial adipose tissue is related to arterial stiffness and inflammation in patients with cardiovascular disease and type 2 diabetes. BMC Cardiovasc Disord. 2018;18:31. doi: 10.1186/s12872-018-0770-z 176. Homsi R, Sprinkart AM, Gieseke J, Meier-Schroers M, Yuecel S, Fischer S, Nadal J, Dabir D, Luetkens JA, Kuetting DL, et al. Cardiac magnetic resonance based evaluation of aortic stiffness and epicardial fat volume in patients with hypertension, diabetes mellitus, and myocardial infarction. Acta Radiol. 2018;59:65-71. doi: 10.1177/0284185117706201 177. Huang S, Li Y, Jiang L, Ren Y, Wang J, Shi K, Yan WF, Qian WL, Yang ZG. Impact of Type 2 Diabetes Mellitus on Epicardial Adipose Tissue and Myocardial Microcirculation by MRI in Postmenopausal Women. J Magn Reson Imaging. 2022;56:1404-1413. doi: 10.1002/jmri.28121 178. Taylor R, Holman RR. Normal weight individuals who develop type 2 diabetes: the personal fat threshold. Clin Sci (Lond). 2015;128:405-410. doi: 10.1042/CS20140553 179. Trayhurn P, Wang B, Wood IS. Hypoxia in adipose tissue: a basis for the dysregulation of tissue function in obesity? British Journal of Nutrition. 2008;100:227-235. doi: 10.1017/s0007114508971282 180. Virtue S, Vidal-Puig A. Adipose tissue expandability, lipotoxicity and the Metabolic Syndrome--an allostatic perspective. Biochim Biophys Acta. 2010;1801:338-349. doi: 10.1016/j.bbalip.2009.12.006 181. Levelt E, Pavlides M, Banerjee R, Mahmod M, Kelly C, Sellwood J, Ariga R, Thomas S, Francis J, Rodgers C, et al. Ectopic and Visceral Fat Deposition in Lean and Obese Patients With Type 2 Diabetes. J Am Coll Cardiol. 2016;68:53-63. doi: 10.1016/j.jacc.2016.03.597 182. Guglielmo M, Lin A, Dey D, Baggiano A, Fusini L, Muscogiuri G, Pontone G. Epicardial fat and coronary artery disease: Role of cardiac imaging. Atherosclerosis. 2021;321:30-38. doi: 10.1016/j.atherosclerosis.2021.02.008 183. Monti CB, Capra D, Zanardo M, Guarnieri G, Schiaffino S, Secchi F, Sardanelli F. CT-derived epicardial adipose tissue density: Systematic review and meta-analysis. Eur J Radiol. 2021;143:109902. doi: 10.1016/j.ejrad.2021.109902 184. Mancio J, Azevedo D, Saraiva F, Azevedo AI, Pires-Morais G, Leite-Moreira A, Falcao-Pires I, Lunet N, Bettencourt N. Epicardial adipose tissue volume assessed by computed tomography and coronary artery disease: a systematic review and meta-analysis. Eur Heart J Cardiovasc Imaging. 2018;19:490-497. doi: 10.1093/ehjci/jex314 185. Machann JR, Thamer C, Schnoedt B, Haap M, Haring H-U, Claussen CD, Stumvoll M, Fritsche A, Schick F. Standardized assessment of whole body adipose tissue topography by MRI. Journal of Magnetic Resonance Imaging. 2005;21:455-462. doi: 10.1002/jmri.20292 186. Leo LA, Paiocchi VL, Schlossbauer SA, Ho SY, Faletra FF. The Intrusive Nature of Epicardial Adipose Tissue as Revealed by Cardiac Magnetic Resonance. J Cardiovasc Echogr. 2019;29:45-51. doi: 10.4103/jcecho.jcecho_22_19 187. Leiner T, Bogaert J, Friedrich MG, Mohiaddin R, Muthurangu V, Myerson S, Powell AJ, Raman SV, Pennell DJ. SCMR Position Paper (2020) on clinical indications for cardiovascular magnetic resonance. Journal of Cardiovascular Magnetic Resonance. 2020;22. doi: 10.1186/s12968-020-00682-4 188. Levelt E, Gulsin G, Neubauer S, McCann GP. MECHANISMS IN ENDOCRINOLOGY: Diabetic cardiomyopathy: pathophysiology and potential metabolic interventions state of the art review. European Journal of Endocrinology. 2018;178:R127-R139. doi: 10.1530/EJE-17-0724 189. Marwick TH, Gimelli A, Plein S, Bax JJ, Charron P, Delgado V, Donal E, Lancellotti P, Levelt E, Maurovich-Horvat P, et al. Multimodality imaging approach to left ventricular dysfunction in diabetes: an expert consensus document from the European Association of Cardiovascular Imaging. European Heart Journal - Cardiovascular Imaging. 2022;23:e62-e84. doi: 10.1093/ehjci/jeab220 190. Salerno M, Sharif B, Arheden H, Kumar A, Axel L, Li D, Neubauer S. Recent Advances in Cardiovascular Magnetic Resonance. Circulation: Cardiovascular Imaging. 2017;10:e003951. doi: 10.1161/circimaging.116.003951 191. Patel AR, Salerno M, Kwong RY, Singh A, Heydari B, Kramer CM. Stress Cardiac Magnetic Resonance Myocardial Perfusion Imaging: JACC Review Topic of the Week. J Am Coll Cardiol. 2021;78:1655-1668. doi: 10.1016/j.jacc.2021.08.022 192. Garcia MJ, Kwong RY, Scherrer-Crosbie M, Taub CC, Blankstein R, Lima J, Bonow RO, Eshtehardi P, Bois JP. State of the Art: Imaging for Myocardial Viability: A Scientific Statement From the American Heart Association. Circulation: Cardiovascular Imaging. 2020;13. doi: 10.1161/hci.0000000000000053 193. Flüchter S, Haghi D, Dinter D, Heberlein W, Kühl HP, Neff W, Sueselbeck T, Borggrefe M, Papavassiliu T. Volumetric Assessment of Epicardial Adipose Tissue With Cardiovascular Magnetic Resonance Imaging*. Obesity. 2007;15:870-878. doi: 10.1038/oby.2007.591 194. Homsi R, Thomas D, Gieseke J, Meier-Schroers M, Dabir D, Kuetting D, Luetkens J, Marx C, Schild H, Sprinkart A. Epicardial Fat Volume and Aortic Stiffness in Healthy Individuals: A Quantitative Cardiac Magnetic Resonance Study. RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren. 2016;188:853-858. doi: 10.1055/s-0042-110098 195. Daudé P, Ancel P, Confort Gouny S, Jacquier A, Kober F, Dutour A, Bernard M, Gaborit B, Rapacchi S. Deep-Learning Segmentation of Epicardial Adipose Tissue Using Four-Chamber Cardiac Magnetic Resonance Imaging. Diagnostics. 2022;12:126. doi: 10.3390/diagnostics12010126 196. Evin M, Broadhouse KM, Callaghan FM, McGrath RT, Glastras S, Kozor R, Hocking SL, Lamy J, Redheuil A, Kachenoura N, et al. Impact of obesity and epicardial fat on early left atrial dysfunction assessed by cardiac MRI strain analysis. Cardiovascular Diabetology. 2016;15. doi: 10.1186/s12933-016-0481-7 197. Cristobal-Huerta A, Torrado-Carvajal A, Malpica N, Luaces M, Hernandez-Tamames JA. Automated quantification of epicardial adipose tissue in cardiac magnetic resonance imaging. Paper/Poster presented 2015, 2015; https://dx.doi.org/10.1109/embc.2015.7320079 [link]. 198. He F, Chen W, Xu W, Liu D, Xiao Z, Tang Y, Lin Z, Liao Y, Bin J, Chen G, Chen Y. Safety and efficacy of liraglutide on reducing visceral and ectopic fat in adults with or without type 2 diabetes mellitus: A systematic review and meta‐analysis. Diabetes, Obesity and Metabolism. 2023;25:664-674. doi: 10.1111/dom.14908 199. Launbo N, Zobel EH, Scholten BJ, Færch K, Jørgensen PG, Christensen RH. Targeting epicardial adipose tissue with exercise, diet, bariatric surgery or pharmaceutical interventions: A systematic review and meta‐analysis. Obesity Reviews. 2021;22. doi: 10.1111/obr.13136 200. Berg G, Barchuk M, Lobo M, Nogueira JP. Effect of glucagon-like peptide-1 (GLP-1) analogues on epicardial adipose tissue: A meta-analysis. Diabetes Metab Syndr. 2022;16:102562. doi: 10.1016/j.dsx.2022.102562 201. Li Y, Liu B, Li Y, Jing X, Deng S, Yan Y, She Q. Epicardial fat tissue in patients with diabetes mellitus: a systematic review and meta-analysis. Cardiovascular Diabetology. 2019;18. doi: 10.1186/s12933-019-0807-3 202. Nerlekar N, Muthalaly RG, Wong N, Thakur U, Wong DTL, Brown AJ, Marwick TH. Association of Volumetric Epicardial Adipose Tissue Quantification and Cardiac Structure and Function. Journal of the American Heart Association. 2018;7. doi: 10.1161/jaha.118.009975 203. Gaborit B, Kober F, Jacquier A, Moro PJ, Cuisset T, Boullu S, Dadoun F, Alessi MC, Morange P, Clément K, et al. Assessment of epicardial fat volume and myocardial triglyceride content in severely obese subjects: relationship to metabolic profile, cardiac function and visceral fat. International Journal of Obesity. 2012;36:422-430. doi: 10.1038/ijo.2011.117 204. Kim HM, Kim KJ, Lee HJ, Yu HT, Moon JH, Kang ES, Cha BS, Lee HC, Lee BW, Kim YJ. Epicardial adipose tissue thickness is an indicator for coronary artery stenosis in asymptomatic type 2 diabetic patients: its assessment by cardiac magnetic resonance. Cardiovasc Diabetol. 2012;11:83. doi: 10.1186/1475-2840-11-83 205. Edin C, Ekstedt M, Scheffel T, Karlsson M, Swahn E, Östgren CJ, Engvall J, Ebbers T, Leinhard OD, Lundberg P, Carlhäll CJ. Ectopic fat is associated with cardiac remodeling-A comprehensive assessment of regional fat depots in type 2 diabetes using multi-parametric MRI. Front Cardiovasc Med. 2022;9:813427. doi: 10.3389/fcvm.2022.813427 206. Rado SD, Lorbeer R, Gatidis S, Machann J, Storz C, Nikolaou K, Rathmann W, Hoffmann U, Peters A, Bamberg F, Schlett CL. MRI-based assessment and characterization of epicardial and paracardial fat depots in the context of impaired glucose metabolism and subclinical left-ventricular alterations. The British Journal of Radiology. 2019;92:20180562. doi: 10.1259/bjr.20180562 207. Haberka M, Machnik G, Kowalowka A, Biedron M, Skudrzyk E, Regulska-Ilow B, Gajos G, Manka R, Deja M, Okopien B, Gasior Z. Epicardial, paracardial, and perivascular fat quantity, gene expressions, and serum cytokines in patients with coronary artery disease and diabetes. Pol Arch Intern Med. 2019;129:738-746. doi: 10.20452/pamw.14961 208. Zhu J, Li W, Xie Z, Zhuo K. Relationship Between Epicardial Adipose Tissue and Biventricular Longitudinal Strain and Strain Rate in Patients with Type 2 Diabetes Mellitus. Acad Radiol. 2023;30:833-840. doi: 10.1016/j.acra.2022.08.019 209. Huang S, Li Y, Jiang L, Ren Y, Wang J, Shi K, Yan WF, Qian WL, Yang ZG. Impact of Type 2 Diabetes Mellitus on Epicardial Adipose Tissue and Myocardial Microcirculation by <scp>MRI</scp> in Postmenopausal Women. Journal of Magnetic Resonance Imaging. 2022;56:1404-1413. doi: 10.1002/jmri.28121 210. Kim H, Kim K, Lee H-J, Yu H, Moon J, Kang E, Cha B, Lee H, Lee B-W, Kim Y. Epicardial adipose tissue thickness is an indicator for coronary artery stenosis in asymptomatic type 2 diabetic patients: its assessment by cardiac magnetic resonance. Cardiovascular Diabetology. 2012;11:83. doi: 10.1186/1475-2840-11-83 211. Gaborit B, Ancel P, Abdullah AE, Maurice F, Abdesselam I, Calen A, Soghomonian A, Houssays M, Varlet I, Eisinger M, et al. Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study. Cardiovasc Diabetol. 2021;20:57. doi: 10.1186/s12933-021-01237-2 212. Bouchi R, Terashima M, Sasahara Y, Asakawa M, Fukuda T, Takeuchi T, Nakano Y, Murakami M, Minami I, Izumiyama H, et al. Luseogliflozin reduces epicardial fat accumulation in patients with type 2 diabetes: a pilot study. Cardiovasc Diabetol. 2017;16:32. doi: 10.1186/s12933-017-0516-8 213. Fukuda T, Bouchi R, Terashima M, Sasahara Y, Asakawa M, Takeuchi T, Nakano Y, Murakami M, Minami I, Izumiyama H, et al. Ipragliflozin Reduces Epicardial Fat Accumulation in Non-Obese Type 2 Diabetic Patients with Visceral Obesity: A Pilot Study. Diabetes Therapy. 2017;8:851-861. doi: 10.1007/s13300-017-0279-y 214. Dutour A, Abdesselam I, Ancel P, Kober F, Mrad G, Darmon P, Ronsin O, Pradel V, Lesavre N, Martin JC, et al. Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy. Diabetes Obes Metab. 2016;18:882-891. doi: 10.1111/dom.12680 215. van Eyk HJ, Paiman EHM, Bizino MB, de Heer P, Geelhoed-Duijvestijn PH, Kharagjitsingh AV, Smit JWA, Lamb HJ, Rensen PCN, Jazet IM. A double-blind, placebo-controlled, randomised trial to assess the effect of liraglutide on ectopic fat accumulation in South Asian type 2 diabetes patients. Cardiovasc Diabetol. 2019;18:87. doi: 10.1186/s12933-019-0890-5 216. Bizino MB, Jazet IM, de Heer P, van Eyk HJ, Dekkers IA, Rensen PCN, Paiman EHM, Lamb HJ, Smit JW. Placebo-controlled randomised trial with liraglutide on magnetic resonance endpoints in individuals with type 2 diabetes: a pre-specified secondary study on ectopic fat accumulation. Diabetologia. 2020;63:65-74. doi: 10.1007/s00125-019-05021-6 217. Zhao N, Wang X, Wang Y, Yao J, Shi C, Du J, Bai R. The Effect of Liraglutide on Epicardial Adipose Tissue in Type 2 Diabetes. J Diabetes Res. 2021;2021:5578216. doi: 10.1155/2021/5578216 218. Moody AJ, Molina-Wilkins M, Clarke GD, Merovci A, Solis-Herrera C, Cersosimo E, Chilton RJ, Iozzo P, Gastaldelli A, Abdul-Ghani M, DeFronzo RA. Pioglitazone reduces epicardial fat and improves diastolic function in patients with type 2 diabetes. Diabetes Obes Metab. 2022. doi: 10.1111/dom.14885 219. Fiore D, Gianfrilli D, Giannetta E, Galea N, Panio G, di Dato C, Pofi R, Pozza C, Sbardella E, Carbone I, et al. PDE5 Inhibition Ameliorates Visceral Adiposity Targeting the miR-22/SIRT1 Pathway: Evidence From the CECSID Trial. J Clin Endocrinol Metab. 2016;101:1525-1534. doi: 10.1210/jc.2015-4252 220. Zhao N, Wang X, Wang Y, Yao J, Shi C, Du J, Bai R. The Effect of Liraglutide on Epicardial Adipose Tissue in Type 2 Diabetes. Journal of Diabetes Research. 2021;2021:1-6. doi: 10.1155/2021/5578216 221. Gaborit B, Ancel P, Abdullah AE, Maurice F, Abdesselam I, Calen A, Soghomonian A, Houssays M, Varlet I, Eisinger M, et al. Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study. Cardiovascular Diabetology. 2021;20. doi: 10.1186/s12933-021-01237-2 222. Van Eyk HJ, Paiman EHM, Bizino MB, De Heer P, Geelhoed-Duijvestijn PH, Kharagjitsingh AV, Smit JWA, Lamb HJ, Rensen PCN, Jazet IM. A double-blind, placebo-controlled, randomised trial to assess the effect of liraglutide on ectopic fat accumulation in South Asian type 2 diabetes patients. Cardiovascular Diabetology. 2019;18. doi: 10.1186/s12933-019-0890-5 223. Dutour A, Abdesselam I, Ancel P, Kober F, Mrad G, Darmon P, Ronsin O, Pradel V, Lesavre N, Martin JC, et al. Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy. Diabetes, Obesity and Metabolism. 2016;18:882-891. doi: 10.1111/dom.12680 224. van Schinkel LD, Sleddering MA, Lips MA, Jonker JT, de Roos A, Lamb HJ, Jazet IM, Pijl H, Smit JW. Effects of bariatric surgery on pericardial ectopic fat depositions and cardiovascular function. Clin Endocrinol (Oxf). 2014;81:689-695. doi: 10.1111/cen.12402 225. Jonker JT, de Mol P, de Vries ST, Widya RL, Hammer S, van Schinkel LD, van der Meer RW, Gans RO, Webb AG, Kan HE, et al. Exercise and type 2 diabetes mellitus: changes in tissue-specific fat distribution and cardiac function. Radiology. 2013;269:434-442. doi: 10.1148/radiol.13121631 226. Ardissino M, McCracken C, Bard A, Antoniades C, Neubauer S, Harvey NC, Petersen SE, Raisi-Estabragh Z. Pericardial adiposity is independently linked to adverse cardiovascular phenotypes: a CMR study of 42 598 UK Biobank participants. Eur Heart J Cardiovasc Imaging. 2022;23:1471-1481. doi: 10.1093/ehjci/jeac101 227. Thirunavukarasu S, Ansari F, Cubbon R, Forbes K, Bucciarelli-Ducci C, Newby DE, Dweck MR, Rider OJ, Valkovič L, Rodgers CT, et al. Maternal Cardiac Changes in Women With Obesity and Gestational Diabetes Mellitus. Diabetes Care. 2022;45:3007-3015. doi: 10.2337/dc22-0401 228. Pennell DJ, Sechtem UP, Higgins CB, Manning WJ, Pohost GM, Rademakers FE, van Rossum AC, Shaw LJ, Yucel EK. Clinical indications for cardiovascular magnetic resonance (CMR): Consensus Panel report. J Cardiovasc Magn Reson. 2004;6:727-765. 229. Wei L, Dong JX, Jin LX, He J, Zhao CX, Kong LC, An DA, Ding S, Yang F, Yang YN, et al. Peak early diastolic strain rate improves prediction of adverse cardiovascular outcomes in patients with ST-elevation myocardial infarction. Radiol Med. 2023;128:1372-1385. doi: 10.1007/s11547-023-01700-y 230. Nazir SA, Shetye AM, Khan JN, Singh A, Arnold JR, Squire I, McCann GP. Inter-study repeatability of circumferential strain and diastolic strain rate by CMR tagging, feature tracking and tissue tracking in ST-segment elevation myocardial infarction. Int J Cardiovasc Imaging. 2020;36:1133-1146. doi: 10.1007/s10554-020-01806-8 231. American Heart Association Writing Group on Myocardial S, Registration for Cardiac I, Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK, Pennell DJ, Rumberger JA, et al. Standardized Myocardial Segmentation and Nomenclature for Tomographic Imaging of the Heart. Circulation. 2002;105:539-542. doi: 10.1161/hc0402.102975 232. Xue H, Artico J, Fontana M, Moon JC, Davies RH, Kellman P. Landmark Detection in Cardiac MRI Using a Convolutional Neural Network. Radiology: Artificial Intelligence. 2021:e200197. doi: 10.1148/ryai.2021200197 233. Xue H, Artico J, Fontana M, Moon JC, Davies RH, Kellman P. Landmark Detection in Cardiac MRI by Using a Convolutional Neural Network. Radiol Artif Intell. 2021;3:e200197. doi: 10.1148/ryai.2021200197 234. Kellman Peter, Hernando D, Shah S, Liang Z-P, Bluemke DA, AE A. Rapid, multi-slice fat water separated imaging for mapping body fat. In: ISMRM. Stockholm, Sweden; 2010. 235. Kellman P, Hernanado, D., Shah, S.,Liang, Z-P., Bluemke, DA., Arai, AE. Rapid, multi‐slice fat water separated imaging for mapping body fat. In: Annual Meeting of the International Society for Magnetic Resonance Medicine. Stockholm; 2010. 236. Jerosch-Herold M, Sheridan DC, Kushner JD, Nauman D, Burgess D, Dutton D, Alharethi R, Li D, Hershberger RE. Cardiac magnetic resonance imaging of myocardial contrast uptake and blood flow in patients affected with idiopathic or familial dilated cardiomyopathy. Am J Physiol Heart Circ Physiol. 2008;295:H1234-h1242. doi: 10.1152/ajpheart.00429.2008 237. Park YJ, Park SJ, Kim EK, Park KM, Lee SC, On YK, Kim JS. Semi-quantitative versus quantitative assessments of late gadolinium enhancement extent for predicting spontaneous ventricular tachyarrhythmia events in patients with hypertrophic cardiomyopathy. Sci Rep. 2020;10:2920. doi: 10.1038/s41598-020-59804-8 238. Kellman P, Hansen MS, Nielles-Vallespin S, Nickander J, Themudo R, Ugander M, Xue H. Myocardial perfusion cardiovascular magnetic resonance: optimized dual sequence and reconstruction for quantification. Journal of Cardiovascular Magnetic Resonance. 2016;19:43. doi: https://doi.org/10.1186/s12968-017-0355-5 239. Kramer CM, Barkhausen J, Flamm SD, Kim RJ, Nagel E. Standardized cardiovascular magnetic resonance (CMR) protocols 2013 update. Journal of Cardiovascular Magnetic Resonance. 2013;15:91. doi: 10.1186/1532-429x-15-91 240. Chong C-R, Clarke K, Levelt E. Metabolic remodelling in diabetic cardiomyopathy. Cardiovascular Research. 2017;113:422-430. doi: 10.1093/cvr/cvx018 241. Hudsmith LE, Petersen SE, Tyler DJ, Francis JM, Cheng AS, Clarke K, Selvanayagam JB, Robson MD, Neubauer S. Determination of cardiac volumes and mass with FLASH and SSFP cine sequences at 1.5 vs. 3 Tesla: a validation study. J Magn Reson Imaging. 2006;24:312-318. doi: 10.1002/jmri.20638 242. Ferreira VM, Piechnik SK. CMR Parametric Mapping as a Tool for Myocardial Tissue Characterization. Korean Circ J. 2020;50:658-676. 243. Greenwood JP, Maredia N, Younger JF, Brown JM, Nixon J, Everett CC, Bijsterveld P, Ridgway JP, Radjenovic A, Dickinson CJ, et al. Cardiovascular magnetic resonance and single-photon emission computed tomography for diagnosis of coronary heart disease (CE-MARC): a prospective trial. Lancet. 2012;379:453-460. doi: 10.1016/s0140-6736(11)61335-4 244. Neumann F-J, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, Byrne RA, Collet J-P, Falk V, Head SJ, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. European Heart Journal. 2018;40:87-165. doi: 10.1093/eurheartj/ehy394 245. Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, Capodanno D, Conradi L, De Bonis M, De Paulis R, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease: Developed by the Task Force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal. 2022;43:561-632. doi: 10.1093/eurheartj/ehab395 246. Jex N, Greenwood JP, Cubbon RM, Rider OJ, Chowdhary A, Thirunavukarasu S, Kotha S, Giannoudi M, McGrane A, Maccannell A, et al. Association Between Type 2 Diabetes and Changes in Myocardial Structure, Contractile Function, Energetics, and Blood Flow Before and After Aortic Valve Replacement in Patients With Severe Aortic Stenosis. Circulation. 2023;148:1138-1153. doi: 10.1161/CIRCULATIONAHA.122.063444 247. Haywood NJ, Luk C, Bridge KI, Drozd M, Makava N, Skromna A, Maccannell A, Ozber CH, Warmke N, Wilkinson CG, et al. Endothelial IGF‐1 receptor mediates crosstalk with the gut wall to regulate microbiota in obesity. EMBO reports. 2021;22:e50767. doi: https://doi.org/10.15252/embr.202050767 248. Cinti S, Mitchell G, Barbatelli G, Murano I, Ceresi E, Faloia E, Wang S, Fortier M, Greenberg AS, Obin MS. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. Journal of Lipid Research. 2005;46:2347-2355. doi: 10.1194/jlr.M500294-JLR200 249. Nakamura K, Fuster JJ, Walsh K. Adipokines: A link between obesity and cardiovascular disease. Journal of Cardiology. 2014;63:250-259. doi: https://doi.org/10.1016/j.jjcc.2013.11.006 250. Johansson I, Dahlström U, Edner M, Näsman P, Rydén L, Norhammar A. Prognostic Implications of Type 2 Diabetes Mellitus in Ischemic and Nonischemic Heart Failure. Journal of the American College of Cardiology. 2016;68:1404-1416. doi: https://doi.org/10.1016/j.jacc.2016.06.061 251. Kotha S, Plein S, Greenwood JP, Levelt E. Role of epicardial adipose tissue in diabetic cardiomyopathy through the lens of cardiovascular magnetic resonance imaging - a narrative review. Ther Adv Endocrinol Metab. 2024;15:20420188241229540. doi: 10.1177/20420188241229540 252. Kristiansen OP, Mandrup-Poulsen T. Interleukin-6 and Diabetes: The Good, the Bad, or the Indifferent? Diabetes. 2005;54:S114-S124. doi: 10.2337/diabetes.54.suppl_2.S114 253. Chia YC, Kieneker LM, van Hassel G, Binnenmars SH, Nolte IM, van Zanden JJ, van der Meer P, Navis G, Voors AA, Bakker SJL, et al. Interleukin 6 and Development of Heart Failure With Preserved Ejection Fraction in the General Population. Journal of the American Heart Association. 2021;10:e018549. doi: 10.1161/JAHA.120.018549 254. Ridker PM. From RESCUE to ZEUS: will interleukin-6 inhibition with ziltivekimab prove effective for cardiovascular event reduction? Cardiovasc Res. 2021;117:e138-e140. doi: 10.1093/cvr/cvab231 255. Reilly MP, Iqbal N, Schutta M, Wolfe ML, Scally M, Localio AR, Rader DJ, Kimmel SE. Plasma Leptin Levels Are Associated with Coronary Atherosclerosis in Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism. 2004;89:3872-3878. doi: 10.1210/jc.2003-031676 256. Martin SS, Blaha MJ, Muse ED, Qasim AN, Reilly MP, Blumenthal RS, Nasir K, Criqui MH, McClelland RL, Hughes-Austin JM, Allison MA. Leptin and incident cardiovascular disease: the Multi-ethnic Study of Atherosclerosis (MESA). Atherosclerosis. 2015;239:67-72. doi: 10.1016/j.atherosclerosis.2014.12.033 257. Laurencikiene J, Skurk T, Kulyté A, Hedén P, Åström G, Sjölin E, Rydén M, Hauner H, Arner P. Regulation of Lipolysis in Small and Large Fat Cells of the Same Subject. The Journal of Clinical Endocrinology & Metabolism. 2011;96:E2045-E2049. doi: 10.1210/jc.2011-1702 258. Skurk T, Alberti-Huber C, Herder C, Hauner H. Relationship between Adipocyte Size and Adipokine Expression and Secretion. The Journal of Clinical Endocrinology & Metabolism. 2007;92:1023-1033. doi: 10.1210/jc.2006-1055 259. Ritterhoff J, Tian R. Metabolism in cardiomyopathy: every substrate matters. Cardiovasc Res. 2017;113:411-421. doi: 10.1093/cvr/cvx017 260. Burrage MK, Hundertmark M, Valkovic L, Watson WD, Rayner J, Sabharwal N, Ferreira VM, Neubauer S, Miller JJ, Rider OJ, Lewis AJM. Energetic Basis for Exercise-Induced Pulmonary Congestion in Heart Failure With Preserved Ejection Fraction. Circulation. 2021;144:1664-1678. doi: 10.1161/CIRCULATIONAHA.121.054858 261. Thornton GD, Vassiliou VS, Musa TA, Aziminia N, Craig N, Dattani A, Davies RH, Captur G, Moon JC, Dweck MR, et al. Myocardial Scar and Remodelling Predict Long-Term Mortality in Severe Aortic Stenosis Beyond 10 Years. European Heart Journal. 2024:ehae067. doi: 10.1093/eurheartj/ehae067 262. Halliday BP, Gulati A, Ali A, Guha K, Newsome S, Arzanauskaite M, Vassiliou VS, Lota A, Izgi C, Tayal U, et al. Association Between Midwall Late Gadolinium Enhancement and Sudden Cardiac Death in Patients With Dilated Cardiomyopathy and Mild and Moderate Left Ventricular Systolic Dysfunction. Circulation. 2017;135:2106-2115. doi: 10.1161/circulationaha.116.026910 263. Treibel TA, López B, González A, Menacho K, Schofield RS, Ravassa S, Fontana M, White SK, DiSalvo C, Roberts N, et al. Reappraising myocardial fibrosis in severe aortic stenosis: an invasive and non-invasive study in 133 patients. Eur Heart J. 2018;39:699-709. doi: 10.1093/eurheartj/ehx353 264. Zinman B, Wanner C, Lachin John M, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen Odd E, Woerle Hans J, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine.373:2117-2128. doi: 10.1056/NEJMoa1504720 265. Marso Steven P, Bain Stephen C, Consoli A, Eliaschewitz Freddy G, Jódar E, Leiter Lawrence A, Lingvay I, Rosenstock J, Seufert J, Warren Mark L, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine.375:1834-1844. doi: 10.1056/NEJMoa1607141 266. Chowdhary A, Thirunavukarasu S, Joseph T, Jex N, Kotha S, Giannoudi M, Procter H, Cash L, Akkaya S, Broadbent D, et al. Liraglutide Improves Myocardial Perfusion and Energetics and Exercise Tolerance in Patients With Type 2 Diabetes. Journal of the American College of Cardiology. 2024;84:540-557. doi: 10.1016/j.jacc.2024.04.064 267. Gregg EW, Sattar N, Ali MK. The changing face of diabetes complications. Lancet Diabetes Endocrinol. 2016;4:537-547. doi: 10.1016/s2213-8587(16)30010-9 268. Wong ND, Sattar N. Cardiovascular risk in diabetes mellitus: epidemiology, assessment and prevention. Nature Reviews Cardiology. 2023;20:685-695. doi: 10.1038/s41569-023-00877-z 269. Investigators TBARIB. Comparison of Coronary Bypass Surgery with Angioplasty in Patients with Multivessel Disease. New England Journal of Medicine. 1996;335:217-225. doi: 10.1056/nejm199607253350401 270. Farkouh ME, Domanski M, Sleeper LA, Siami FS, Dangas G, Mack M, Yang M, Cohen DJ, Rosenberg Y, Solomon SD, et al. Strategies for Multivessel Revascularization in Patients with Diabetes. New England Journal of Medicine. 2012;367:2375-2384. doi: doi:10.1056/NEJMoa1211585 271. Ramanathan K, Abel JG, Park JE, Fung A, Mathew V, Taylor CM, Mancini GBJ, Gao M, Ding L, Verma S, et al. Surgical Versus Percutaneous Coronary Revascularization in Patients With Diabetes and Acute Coronary Syndromes. Journal of the American College of Cardiology. 2017;70:2995-3006. doi: https://doi.org/10.1016/j.jacc.2017.10.029 272. Pezeshki PS, Masoudkabir F, Pashang M, Vasheghani-Farahani A, Jalali A, Sadeghian S, Hosseini K, Mansourian S, Momtahan S, Karimi A. 7-year outcomes in diabetic patients after coronary artery bypass graft in a developing country. BMC Cardiovascular Disorders. 2023;23. doi: 10.1186/s12872-023-03279-8 273. Rajakaruna C, Rogers CA, Suranimala C, Angelini GD, Ascione R. The effect of diabetes mellitus on patients undergoing coronary surgery: A risk-adjusted analysis. The Journal of Thoracic and Cardiovascular Surgery. 2006;132:802-810. doi: 10.1016/j.jtcvs.2006.05.056 274. Thourani VH, Weintraub WS, Stein B, Gebhart SSP, Craver JM, Jones EL, Guyton RA. Influence of diabetes mellitus on early and late outcome after coronary artery bypass grafting. The Annals of Thoracic Surgery. 1999;67:1045-1052. doi: 10.1016/s0003-4975(99)00143-5 275. Banning AP, Westaby S, Morice M-C, Kappetein AP, Mohr FW, Berti S, Glauber M, Kellett MA, Kramer RS, Leadley K, et al. Diabetic and Nondiabetic Patients With Left Main and/or 3-Vessel Coronary Artery Disease: Comparison of Outcomes With Cardiac Surgery and Paclitaxel-Eluting Stents. Journal of the American College of Cardiology. 2010;55:1067-1075. doi: https://doi.org/10.1016/j.jacc.2009.09.057 276. Krasivskyi I, Ivanov B, Msallati Z, Großmann C, Gerfer S, Mihaylova M, Eghbalzadeh K, Origel Romero C, Djordjevic I, Wahlers T, et al. Impact of diabetes on short-term outcomes in patients undergoing coronary artery bypass grafting surgery in acute coronary syndrome. Perfusion. 2024:02676591241253461. doi: 10.1177/02676591241253461 277. Seraphim A, Dowsing B, Rathod KS, Shiwani H, Patel K, Knott KD, Zaman S, Johns I, Razvi Y, Patel R, et al. Quantitative Myocardial Perfusion Predicts Outcomes in Patients With Prior Surgical Revascularization. J Am Coll Cardiol. 2022;79:1141-1151. doi: 10.1016/j.jacc.2021.12.037 278. Kinnel M, Sanguineti F, Pezel T, Unterseeh T, Hovasse T, Toupin S, Landon V, Champagne S, Morice MC, Garot P, et al. Prognostic value of vasodilator stress perfusion CMR in patients with previous coronary artery bypass graft. European Heart Journal - Cardiovascular Imaging. 2020;22:1264-1272. doi: 10.1093/ehjci/jeaa316 279. Lawton JS, Tamis-Holland JE, Bangalore S, Bates ER, Beckie TM, Bischoff JM, Bittl JA, Cohen MG, DiMaio JM, Don CW, et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145:e18-e114. doi: doi:10.1161/CIR.0000000000001038 280. Casanova C, Celli BR, Barria P, Casas A, Cote C, Torres JPd, Jardim J, Lopez MV, Marin JM, Oca MMd, et al. The 6-min walk distance in healthy subjects: reference standards from seven countries. European Respiratory Journal. 2011;37:150. doi: 10.1183/09031936.00194909 281. Serruys PW, Morice M-C, Kappetein AP, Colombo A, Holmes DR, Mack MJ, Ståhle E, Feldman TE, Brand Mvd, Bass EJ, et al. Percutaneous Coronary Intervention versus Coronary-Artery Bypass Grafting for Severe Coronary Artery Disease. New England Journal of Medicine. 2009;360:961-972. doi: doi:10.1056/NEJMoa0804626 282. Seraphim A, Knott KD, Beirne AM, Augusto JB, Menacho K, Artico J, Joy G, Hughes R, Bhuva AN, Torii R, et al. Use of quantitative cardiovascular magnetic resonance myocardial perfusion mapping for characterization of ischemia in patients with left internal mammary coronary artery bypass grafts. J Cardiovasc Magn Reson. 2021;23:82. doi: 10.1186/s12968-021-00763-y 283. Kogan A, Ram E, Levin S, Fisman EZ, Tenenbaum A, Raanani E, Sternik L. Impact of type 2 diabetes mellitus on short- and long-term mortality after coronary artery bypass surgery. Cardiovasc Diabetol. 2018;17:151. doi: 10.1186/s12933-018-0796-7 284. Koene RJ, Kealhofer JV, Adabag S, Vakil K, Florea VG. Effect of coronary artery bypass graft surgery on left ventricular systolic function. J Thorac Dis. 2017;9:262-270. doi: 10.21037/jtd.2017.02.09 285. Gozdzik A, Letachowicz K, Grajek BB, Plonek T, Obremska M, Jasinski M, Gozdzik W. Application of strain and other echocardiographic parameters in the evaluation of early and long-term clinical outcomes after cardiac surgery revascularization. BMC Cardiovasc Disord. 2019;19:189. doi: 10.1186/s12872-019-1162-8 286. Aggarwal R, Qi SS, So SW, Swingen C, Reyes CP, Rose R, Wright C, Hocum Stone LL, Nixon JP, McFalls EO, et al. Persistent diastolic dysfunction in chronically ischemic hearts following coronary artery bypass graft. J Thorac Cardiovasc Surg. 2023;165:e269-e279. doi: 10.1016/j.jtcvs.2022.08.010 287. Paterek A, Załęska-Kocięcka M, Wojdyńska Z, Kalisz M, Litwiniuk A, Leszek P, Mączewski M. Epicardial fat in heart failure—Friend, foe, or bystander. Obesity Reviews.n/a:e13820. doi: https://doi.org/10.1111/obr.13820 288. Nakamura M. Lipotoxicity as a therapeutic target in obesity and diabetic cardiomyopathy. J Pharm Pharm Sci. 2024;27:12568. doi: 10.3389/jpps.2024.12568 289. Christensen RH, Hansen CS, Scholten BJ, Jensen MT, Pedersen BK, Schnohr P, Vilsbøll T, Rossing P, Jørgensen PG. Epicardial and pericardial adipose tissues are associated with reduced diastolic and systolic function in type 2 diabetes. Diabetes, Obesity and Metabolism. 2019;21:2006-2011. doi: 10.1111/dom.13758 290. Neubauer S. The Failing Heart — An Engine Out of Fuel. New England Journal of Medicine.356:1140-1151. doi: 10.1056/NEJMra063052 291. Bedi KC, Snyder NW, Brandimarto J, Aziz M, Mesaros C, Worth AJ, Wang LL, Javaheri A, Blair IA, Margulies KB, Rame JE. Evidence for Intramyocardial Disruption of Lipid Metabolism and Increased Myocardial Ketone Utilization in Advanced Human Heart Failure. Circulation. 2016;133:706-716. doi: 10.1161/CIRCULATIONAHA.115.017545 292. Kramer CM, Barkhausen J, Bucciarelli-Ducci C, Flamm SD, Kim RJ, Nagel E. Standardized cardiovascular magnetic resonance imaging (CMR) protocols: 2020 update. Journal of Cardiovascular Magnetic Resonance. 2020;22:17. doi: 10.1186/s12968-020-00607-1 293. Kellman P, Hansen MS, Nielles-Vallespin S, Nickander J, Themudo R, Ugander M, Xue H. Myocardial perfusion cardiovascular magnetic resonance: optimized dual sequence and reconstruction for quantification. Journal of Cardiovascular Magnetic Resonance. 2017;19:43. doi: 10.1186/s12968-017-0355-5 294. Clarke K, Tchabanenko K, Pawlosky R, Carter E, Todd King M, Musa-Veloso K, Ho M, Roberts A, Robertson J, Vanitallie TB, Veech RL. Kinetics, safety and tolerability of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate in healthy adult subjects. Regul Toxicol Pharmacol. 2012;63:401-408. doi: 10.1016/j.yrtph.2012.04.008 295. Flood D, Brant LCC, Sussman JB. The triglyceride glucose index and cardiovascular disease outcomes. The Lancet Healthy Longevity. 2023;4:e2-e3. doi: 10.1016/s2666-7568(22)00269-0 296. Lopez-Jaramillo P, Gomez-Arbelaez D, Martinez-Bello D, Abat MEM, Alhabib KF, Avezum Á, Barbarash O, Chifamba J, Diaz ML, Gulec S, et al. Association of the triglyceride glucose index as a measure of insulin resistance with mortality and cardiovascular disease in populations from five continents (PURE study): a prospective cohort study. The Lancet Healthy Longevity. 2023;4:e23-e33. doi: 10.1016/S2666-7568(22)00247-1 297. Purvis LAB, Clarke WT, Biasiolli L, Valkovič L, Robson MD, Rodgers CT. OXSA: An open-source magnetic resonance spectroscopy analysis toolbox in MATLAB. PLOS ONE. 2017;12:e0185356. doi: 10.1371/journal.pone.0185356 298. Xue H, Artico J, Davies RH, Adam R, Shetye A, Augusto JB, Bhuva A, Fröjdh F, Wong TC, Fukui M, et al. Automated In-Line Artificial Intelligence Measured Global Longitudinal Shortening and Mitral Annular Plane Systolic Excursion: Reproducibility and Prognostic Significance. J Am Heart Assoc. 2022;11:e023849. doi: 10.1161/jaha.121.023849 299. Mogensen M, Sahlin K, Fernström M, Glintborg D, Vind BF, Beck-Nielsen H, Højlund K. Mitochondrial Respiration Is Decreased in Skeletal Muscle of Patients With Type 2 Diabetes. Diabetes. 2007;56:1592. 300. Mazumder PK, O’Neill BT, Roberts MW, Buchanan J, Yun UJ, Cooksey RC, Boudina S, Abel ED. Impaired Cardiac Efficiency and Increased Fatty Acid Oxidation in Insulin-Resistant ob/ob Mouse Hearts. Diabetes. 2004;53:2366-2374. 301. Nielsen R, Møller N, Gormsen LC, Tolbod LP, Hansson NH, Sorensen J, Harms HJ, Frøkiær J, Eiskjaer H, Jespersen NR, et al. Cardiovascular Effects of Treatment With the Ketone Body 3-Hydroxybutyrate in Chronic Heart Failure Patients. Circulation. 2019;139:2129-2141. doi: doi:10.1161/CIRCULATIONAHA.118.036459 302. Berg-Hansen K, Gopalasingam N, Christensen KH, Ladefoged B, Andersen MJ, Poulsen SH, Borlaug BA, Nielsen R, Møller N, Wiggers H. Cardiovascular Effects of Oral Ketone Ester Treatment in Patients With Heart Failure With Reduced Ejection Fraction: A Randomized, Controlled, Double-Blind Trial. Circulation. 2024;149:1474-1489. doi: 10.1161/circulationaha.123.067971 303. Cameron D, Soto-Mota A, Willis DR, Ellis J, Procter NEK, Greenwood R, Saunders N, Schulte RF, Vassiliou VS, Tyler DJ, et al. Evaluation of Acute Supplementation With the Ketone Ester (R)-3-Hydroxybutyl-(R)-3-Hydroxybutyrate (deltaG) in Healthy Volunteers by Cardiac and Skeletal Muscle (31)P Magnetic Resonance Spectroscopy. Front Physiol. 2022;13:793987. doi: 10.3389/fphys.2022.793987 304. Oneglia AP, Young BE, Cipher DJ, Zaha V, Nelson MD. Acute effects of β-hydroxybutyrate on left ventricular function in young, healthy adults. Journal of Applied Physiology. 2023;135:1440-1445. doi: 10.1152/japplphysiol.00630.2023 305. Selvaraj S, Hu R, Vidula MK, Dugyala S, Tierney A, Ky B, Margulies KB, Shah SH, Kelly DP, Bravo PE. Acute Echocardiographic Effects of Exogenous Ketone Administration in Healthy Participants. Journal of the American Society of Echocardiography. 2022;35:305-311. doi: https://doi.org/10.1016/j.echo.2021.10.017 306. Gormsen LC, Svart M, Thomsen HH, Søndergaard E, Vendelbo MH, Christensen N, Tolbod LP, Harms HJ, Nielsen R, Wiggers H, et al. Ketone Body Infusion With 3-Hydroxybutyrate Reduces Myocardial Glucose Uptake and Increases Blood Flow in Humans: A Positron Emission Tomography Study. J Am Heart Assoc. 2017;6. doi: 10.1161/jaha.116.005066 307. Homilius C, Seefeldt JM, Axelsen JS, Pedersen TM, Sørensen TM, Nielsen R, Wiggers H, Hansen J, Matchkov VV, Bøtker HE, Boedtkjer E. Ketone body 3-hydroxybutyrate elevates cardiac output through peripheral vasorelaxation and enhanced cardiac contractility. Basic Research in Cardiology. 2023;118:37. doi: 10.1007/s00395-023-01008-y 308. Neudorf H, Little JP. Impact of fasting & ketogenic interventions on the NLRP3 inflammasome: A narrative review. Biomed J. 2024;47:100677. doi: 10.1016/j.bj.2023.100677 309. Falkenhain K, Daraei A, Forbes SC, Little JP. Effects of Exogenous Ketone Supplementation on Blood Glucose: A Systematic Review and Meta-analysis. Adv Nutr. 2022;13:1697-1714. doi: 10.1093/advances/nmac036 310. Falkenhain K, Oliveira BF, Islam H, Neudorf H, Cen HH, Johnson JD, Madden K, Singer J, Walsh JJ, Little JP. The effect of acute and 14-day exogenous ketone supplementation on glycemic control in adults with type 2 diabetes: two randomized controlled trials. American Journal of Physiology-Endocrinology and Metabolism. 2024;326:E61-E72. doi: 10.1152/ajpendo.00332.2023 311. Monteyne AJ, Falkenhain K, Whelehan G, Neudorf H, Abdelrahman DR, Murton AJ, Wall BT, Stephens FB, Little JP. A ketone monoester drink reduces postprandial blood glucose concentrations in adults with type 2 diabetes: a randomised controlled trial. Diabetologia. 2024;67:1107-1113. doi: 10.1007/s00125-024-06122-7 312. Tahara A, Kurosaki E, Yokono M, Yamajuku D, Kihara R, Hayashizaki Y, Takasu T, Imamura M, Li Q, Tomiyama H, et al. Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats. J Pharm Pharmacol. 2014;66:975-987. doi: 10.1111/jphp.12223 313. Iacobellis G, Bianco AC. Epicardial adipose tissue: emerging physiological, pathophysiological and clinical features. Trends Endocrinol Metab. 2011;22:450-457. doi: 10.1016/j.tem.2011.07.003 314. Malavazos AE, Di Leo G, Secchi F, Lupo EN, Dogliotti G, Coman C, Morricone L, Corsi MM, Sardanelli F, Iacobellis G. Relation of Echocardiographic Epicardial Fat Thickness and Myocardial Fat. American Journal of Cardiology. 2010;105:1831-1835. doi: 10.1016/j.amjcard.2010.01.368 315. Kankaanpää M, Lehto H-R, Pärkkä JP, Komu M, Viljanen A, Ferrannini E, Knuuti J, Nuutila P, Parkkola R, Iozzo P. Myocardial Triglyceride Content and Epicardial Fat Mass in Human Obesity: Relationship to Left Ventricular Function and Serum Free Fatty Acid Levels. The Journal of Clinical Endocrinology & Metabolism. 2006;91:4689-4695. doi: 10.1210/jc.2006-0584 316. Sacks HS, Fain JN. Human epicardial adipose tissue: A review. American Heart Journal. 2007;153:907-917. doi: https://doi.org/10.1016/j.ahj.2007.03.019 317. Ding B, Peterzan M, Mózes FE, Rider OJ, Valkovič L, Rodgers CT. Water-suppression cycling 3-T cardiac (1) H-MRS detects altered creatine and choline in patients with aortic or mitral stenosis. NMR Biomed. 2021;34:e4513. doi: 10.1002/nbm.4513 318. Sharma S, Adrogue JV, Golfman L, Uray I, Lemm J, Youker K, Noon GP, Frazier OH, Taegtmeyer H. Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. Faseb j. 2004;18:1692-1700. doi: 10.1096/fj.04-2263com 319. Ugurbil K, Petein M, Maidan R, Michurski S, Cohn JN, From AH. High resolution proton NMR studies of perfused rat hearts. FEBS Letters. 1984;167:73-78. doi: https://doi.org/10.1016/0014-5793(84)80835-2 320. Faller KME, Lygate CA, Neubauer S, Schneider JE. 1H-MR spectroscopy for analysis of cardiac lipid and creatine metabolism. Heart Failure Reviews. 2013;18:657-668. doi: 10.1007/s10741-012-9341-z 321. Esmaeili M, Vettukattil R. In Vivo Magnetic Resonance Spectroscopy Methods for Investigating Cardiac Metabolism. Metabolites. 2022;12. doi: 10.3390/metabo12020189 322. de Heer P, Bizino MB, Lamb HJ, Webb AG. Parameter optimization for reproducible cardiac 1H-MR spectroscopy at 3 Tesla. Journal of Magnetic Resonance Imaging. 2016;44:1151-1158. doi: https://doi.org/10.1002/jmri.25254 323. Rial B, Robson MD, Neubauer S, Schneider JE. Rapid quantification of myocardial lipid content in humans using single breath-hold 1H MRS at 3 Tesla. Magn Reson Med. 2011;66:619-624. doi: 10.1002/mrm.23011 324. Bakermans AJ, Boekholdt SM, de Vries DK, Reckman YJ, Farag ES, de Heer P, Uthman L, Denis SW, Zuurbier CJ, Houtkooper RH, et al. Quantification of Myocardial Creatine and Triglyceride Content in the Human Heart: Precision and Accuracy of in vivo Proton Magnetic Resonance Spectroscopy. J Magn Reson Imaging. 2021;54:411-420. doi: 10.1002/jmri.27531 325. Ith M, Stettler C, Xu J, Boesch C, Kreis R. Cardiac lipid levels show diurnal changes and long-term variations in healthy human subjects. NMR in Biomedicine. 2014;27:1285-1292. doi: https://doi.org/10.1002/nbm.3186 326. Weiss K, Summermatter S, Stoeck CT, Kozerke S. Compensation of signal loss due to cardiac motion in point-resolved spectroscopy of the heart. Magn Reson Med. 2014;72:1201-1207. doi: 10.1002/mrm.25028 327. Gastl M, Peereboom SM, Fuetterer M, Boenner F, Kelm M, Manka R, Kozerke S. Retrospective phase-based gating for cardiac proton spectroscopy with fixed scan time. Journal of Magnetic Resonance Imaging. 2019;50:1973-1981. doi: https://doi.org/10.1002/jmri.26802 328. Gastl M, Peereboom SM, Fuetterer M, Boenner F, Kelm M, Manka R, Kozerke S. Cardiac- versus diaphragm-based respiratory navigation for proton spectroscopy of the heart. Magma. 2019;32:259-268. doi: 10.1007/s10334-018-0711-y 329. Lopaschuk GD, Karwi QG, Tian R, Wende AR, Abel ED. Cardiac Energy Metabolism in Heart Failure. Circulation Research. 2021;128:1487-1513. doi: 10.1161/circresaha.121.318241 330. Zlobine I, Gopal K, Ussher JR. Lipotoxicity in obesity and diabetes-related cardiac dysfunction. Biochim Biophys Acta. 2016;1861:1555-1568. doi: 10.1016/j.bbalip.2016.02.011 331. Rijzewijk LJ, van der Meer RW, Lamb HJ, de Jong HWAM, Lubberink M, Romijn JA, Bax JJ, de Roos A, Twisk JW, Heine RJ, et al. Altered Myocardial Substrate Metabolism and Decreased Diastolic Function in Nonischemic Human Diabetic Cardiomyopathy: Studies With Cardiac Positron Emission Tomography and Magnetic Resonance Imaging. Journal of the American College of Cardiology. 2009;54:1524-1532. doi: https://doi.org/10.1016/j.jacc.2009.04.074 332. Buchanan J, Mazumder PK, Hu P, Chakrabarti G, Roberts MW, Yun UJ, Cooksey RC, Litwin SE, Abel ED. Reduced Cardiac Efficiency and Altered Substrate Metabolism Precedes the Onset of Hyperglycemia and Contractile Dysfunction in Two Mouse Models of Insulin Resistance and Obesity. Endocrinology. 2005;146:5341-5349. doi: 10.1210/en.2005-0938 333. Stanley WC, Recchia FA, Lopaschuk GD. Myocardial Substrate Metabolism in the Normal and Failing Heart. Physiological Reviews. 2005;85:1093-1129. doi: 10.1152/physrev.00006.2004 334. Unger RH. Lipotoxicity in the Pathogenesis of Obesity-Dependent NIDDM: Genetic and Clinical Implications. Diabetes. 1995;44:863-870. doi: 10.2337/diab.44.8.863 335. van de Weijer T, Schrauwen-Hinderling VB, Schrauwen P. Lipotoxicity in type 2 diabetic cardiomyopathy. Cardiovasc Res. 2011;92:10-18. doi: 10.1093/cvr/cvr212 336. Rijzewijk LJ, van der Meer RW, Smit JW, Diamant M, Bax JJ, Hammer S, Romijn JA, de Roos A, Lamb HJ. Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. J Am Coll Cardiol. 2008;52:1793-1799. doi: 10.1016/j.jacc.2008.07.062 337. Saddik M, Lopaschuk GD. Triacylglycerol turnover in isolated working hearts of acutely diabetic rats. Canadian Journal of Physiology and Pharmacology. 1994;72:1110-1119. doi: 10.1139/y94-157 %M 7882174 338. Chang KF, Lin G, Huang PC, Juan YH, Wang CH, Tsai SY, Lin YC, Wu MT, Liao PA, Yang LY, et al. Left Ventricular Function and Myocardial Triglyceride Content on 3T Cardiac MR Predict Major Cardiovascular Adverse Events and Readmission in Patients Hospitalized with Acute Heart Failure. J Clin Med. 2020;9. doi: 10.3390/jcm9010169 339. Wende AR, Abel ED. Lipotoxicity in the heart. Biochim Biophys Acta. 2010;1801:311-319. doi: 10.1016/j.bbalip.2009.09.023 340. Nakae I, Mitsunami K, Yoshino T, Omura T, Tsutamoto T, Matsumoto T, Morikawa S, Inubushi T, Horie M. Clinical features of myocardial triglyceride in different types of cardiomyopathy assessed by proton magnetic resonance spectroscopy: comparison with myocardial creatine. J Card Fail. 2010;16:812-822. doi: 10.1016/j.cardfail.2010.05.006 341. Hannukainen JC, Lautamäki R, Mari A, Pärkkä JP, Bucci M, Guzzardi MA, Kajander S, Tuokkola T, Knuuti J, Iozzo P. Elevated Glucose Oxidation, Reduced Insulin Secretion, and a Fatty Heart May Be Protective Adaptions in Ischemic CAD. J Clin Endocrinol Metab. 2016;101:2701-2710. doi: 10.1210/jc.2015-4091 342. Mahmod M, Bull S, Suttie JJ, Pal N, Holloway C, Dass S, Myerson SG, Schneider JE, De Silva R, Petrou M, et al. Myocardial Steatosis and Left Ventricular Contractile Dysfunction in Patients With Severe Aortic Stenosis. Circulation: Cardiovascular Imaging. 2013;6:808-816. doi: 10.1161/CIRCIMAGING.113.000559 343. Sharma S, Adrogue JV, Golfman L, Uray I, Lemm J, Youker K, Noon GP, Frazier OH, Taegtmeyer H. Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. The FASEB Journal. 2004;18:1692-1700. doi: https://doi.org/10.1096/fj.04-2263com 344. O'Donnell JM, Fields AD, Sorokina N, Lewandowski ED. The absence of endogenous lipid oxidation in early stage heart failure exposes limits in lipid storage and turnover. Journal of Molecular and Cellular Cardiology. 2008;44:315-322. doi: https://doi.org/10.1016/j.yjmcc.2007.11.006 345. Nakae I, Mitsunami K, Yoshino T, Omura T, Tsutamoto T, Matsumoto T, Morikawa S, Inubushi T, Horie M. Clinical Features of Myocardial Triglyceride in Different Types of Cardiomyopathy Assessed by Proton Magnetic Resonance Spectroscopy: Comparison With Myocardial Creatine. Journal of Cardiac Failure. 2010;16:812-822. doi: https://doi.org/10.1016/j.cardfail.2010.05.006 346. Iacobellis G, Barbaro G. Epicardial adipose tissue feeding and overfeeding the heart. Nutrition. 2019;59:1-6. doi: https://doi.org/10.1016/j.nut.2018.07.002"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]},{"key":"dc:type.qualificationlevel","label":"Dc Type Qualificationlevel","values":["doctoral"]},{"key":"dc:type.qualificationname","label":"Dc Type Qualificationname","values":["Ph.D"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.dcterms_iso639_2","label":"Language (ISO 639-2)","values":["eng"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://etheses.whiterose.ac.uk/id/eprint/36645/1/S%20Kotha%20thesis%20updated%20with%20corrections.pdf"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:format","label":"Dc Format","values":["text"]},{"key":"dcterms:accessrights","label":"Dcterms Accessrights","values":["public"]},{"key":"dc:title","label":"Title","values":["Epicardial adipose tissue remodelling in type 2 diabetes and the potential therapeutic role of ketosis in diabetic heart disease"]}]}],"canonical_facts":{"dc:contributor.advisor":["Levelt, Eylem","Greenwood, John P","Plein, Sven"],"dc:creator":["Kotha, Sindhoora"],"dc:date":["2024-10"],"dc:date.issued":["2024-10"],"dc:format":["text"],"dc:identifier.uri":["https://etheses.whiterose.ac.uk/id/eprint/36645/1/S%20Kotha%20thesis%20updated%20with%20corrections.pdf"],"dc:language.dcterms_iso639_2":["eng"],"dc:publisher.department":["School of Medicine (Leeds)"],"dc:publisher.institution":["University of Leeds"],"dc:relation.isreferencedby":["https://etheses.whiterose.ac.uk/id/eprint/36645/"],"dc:relation.references":["1. Levelt E, Rodgers CT, Clarke WT, Mahmod M, Ariga R, Francis JM, Liu A, Wijesurendra RS, Dass S, Sabharwal N, et al. Cardiac energetics, oxygenation, and perfusion during increased workload in patients with type 2 diabetes mellitus. Eur Heart J. 2016;37:3461-3469. doi: 10.1093/eurheartj/ehv442 2. Lopaschuk GD, Karwi QG, Tian R, Wende AR, Abel ED. Cardiac Energy Metabolism in Heart Failure. Circ Res. 2021;128:1487-1513. doi: 10.1161/circresaha.121.318241 3. Nowakowska M, Zghebi SS, Ashcroft DM, Buchan I, Chew-Graham C, Holt T, Mallen C, Van Marwijk H, Peek N, Perera-Salazar R, et al. The comorbidity burden of type 2 diabetes mellitus: patterns, clusters and predictions from a large English primary care cohort. BMC Med. 2019;17:145. doi: 10.1186/s12916-019-1373-y 4. Whicher CA, O’Neill S, Holt RIG. Diabetes in the UK: 2019. Diabetic Medicine. 2020;37:242-247. doi: 10.1111/dme.14225 5. Nichols GA, Gullion CM, Koro CE, Ephross SA, Brown JB. The Incidence of Congestive Heart Failure in Type 2 Diabetes. An update. 2004;27:1879-1884. doi: 10.2337/diacare.27.8.1879 6. Maack C, Lehrke M, Backs J, Heinzel FR, Hulot J-S, Marx N, Paulus WJ, Rossignol P, Taegtmeyer H, Bauersachs J, et al. Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association–European Society of Cardiology. European Heart Journal. 2018;39:4243-4254. doi: 10.1093/eurheartj/ehy596 7. Jia G, Hill MA, Sowers JR. Diabetic Cardiomyopathy: An Update of Mechanisms Contributing to This Clinical Entity. Circ Res. 2018;122:624-638. doi: 10.1161/circresaha.117.311586 8. Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, Grishman A. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol. 1972;30:595-602. doi: 10.1016/0002-9149(72)90595-4 9. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol. 1974;34:29-34. doi: 10.1016/0002-9149(74)90089-7 10. Norhammar A, Bodegard J, Nystrom T, Thuresson M, Eriksson JW, Nathanson D. Incidence, prevalence and mortality of type 2 diabetes requiring glucose-lowering treatment, and associated risks of cardiovascular complications: a nationwide study in Sweden, 2006-2013. Diabetologia. 2016;59:1692-1701. doi: 10.1007/s00125-016-3971-y 11. Rawshani A, Rawshani A, Franzén S, Eliasson B, Svensson A-M, Miftaraj M, McGuire DK, Sattar N, Rosengren A, Gudbjörnsdottir S. Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes. New England Journal of Medicine. 2017;376:1407-1418. doi: 10.1056/NEJMoa1608664 12. Hippisley-Cox J, Coupland C. Diabetes treatments and risk of heart failure, cardiovascular disease, and all cause mortality: cohort study in primary care. BMJ. 2016;354. doi: 10.1136/bmj.i3477 13. Jia G, DeMarco VG, Sowers JR. Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy. Nat Rev Endocrinol. 2016;12:144-153. doi: 10.1038/nrendo.2015.216 14. Zarich SW, Arbuckle BE, Cohen LR, Roberts M, Nesto RW. Diastolic abnormalities in young asymptomatic diabetic patients assessed by pulsed Doppler echocardiography. J Am Coll Cardiol. 1988;12:114-120. doi: 10.1016/0735-1097(88)90364-6 15. Levelt E, Mahmod M, Piechnik SK, Ariga R, Francis JM, Rodgers CT, Clarke WT, Sabharwal N, Schneider JE, Karamitsos TD, et al. Relationship Between Left Ventricular Structural and Metabolic Remodeling in Type 2 Diabetes. Diabetes. 2016;65:44-52. doi: 10.2337/db15-0627 16. Galderisi M, Anderson KM, Wilson PW, Levy D. Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (the Framingham Heart Study). Am J Cardiol. 1991;68:85-89. doi: 10.1016/0002-9149(91)90716-x 17. de Simone G, Devereux RB, Roman MJ, Ganau A, Saba PS, Alderman MH, Laragh JH. Assessment of left ventricular function by the midwall fractional shortening/end-systolic stress relation in human hypertension. J Am Coll Cardiol. 1994;23:1444-1451. doi: 10.1016/0735-1097(94)90390-5 18. Negishi K. Echocardiographic feature of diabetic cardiomyopathy: where are we now? Cardiovasc Diagn Ther. 2018;8:47-56. doi: 10.21037/cdt.2018.01.03 19. Levelt E, Mahmod M, Piechnik SK, Ariga R, Francis JM, Rodgers CT, Clarke WT, Sabharwal N, Schneider JE, Karamitsos TD, et al. Relationship Between Left Ventricular Structural and Metabolic Remodeling in Type 2 Diabetes. Diabetes. 2015;65:44-52. doi: 10.2337/db15-0627 20. Ernande L, Bergerot C, Rietzschel ER, De Buyzere ML, Thibault H, PignonBlanc PG, Croisille P, Ovize M, Groisne L, Moulin P, et al. Diastolic Dysfunction in Patients with Type 2 Diabetes Mellitus: Is It Really the First Marker of Diabetic Cardiomyopathy? Journal of the American Society of Echocardiography. 2011;24:1268-1275.e1261. doi: https://doi.org/10.1016/j.echo.2011.07.017 21. Taegtmeyer H, McNulty P, Young ME. Adaptation and maladaptation of the heart in diabetes: Part I: general concepts. Circulation. 2002;105:1727-1733. doi: 10.1161/01.cir.0000012466.50373.e8 22. Scheuermann-Freestone M, Madsen PL, Manners D, Blamire AM, Buckingham RE, Styles P, Radda GK, Neubauer S, Clarke K. Abnormal cardiac and skeletal muscle energy metabolism in patients with type 2 diabetes. Circulation. 2003;107:3040-3046. doi: 10.1161/01.Cir.0000072789.89096.10 23. McGavock JM, Lingvay I, Zib I, Tillery T, Salas N, Unger R, Levine BD, Raskin P, Victor RG, Szczepaniak LS. Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study. Circulation. 2007;116:1170-1175. doi: 10.1161/CIRCULATIONAHA.106.645614 24. Chowdhary A, Javed W, Thirunavukarasu S, Jex N, Kotha S, Kellman P, Swoboda P, Greenwood JP, Plein S, Levelt E. Cardiac Adaptations to Acute Hemodynamic Stress in Function, Perfusion, and Energetics in Type 2 Diabetes With Overweight and Obesity. Diabetes Care. 2022;45:e176-e178. doi: 10.2337/dc22-0887 25. Thirunavukarasu S, Jex N, Chowdhary A, Hassan IU, Straw S, Craven TP, Gorecka M, Broadbent D, Swoboda P, Witte KK, et al. Empagliflozin Treatment Is Associated With Improvements in Cardiac Energetics and Function and Reductions in Myocardial Cellular Volume in Patients With Type 2 Diabetes. Diabetes. 2021;70:2810-2822. doi: 10.2337/db21-0270 26. Young ME, McNulty P, Taegtmeyer H. Adaptation and Maladaptation of the Heart in Diabetes: Part II. Circulation. 2002;105:1861-1870. doi: 10.1161/01.cir.0000012467.61045.87 27. Poornima IG, Parikh P, Shannon RP. Diabetic Cardiomyopathy. Circulation Research. 2006;98:596-605. doi: 10.1161/01.res.0000207406.94146.c2 28. Dhalla NS, Liu X, Panagia V, Takeda N. Subcellular remodeling and heart dysfunction in chronic diabetes. 1998. 29. Hardin NJ. The myocardial and vascular pathology of diabetic cardiomyopathy. Coronary Artery Disease. 1996;7:99-108. 30. McGarry JD, Brown NF. The Mitochondrial Carnitine Palmitoyltransferase System — From Concept to Molecular Analysis. European Journal of Biochemistry. 1997;244:1-14. doi: 10.1111/j.1432-1033.1997.00001.x 31. Finck BN, Lehman JJ, Leone TC, Welch MJ, Bennett MJ, Kovacs A, Han X, Gross RW, Kozak R, Lopaschuk GD, Kelly DP. The cardiac phenotype induced by PPARα overexpression mimics that caused by diabetes mellitus. J Clin Invest. 2002;109:121-130. doi: 10.1172/jci0214080 32. Gulick T, Cresci S, Caira T, Moore DD, Kelly DP. The peroxisome proliferator-activated receptor regulates mitochondrial fatty acid oxidative enzyme gene expression. Proc Natl Acad Sci U S A. 1994;91:11012-11016. doi: 10.1073/pnas.91.23.11012 33. Mather KJ, Hutchins GD, Perry K, Territo W, Chisholm R, Acton A, Glick-Wilson B, Considine RV, Moberly S, DeGrado TR. Assessment of myocardial metabolic flexibility and work efficiency in human type 2 diabetes using 16-[<sup>18</sup>F]fluoro-4-thiapalmitate, a novel PET fatty acid tracer. American Journal of Physiology - Endocrinology And Metabolism. 2016;310:E452. 34. Peterson LR, Herrero P, Schechtman KB, Racette SB, Waggoner AD, Kisrieva-Ware Z, Dence C, Klein S, Marsala J, Meyer T, Gropler RJ. Effect of Obesity and Insulin Resistance on Myocardial Substrate Metabolism and Efficiency in Young Women. Circulation. 2004;109:2191. 35. Taegtmeyer H, McNulty P, Young ME. Adaptation and Maladaptation of the Heart in Diabetes: Part I: General Concepts. Circulation. 2002;105:1727-1733. doi: 10.1161/01.cir.0000012466.50373.e8 36. Park T-S, Yamashita H, Blaner WS, Goldberg IJ. Lipids in the heart: a source of fuel and a source of toxins. Current Opinion in Lipidology. 2007;18:277-282. doi: 10.1097/MOL.0b013e32814a57db 37. Finck BN, Han X, Courtois M, Aimond F, Nerbonne JM, Kovacs A, Gross RW, Kelly DP. A critical role for PPARα-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: Modulation by dietary fat content. Proceedings of the National Academy of Sciences. 2003;100:1226-1231. doi: 10.1073/pnas.0336724100 38. Unger RH. The Physiology of Cellular Liporegulation. Annual Review of Physiology. 2003;65:333-347. doi: 10.1146/annurev.physiol.65.092101.142622 39. Unger RH. Lipotoxic Diseases. Annual Review of Medicine. 2002;53:319-336. doi: 10.1146/annurev.med.53.082901.104057 40. Finck BN, Lehman JJ, Leone TC, Welch MJ, Bennett MJ, Kovacs A, Han X, Gross RW, Kozak R, Lopaschuk GD, Kelly DP. The cardiac phenotype induced by PPARα overexpression mimics that caused by diabetes mellitus. The Journal of Clinical Investigation. 2002;109:121-130. doi: 10.1172/JCI14080 41. Chiu H-C, Kovacs A, Ford DA, Hsu F-F, Garcia R, Herrero P, Saffitz JE, Schaffer JE. A novel mouse model of lipotoxic cardiomyopathy. The Journal of Clinical Investigation. 2001;107:813-822. doi: 10.1172/JCI10947 42. Bielawska AE, Shapiro JP, Jiang L, Melkonyan HS, Piot C, Wolfe CL, Tomei LD, Hannun YA, Umansky SR. Ceramide is involved in triggering of cardiomyocyte apoptosis induced by ischemia and reperfusion. The American Journal of Pathology. 1997;151:1257-1263. 43. Poornima IG, Parikh P, Shannon RP. Diabetic cardiomyopathy: the search for a unifying hypothesis. Circulation research. 2006;98:596-605. doi: 10.1161/01.RES.0000207406.94146.c2 44. Murthy VK, Shipp JC. Accumulation of Myocardial Triglycerides in Ketotic Diabetes: Evidence for Increased Biosynthesis. Diabetes. 1977;26:222-229. 45. Paulson DJ, Crass MF. Endogenous triacylglycerol metabolism in diabetic heart. American Journal of Physiology - Heart and Circulatory Physiology. 1982;242:H1084-H1094. 46. Glenn DJ, Cardema MC, Ni W, Zhang Y, Yeghiazarians Y, Grapov D, Fiehn O, Gardner DG. Cardiac steatosis potentiates angiotensin II effects in the heart. American Journal of Physiology - Heart and Circulatory Physiology. 2015;308:H339-H350. 47. Levelt E, Mahmod M, Piechnik SK, Ariga R, Francis JM, Rodgers CT, Clarke WT, Sabharwal N, Schneider JE, Karamitsos TD, et al. Relationship between Left Ventricular Structural and Metabolic Remodelling in Type 2 Diabetes Mellitus. Diabetes. 2015. doi: 10.2337/db15-0627 48. Ritchie RH, Abel ED. Basic Mechanisms of Diabetic Heart Disease. Circ Res. 2020;126:1501-1525. doi: 10.1161/circresaha.120.315913 49. Neubauer S, Horn M, Cramer M, Harre K, Newell JB, Peters W, Pabst T, Ertl G, Hahn D, Ingwall JS, Kochsiek K. Myocardial Phosphocreatine-to-ATP Ratio Is a Predictor of Mortality in Patients With Dilated Cardiomyopathy. Circulation. 1997;96:2190-2196. doi: 10.1161/01.CIR.96.7.2190 50. Bluemke DA, Kronmal RA, Lima JAC, Liu K, Olson J, Burke GL, Folsom AR. The Relationship of Left Ventricular Mass and Geometry to Incident Cardiovascular Events: The MESA Study. Journal of the American College of Cardiology. 2008;52:2148-2155. doi: 10.1016/j.jacc.2008.09.014 51. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic Implications of Echocardiographically Determined Left Ventricular Mass in the Framingham Heart Study. New England Journal of Medicine. 1990;322:1561-1566. doi: 10.1056/NEJM199005313222203 52. Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovascular Diabetology. 2018;17. doi: 10.1186/s12933-018-0728-6 53. Sethi SS, Akl EG, Farkouh ME. Diabetes Mellitus and Acute Coronary Syndrome: Lessons From Randomized Clinical Trials. Current Diabetes Reports. 2012;12:294-304. doi: 10.1007/s11892-012-0272-9 54. Cavender MA, Steg PG, Smith SC, Eagle K, Ohman EM, Goto S, Kuder J, Im K, Wilson PWF, Bhatt DL. Impact of Diabetes Mellitus on Hospitalization for Heart Failure, Cardiovascular Events, and Death. Circulation. 2015;132:923-931. doi: 10.1161/circulationaha.114.014796 55. Søren Christensen Kjærgaard H-H. In-hospital Outcome for Diabetic Patients with Acute Myocardial Infarction in the Thrombolytic Era. Scandinavian Cardiovascular Journal. 1999;33:166-170. doi: 10.1080/14017439950141803 56. Malmberg K, Yusuf S, Gerstein HC, Brown J, Zhao F, Hunt D, Piegas L, Calvin J, Keltai M, Budaj A, Investigators FTOR. Impact of Diabetes on Long-Term Prognosis in Patients With Unstable Angina and Non–Q-Wave Myocardial Infarction. Circulation. 2000;102:1014-1019. doi: 10.1161/01.cir.102.9.1014 57. Newman JD, Anthopolos R, Mancini GBJ, Bangalore S, Reynolds HR, Kunichoff DF, Senior R, Peteiro J, Bhargava B, Garg P, et al. Outcomes of Participants With Diabetes in the ISCHEMIA Trials. Circulation. 2021;144:1380-1395. doi: 10.1161/circulationaha.121.054439 58. Martín-Timón I, Sevillano-Collantes C, Segura-Galindo A, Del Cañizo-Gómez FJ. Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength? World J Diabetes. 2014;5:444-470. doi: 10.4239/wjd.v5.i4.444 59. Kolwicz SC, Jr., Purohit S, Tian R. Cardiac metabolism and its interactions with contraction, growth, and survival of cardiomyocytes. Circ Res. 2013;113:603-616. doi: 10.1161/circresaha.113.302095 60. Shivu GN, Phan TT, Abozguia K, Ahmed I, Wagenmakers A, Henning A, Narendran P, Stevens M, Frenneaux M. Relationship Between Coronary Microvascular Dysfunction and Cardiac Energetics Impairment in Type 1 Diabetes Mellitus. Circulation. 2010;121:1209-1215. doi: 10.1161/circulationaha.109.873273 61. Scheuermann-Freestone M, Madsen PL, Manners D, Blamire AM, Buckingham RE, Styles P, Radda GK, Neubauer S, Clarke K. Abnormal Cardiac and Skeletal Muscle Energy Metabolism in Patients With Type 2 Diabetes. Circulation. 2003;107:3040-3046. doi: 10.1161/01.cir.0000072789.89096.10 62. Crilley JG, Boehm EA, Blair E, Rajagopalan B, Blamire AM, Styles P, McKenna WJ, Ostman-Smith I, Clarke K, Watkins H. Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy. J Am Coll Cardiol. 2003;41:1776-1782. doi: S0735109702030097 [pii] 63. Jung WI, Sieverding L, Breuer J, Schmidt O, Widmaier S, Bunse M, van Erckelens F, Apitz J, Dietze GJ, Lutz O. Detection of phosphomonoester signals in proton-decoupled 31P NMR spectra of the myocardium of patients with myocardial hypertrophy. J Magn Reson. 1998;133:232-235. doi: S1090-7807(98)91454-9 [pii] 10.1006/jmre.1998.1454 64. Jung WI, Hoess T, Bunse M, Widmaier S, Sieverding L, Breuer J, Apitz J, Schmidt O, van Erckelens F, Dietze GJ, Lutz O. Differences in cardiac energetics between patients with familial and nonfamilial hypertrophic cardiomyopathy. Circulation. 2000;101:E121. 65. Shivu GN, Abozguia K, Phan TT, Ahmed I, Henning A, Frenneaux M. (31)P magnetic resonance spectroscopy to measure in vivo cardiac energetics in normal myocardium and hypertrophic cardiomyopathy: Experiences at 3T. Eur J Radiol. 2008. doi: S0720-048X(08)00574-3 [pii] 10.1016/j.ejrad.2008.10.018 66. Neubauer S, Krahe T, Schindler R, Horn M, Hillenbrand H, Entzeroth C, Mader H, Kromer EP, Riegger GA, Lackner K, et al. 31P magnetic resonance spectroscopy in dilated cardiomyopathy and coronary artery disease. Altered cardiac high-energy phosphate metabolism in heart failure. Circulation. 1992;86:1810-1818. 67. Neubauer S, Horn M, Pabst T, Godde M, Lubke D, Jilling B, Hahn D, Ertl G. Contributions of 31P-magnetic resonance spectroscopy to the understanding of dilated heart muscle disease. Eur Heart J. 1995;16 Suppl O:115-118. 68. Neubauer S, Horn M, Cramer M, Harre K, Newell JB, Peters W, Pabst T, Ertl G, Hahn D, Ingwall JS, Kochsiek K. Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation. 1997;96:2190-2196. 69. Neubauer S, Horn M, Pabst T, Harre K, Stromer H, Bertsch G, Sandstede J, Ertl G, Hahn D, Kochsiek K. Cardiac high-energy phosphate metabolism in patients with aortic valve disease assessed by 31P-magnetic resonance spectroscopy. J Investig Med. 1997;45:453-462. 70. Sardanelli F, Zandrino F, Molinari G, Cordone S, Delfino L, Levrero F. Magnetic resonance spectroscopy of ischemic heart disease. Rays. 1999;24:149-164. 71. Okada M, K. M, Inubushi T, Kinoshita M. Influence of aging or left ventricular hypertrophy on the human heart: Contents of phosphorus metabolites measured by 31P MRS. MRM. 1998;39:772-782. 72. Beer M, Sandstede J, Landschütz W, Seyfarth T, Lipke C, Köstler H, Pabst T, Kenn W, Meininger M, von Kienlin M, et al. Absolute concentrations of myocardial high-energy phosphate metabolites in normal, hypertrophied and failing human myocardium, measured non-invasively with 31P-SLOOP-magnetic resonance spectroscopy. J Am Coll Cardiol. 2002;40:1267-1274. 73. Conway MA, Allis J, Ouwerkerk R, Niioka T, Rajagopalan B, Radda GK. Detection of low phosphocreatine to ATP ratio in failing hypertrophied human myocardium by 31P magnetic resonance spectroscopy. Lancet. 1991;338:973-976. doi: 0140-6736(91)91838-L [pii] 74. Taegtmeyer H, Lam T, Davogustto G. Cardiac Metabolism in Perspective. Compr Physiol. 2016;6:1675-1699. doi: 10.1002/cphy.c150056 75. Taegtmeyer H. Metabolism—the lost child of cardiology∗. Journal of the American College of Cardiology. 2000;36:1386-1388. doi: 10.1016/S0735-1097(00)00870-6 76. Obrzut S, Jamshidi N, Karimi A, Birgersdotter-Green U, Hoh C. Imaging and modeling of myocardial metabolism. J Cardiovasc Transl Res. 2010;3:384-396. doi: 10.1007/s12265-010-9170-1 77. Hudsmith LE, Neubauer S. Detection of myocardial disorders by magnetic resonance spectroscopy. Nature Clinical Practice Cardiovascular Medicine. 2008;5:S49-S56. doi: 10.1038/ncpcardio1158 78. Neubauer S. The failing heart--an engine out of fuel. N Engl J Med. 2007;356:1140-1151. doi: 10.1056/NEJMra063052 79. Young ME, McNulty P, Taegtmeyer H. Adaptation and Maladaptation of the Heart in Diabetes: Part II: Potential Mechanisms. Circulation. 2002;105:1861-1870. doi: 10.1161/01.cir.0000012467.61045.87 80. Levelt E, Rodgers CT, Clarke WT, Mahmod M, Ariga R, Francis JM, Liu A, Wijesurendra RS, Dass S, Sabharwal N, et al. Cardiac energetics, oxygenation, and perfusion during increased workload in patients with type 2 diabetes mellitus. European Heart Journal. 2015. 81. Bratis K, Child N, Terrovitis J, Nanas J, Felekos I, Aggeli C, Stefanadis C, Mastorakos G, Chiribiri A, Nagel E, Mavrogeni S. Coronary microvascular dysfunction in overt diabetic cardiomyopathy. IJC Metabolic & Endocrine. 2014;5:19-23. doi: http://dx.doi.org/10.1016/j.ijcme.2014.08.007 82. Ungar I, Gilbert M, Siegel A, Blain JM, Bing RJ. Studies on myocardial metabolism: IV. Myocardial metabolism in diabetes. The American Journal of Medicine. 1955;18:385-396. doi: http://dx.doi.org/10.1016/0002-9343(55)90218-7 83. Anderson EJ, Kypson AP, Rodriguez E, Anderson CA, Lehr EJ, Neufer PD. Substrate-Specific Derangements in Mitochondrial Metabolism and Redox Balance in Atrium of Type 2 Diabetic Human Heart. Journal of the American College of Cardiology. 2009;54:1891-1898. doi: 10.1016/j.jacc.2009.07.031 84. Heather LC, Clarke K. Metabolism, hypoxia and the diabetic heart. Journal of Molecular and Cellular Cardiology. 2011;50:598-605. doi: http://dx.doi.org/10.1016/j.yjmcc.2011.01.007 85. Taegtmeyer H. Cardiac Metabolism as a Target for the Treatment of Heart Failure. Circulation. 2004;110:894-896. doi: 10.1161/01.cir.0000139340.88769.d5 86. Evans RD CK. Myocardial substrate metabolism in heart disease. Front Biosci (Schol Ed). 2012;4:556-580. 87. Stanley WC, Chandler MP. Energy Metabolism in the Normal and Failing Heart: Potential for Therapeutic Interventions. Heart failure reviews. 2002;7:115-130. doi: 10.1023/A:1015320423577 88. Veech RL. The therapeutic implications of ketone bodies: the effects of ketone bodies in pathological conditions: ketosis, ketogenic diet, redox states, insulin resistance, and mitochondrial metabolism. Prostaglandins, leukotrienes, and essential fatty acids. 2004;70:309-319. doi: 10.1016/j.plefa.2003.09.007 89. Nagoshi T, Yoshimura M, Rosano GMC, Lopaschuk GD, Mochizuki S. Optimization of Cardiac Metabolism in Heart Failure. Current Pharmaceutical Design. 2011;17:3846-3853. doi: 10.2174/138161211798357773 90. Mjøs OD. Effect of Free Fatty Acids on Myocardial Function and Oxygen Consumption in Intact Dogs. The Journal of Clinical Investigation. 1971;50:1386-1389. doi: 10.1172/JCI106621 91. Veech RL. The therapeutic implications of ketone bodies: the effects of ketone bodies in pathological conditions: ketosis, ketogenic diet, redox states, insulin resistance, and mitochondrial metabolism. Prostaglandins, Leukotrienes and Essential Fatty Acids. 2004;70:309-319. doi: 10.1016/j.plefa.2003.09.007 92. Sato K, Kashiwaya Y, Keon C, Tsuchiya N, King M, Radda G, Chance B, Clarke K, Veech R. Insulin, ketone bodies, and mitochondrial energy transduction. The FASEB journal. 1995;9:651-658. 93. Nielsen R, Møller N, Gormsen Lars C, Tolbod Lars P, Hansson Nils H, Sorensen J, Harms Hendrik J, Frøkiær J, Eiskjaer H, Jespersen Nichlas R, et al. Cardiovascular Effects of Treatment With the Ketone Body 3-Hydroxybutyrate in Chronic Heart Failure Patients. Circulation. 2019;139:2129-2141. doi: 10.1161/CIRCULATIONAHA.118.036459 94. Aubert G, Martin OJ, Horton JL, Lai L, Vega RB, Leone TC, Koves T, Gardell SJ, Krüger M, Hoppel CL, et al. The Failing Heart Relies on Ketone Bodies as a Fuel. Circulation. 2016;133:698-705. doi: 10.1161/CIRCULATIONAHA.115.017355 95. Robinson AM, Williamson DH. Physiological Roles of Ketone-Bodies as Substrates and Signals in Mammalian-Tissues. Physiol Rev. 1980;60:143-187. 96. McGarry JD, Foster DW. Hormonal control of ketogenesis. Advances in experimental medicine and biology. 1979;111:79. 97. McGarry JD, Foster DW. Hormonal control of ketogenesis: Biochemical considerations. Archives of internal medicine. 1977;137:495. 98. Lopaschuk GD, Ussher JR. Evolving Concepts of Myocardial Energy Metabolism. Circulation Research. 2016;119:1173-1176. doi: 10.1161/CIRCRESAHA.116.310078 99. Ferrannini E, Mark M, Mayoux E. CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis. Diabetes Care. 2016;39:1108-1114. doi: 10.2337/dc16-0330 100. Weiss RG, Bottomley PA, Hardy CJ, Gerstenblith G. Regional Myocardial Metabolism of High-Energy Phosphates during Isometric Exercise in Patients with Coronary Artery Disease. New England Journal of Medicine. 1990;323:1593-1600. doi: 10.1056/nejm199012063232304 101. Yabe T, Mitsunami K, Okada M, Morikawa S, Inubushi T, Kinoshita M. Detection of myocardial ischemia by 31P magnetic resonance spectroscopy during handgrip exercise. Circulation. 1994;89:1709-1716. doi: 10.1161/01.cir.89.4.1709 102. Zhang Z, Li J, Wu S, Liu Y, Fan Z, Zhou X, Zhao H, Li D, Huan Y. Cine-MRI and (31)P-MRS for evaluation of myocardial energy metabolism and function following coronary artery bypass graft. Magn Reson Imaging. 2010;28:936-942. doi: 10.1016/j.mri.2010.03.040 103. Schaefer S, Camacho SA, Gober J, Obregon RG, DeGroot MA, Botvinick EH, Massie B, Weiner MW. Response of myocardial metabolites to graded regional ischemia: 31P NMR spectroscopy of porcine myocardium in vivo. Circ Res. 1989;64:968-976. doi: 10.1161/01.res.64.5.968 104. Sourdon J, Lewsey SC, Schär M, Weiss RG. Measuring Myocardial Energetics with Cardiovascular Magnetic Resonance Spectroscopy. Heart Failure Clinics. 2021;17:149-156. doi: 10.1016/j.hfc.2020.08.011 105. Buchthal SD, den Hollander JA, Merz CN, Rogers WJ, Pepine CJ, Reichek N, Sharaf BL, Reis S, Kelsey SF, Pohost GM. Abnormal myocardial phosphorus-31 nuclear magnetic resonance spectroscopy in women with chest pain but normal coronary angiograms. N Engl J Med. 2000;342:829-835. doi: 10.1056/nejm200003233421201 106. Shomanova Z, Florian A, Bietenbeck M, Waltenberger J, Sechtem U, Yilmaz A. Diagnostic value of global myocardial perfusion reserve assessment based on coronary sinus flow measurements using cardiovascular magnetic resonance in addition to myocardial stress perfusion imaging. Eur Heart J Cardiovasc Imaging. 2017;18:851-859. doi: 10.1093/ehjci/jew315 107. Sørensen MH, Bojer AS, Broadbent DA, Plein S, Madsen PL, Gæde P. Cardiac perfusion, structure, and function in type 2 diabetes mellitus with and without diabetic complications. European Heart Journal - Cardiovascular Imaging. 2020;21:887-895. doi: 10.1093/ehjci/jez266 108. Liu X, Yang Z-G, Gao Y, Xie L-J, Jiang L, Hu B-Y, Diao K-Y, Shi K, Xu H-Y, Shen M-T, et al. Left ventricular subclinical myocardial dysfunction in uncomplicated type 2 diabetes mellitus is associated with impaired myocardial perfusion: a contrast-enhanced cardiovascular magnetic resonance study. Cardiovascular Diabetology. 2018;17. doi: 10.1186/s12933-018-0782-0 109. Levelt E, Piechnik SK, Liu A, Wijesurendra RS, Mahmod M, Ariga R, Francis JM, Greiser A, Clarke K, Neubauer S, et al. Adenosine stress CMR T1-mapping detects early microvascular dysfunction in patients with type 2 diabetes mellitus without obstructive coronary artery disease. Journal of Cardiovascular Magnetic Resonance. 2017;19. doi: 10.1186/s12968-017-0397-8 110. Heydari B, Juan Y-H, Liu H, Abbasi S, Shah R, Blankstein R, Steigner M, Jerosch-Herold M, Kwong RY. Stress Perfusion Cardiac Magnetic Resonance Imaging Effectively Risk Stratifies Diabetic Patients With Suspected Myocardial Ischemia. Circulation: Cardiovascular Imaging. 2016;9. doi: 10.1161/circimaging.115.004136 111. Shi Y, Vanhoutte PM. Macro- and microvascular endothelial dysfunction in diabetes. Journal of Diabetes. 2017;9:434-449. doi: 10.1111/1753-0407.12521 112. Levy BI, Schiffrin EL, Mourad J-J, Agostini D, Vicaut E, Safar ME, Struijker-Boudier HAJ. Impaired Tissue Perfusion. Circulation. 2008;118:968-976. doi: 10.1161/circulationaha.107.763730 113. Quiñones MJ, Nicholas SB, Lyon CJ. Insulin resistance and the endothelium. Current Diabetes Reports. 2005;5:246-253. doi: 10.1007/s11892-005-0018-z 114. Kruljac I, Cacic M, Cacic P, Ostojic V, Stefanovic M, Sikic A, Vrkljan M. Diabetic ketosis during hyperglycemic crisis is associated with decreased all-cause mortality in patients with type 2 diabetes mellitus. Endocrine. 2016. doi: 10.1007/s12020-016-1082-7 115. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine. 2015;373:2117-2128. doi: 10.1056/nejmoa1504720 116. Tahara A, Kurosaki E, Yokono M, Yamajuku D, Kihara R, Hayashizaki Y, Takasu T, Imamura M, Li Q, Tomiyama H, et al. Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats. Journal of Pharmacy and Pharmacology. 2014;66:975-987. doi: 10.1111/jphp.12223 117. Ferrannini E, Baldi S, Frascerra S, Astiarraga B, Heise T, Bizzotto R, Mari A, Pieber TR, Muscelli E. Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes. Diabetes. 2016;65:1190-1195. doi: 10.2337/db15-1356 118. Mudaliar S, Alloju S, Henry RR. Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis. Diabetes Care. 2016;39:1115-1122. doi: 10.2337/dc16-0542 119. Ferrannini E, Mark M, Mayoux E. CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis. Diabetes Care. 2016;39:1108. 120. Mudaliar S, Alloju S, Henry RR. Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis. Diabetes Care. 2016;39:1115. 121. Sato K, Kashiwaya Y, Keon CA, Tsuchiya N, King MT, Radda GK, Chance B, Clarke K, Veech RL. Insulin, ketone bodies, and mitochondrial energy transduction. Faseb j. 1995;9:651-658. doi: 10.1096/fasebj.9.8.7768357 122. Selvaraj S, Kelly Daniel P, Margulies Kenneth B. Implications of Altered Ketone Metabolism and Therapeutic Ketosis in Heart Failure. Circulation. 2020;141:1800-1812. doi: 10.1161/CIRCULATIONAHA.119.045033 123. Medium Chain Acyl Coa Dehydrogenase-Deficiency. Lancet. 1991;338:544-545. 124. Van Hove JLK, Grunewald S, Jaeken J, Demaerel P, Declercq PE, Bourdoux P, Niezen-Koning K, Deanfeld JE, Leonard JV. D,L-3-hydroxybutyrate treatment of multiple acyl-CoA dehydrogenase deficiency (MADD). Lancet. 2003;361:1433-1435. 125. Balietti M, Casoli T, Di Stefano G, Giorgetti B, Aicardi G, Fattoretti P. Ketogenic diets: An historical antiepileptic therapy with promising potentialities for the aging brain. Ageing Res Rev. 2010;9:273-279. doi: DOI 10.1016/j.arr.2010.02.003 126. Kossoff EH, Rho JM. Ketogenic Diets: Evidence for Short- and Long-term Efficacy. Neurotherapeutics. 2009;6:406-414. 127. Westman EC, Mavropoulos J, Yancy WS, Volek JS. A review of low-carbohydrate ketogenic diets. Current atherosclerosis reports. 2003;5:476-483. 128. Amari A, Grace NC, Fisher WW. Achieving and maintaining compliance with the ketogenic diet. Journal of applied behavior analysis. 1995;28:341. 129. Rider OJ, Francis JM, Tyler D, Byrne J, Clarke K, Neubauer S. Effects of weight loss on myocardial energetics and diastolic function in obesity. Int J Cardiovasc Imaging. 2013;29:1043-1050. doi: 10.1007/s10554-012-0174-6 130. Fox CS, Massaro JM, Hoffmann U, Pou KM, Maurovich-Horvat P, Liu C-Y, Vasan RS, Murabito JM, Meigs JB, Cupples LA, et al. Abdominal Visceral and Subcutaneous Adipose Tissue Compartments: Association With Metabolic Risk Factors in the Framingham Heart Study. Circulation. 2007;116:39-48. doi: 10.1161/circulationaha.106.675355 131. Okura T, Nakata Y, Yamabuki K, Tanaka K. Regional Body Composition Changes Exhibit Opposing Effects on Coronary Heart Disease Risk Factors. Arteriosclerosis, Thrombosis, and Vascular Biology. 2004;24:923-929. doi: 10.1161/01.ATV.0000125702.26272.f6 132. Fantuzzi G, Mazzone T. Adipose Tissue and Atherosclerosis: Exploring the Connection. Arteriosclerosis, Thrombosis, and Vascular Biology. 2007;27:996-1003. doi: 10.1161/atvbaha.106.131755 133. Montani JP, Carroll JF, Dwyer TM, Antic V, Yang Z, Dulloo AG. Ectopic fat storage in heart, blood vessels and kidneys in the pathogenesis of cardiovascular diseases. Int J Obes Relat Metab Disord. 0000;28:S58-S65. 134. Rabinowitz D, Zierler KL. FOREARM METABOLISM IN OBESITY AND ITS RESPONSE TO INTRA-ARTERIAL INSULIN. CHARACTERIZATION OF INSULIN RESISTANCE AND EVIDENCE FOR ADAPTIVE HYPERINSULINISM. Journal of Clinical Investigation. 1962;41:2173-2181. 135. Felig P, Wahren J, Hendler R, Brundin T. Splanchnic glucose and amino acid metabolism in obesity. Journal of Clinical Investigation. 1974;53:582-590. 136. Caro JF, Dohm LG, Pories WJ, Sinha MK. Cellular alterations in liver, skeletal muscle, and adipose tissue responsible for insulin resistance in obesity and type II diabetes. Diabetes/Metabolism Reviews. 1989;5:665-689. doi: 10.1002/dmr.5610050804 137. RAVUSSIN E, SMITH SR. Increased Fat Intake, Impaired Fat Oxidation, and Failure of Fat Cell Proliferation Result in Ectopic Fat Storage, Insulin Resistance, and Type 2 Diabetes Mellitus. Annals of the New York Academy of Sciences. 2002;967:363-378. doi: https://doi.org/10.1111/j.1749-6632.2002.tb04292.x 138. Fox CS, Gona P, Hoffmann U, Porter SA, Salton CJ, Massaro JM, Levy D, Larson MG, D'Agostino RB, O'Donnell CJ, Manning WJ. Pericardial Fat, Intrathoracic Fat, and Measures of Left Ventricular Structure and Function: The Framingham Heart Study. Circulation. 2009;119:1586-1591. doi: 10.1161/circulationaha.108.828970 139. Fox CS, Massaro JM, Schlett CL, Lehman SJ, Meigs JB, O'Donnell CJ, Hoffmann U, Murabito JM. Periaortic Fat Deposition Is Associated With Peripheral Arterial Disease: The Framingham Heart Study. Circulation: Cardiovascular Imaging. 2010;3:515-519. doi: 10.1161/circimaging.110.958884 140. Rijzewijk LJ, van der Meer RW, Smit JWA, Diamant M, Bax JJ, Hammer S, Romijn JA, de Roos A, Lamb HJ. Myocardial Steatosis Is an Independent Predictor of Diastolic Dysfunction in Type 2 Diabetes Mellitus. Journal of the American College of Cardiology. 2008;52:1793-1799. doi: http://dx.doi.org/10.1016/j.jacc.2008.07.062 141. Rijzewijk LJ, Jonker JT, van der Meer RW, Lubberink M, de Jong HW, Romijn JA, Bax JJ, de Roos A, Heine RJ, Twisk JW, et al. Effects of Hepatic Triglyceride Content on Myocardial Metabolism in Type 2 Diabetes. Journal of the American College of Cardiology. 2010;56:225-233. doi: http://dx.doi.org/10.1016/j.jacc.2010.02.049 142. Greenstein AS, Khavandi K, Withers SB, Sonoyama K, Clancy O, Jeziorska M, Laing I, Yates AP, Pemberton PW, Malik RA, Heagerty AM. Local Inflammation and Hypoxia Abolish the Protective Anticontractile Properties of Perivascular Fat in Obese Patients. Circulation. 2009;119:1661-1670. doi: 10.1161/circulationaha.108.821181 143. Lee Y-C, Chang H-H, Chiang C-L, Liu C-H, Yeh J-I, Chen M-F, Chen P-Y, Kuo J-S, Lee TJF. Role of Perivascular Adipose Tissue–Derived Methyl Palmitate in Vascular Tone Regulation and Pathogenesis of Hypertension. Circulation. 2011;124:1160-1171. doi: 10.1161/circulationaha.111.027375 144. Visceral and Ectopic Fat : Risk Factors for Type 2 Diabetes, Atherosclerosis, and Cardiovascular Disease. United States: Elsevier Science Publishing Co Inc; 2022. 145. Antonopoulos AS, Antoniades C. The role of epicardial adipose tissue in cardiac biology: classic concepts and emerging roles. The Journal of Physiology. 2017;595:3907-3917. doi: 10.1113/jp273049 146. Iacobellis G, Corradi D, Sharma AM. Epicardial adipose tissue: anatomic, biomolecular and clinical relationships with the heart. Nature Clinical Practice Cardiovascular Medicine. 2005;2:536-543. doi: 10.1038/ncpcardio0319 147. Iacobellis G. Epicardial adipose tissue in contemporary cardiology. Nature Reviews Cardiology. 2022;19:593-606. doi: 10.1038/s41569-022-00679-9 148. Aldiss P, Davies G, Woods R, Budge H, Sacks HS, Symonds ME. ‘Browning’ the cardiac and peri-vascular adipose tissues to modulate cardiovascular risk. International Journal of Cardiology. 2017;228:265-274. doi: 10.1016/j.ijcard.2016.11.074 149. Sacks HS, Fain JN, Holman B, Cheema P, Chary A, Parks F, Karas J, Optican R, Bahouth SW, Garrett E, et al. Uncoupling protein-1 and related messenger ribonucleic acids in human epicardial and other adipose tissues: epicardial fat functioning as brown fat. J Clin Endocrinol Metab. 2009;94:3611-3615. doi: 10.1210/jc.2009-0571 150. Frontini A, Cinti S. Distribution and Development of Brown Adipocytes in the Murine and Human Adipose Organ. Cell Metabolism. 2010;11:253-256. doi: 10.1016/j.cmet.2010.03.004 151. Golozoubova V, Cannon B, Nedergaard J. UCP1 is essential for adaptive adrenergic nonshivering thermogenesis. Am J Physiol Endocrinol Metab. 2006;291:E350-357. doi: 10.1152/ajpendo.00387.2005 152. Betz MJ, Enerback S. Human Brown Adipose Tissue: What We Have Learned So Far. Diabetes. 2015;64:2352-2360. doi: 10.2337/db15-0146 153. Ouellet V, Routhier-Labadie A, Bellemare W, Lakhal-Chaieb L, Turcotte E, Carpentier AC, Richard D. Outdoor Temperature, Age, Sex, Body Mass Index, and Diabetic Status Determine the Prevalence, Mass, and Glucose-Uptake Activity of 18F-FDG-Detected BAT in Humans. The Journal of Clinical Endocrinology & Metabolism. 2011;96:192-199. doi: 10.1210/jc.2010-0989 154. Moreno-Santos I, Pérez-Belmonte LM, Macías-González M, Mataró MJ, Castellano D, López-Garrido M, Porras-Martín C, Sánchez-Fernández PL, Gómez-Doblas JJ, Cardona F, et al. Type 2 diabetes is associated with decreased PGC1α expression in epicardial adipose tissue of patients with coronary artery disease. J Transl Med. 2016;14:243. doi: 10.1186/s12967-016-0999-1 155. Oikonomou EK, Antoniades C. The role of adipose tissue in cardiovascular health and disease. Nature Reviews Cardiology. 2019;16:83-99. doi: 10.1038/s41569-018-0097-6 156. Lodewijks F, McKinsey TA, Robinson EL. Fat-to-heart crosstalk in health and disease. Front Genet. 2023;14:990155. doi: 10.3389/fgene.2023.990155 157. Yang H, Xiong B, Xiong T, Wang D, Yu W, Liu B, She Q. Identification of key genes and mechanisms of epicardial adipose tissue in patients with diabetes through bioinformatic analysis. Front Cardiovasc Med. 2022;9:927397. doi: 10.3389/fcvm.2022.927397 158. Iacobellis G, Leonetti F. Epicardial Adipose Tissue and Insulin Resistance in Obese Subjects. The Journal of Clinical Endocrinology & Metabolism. 2005;90:6300-6302. doi: doi:10.1210/jc.2005-1087 159. Mazurek T, Zhang L, Zalewski A, Mannion JD, Diehl JT, Arafat H, Sarov-Blat L, O’Brien S, Keiper EA, Johnson AG, et al. Human Epicardial Adipose Tissue Is a Source of Inflammatory Mediators. Circulation. 2003;108:2460-2466. doi: 10.1161/01.cir.0000099542.57313.c5 160. Levelt E, Pavlides M, Banerjee R, Mahmod M, Kelly C, Sellwood J, Ariga R, Thomas S, Francis J, Rodgers C, et al. Ectopic and Visceral Fat Deposition in Lean and Obese Patients With Type 2 Diabetes. Journal of the American College of Cardiology. 2016;68:53-63. doi: 10.1016/j.jacc.2016.03.597 161. Cherian S, Lopaschuk GD, Carvalho E. Cellular cross-talk between epicardial adipose tissue and myocardium in relation to the pathogenesis of cardiovascular disease. American Journal of Physiology-Endocrinology and Metabolism. 2012;303:E937-E949. doi: 10.1152/ajpendo.00061.2012 162. Ansaldo AM, Montecucco F, Sahebkar A, Dallegri F, Carbone F. Epicardial adipose tissue and cardiovascular diseases. Int J Cardiol. 2019;278:254-260. doi: 10.1016/j.ijcard.2018.09.089 163. Nerlekar N, Brown AJ, Muthalaly RG, Talman A, Hettige T, Cameron JD, Wong DTL. Association of Epicardial Adipose Tissue and High-Risk Plaque Characteristics: A Systematic Review and Meta-Analysis. J Am Heart Assoc. 2017;6. doi: 10.1161/jaha.117.006379 164. Mancio J, Azevedo D, Saraiva F, Azevedo AI, Pires-Morais G, Leite-Moreira A, Falcao-Pires I, Lunet N, Bettencourt N. Epicardial adipose tissue volume assessed by computed tomography and coronary artery disease: a systematic review and meta-analysis. European Heart Journal - Cardiovascular Imaging. 2018;19:490-497. doi: 10.1093/ehjci/jex314 165. Gaeta M, Bandera F, Tassinari F, Capasso L, Cargnelutti M, Pelissero G, Malavazos AE, Ricci C. Is epicardial fat depot associated with atrial fibrillation? A systematic review and meta-analysis. EP Europace. 2017;19:747-752. doi: 10.1093/europace/euw398 166. Chen J, Mei Z, Yang Y, Dai C, Wang Y, Zeng R, Liu Q. Epicardial adipose tissue is associated with higher recurrence risk after catheter ablation in atrial fibrillation patients: a systematic review and meta-analysis. BMC Cardiovasc Disord. 2022;22:264. doi: 10.1186/s12872-022-02703-9 167. Wu A, Yang Z, Zhang X, Lin Z, Lu H. Association between epicardial adipose tissue and left atrial and ventricular function in patients with heart failure-a systematic review and meta-analysis. Curr Probl Cardiol. 2023:101979. doi: 10.1016/j.cpcardiol.2023.101979 168. Dozio E, Vianello E, Briganti S, Fink B, Malavazos AE, Scognamiglio ET, Dogliotti G, Sigrüener A, Schmitz G, Corsi Romanelli MM. Increased reactive oxygen species production in epicardial adipose tissues from coronary artery disease patients is associated with brown-to-white adipocyte trans-differentiation. Int J Cardiol. 2014;174:413-414. doi: 10.1016/j.ijcard.2014.04.045 169. Li C, Li S, Zhang F, Wu M, Liang H, Song J, Lee C, Chen H. Endothelial microparticles-mediated transfer of microRNA-19b promotes atherosclerosis via activating perivascular adipose tissue inflammation in apoE−/− mice. Biochemical and Biophysical Research Communications. 2018;495:1922-1929. doi: https://doi.org/10.1016/j.bbrc.2017.11.195 170. Cabaro S, Conte M, Moschetta D, Petraglia L, Valerio V, Romano S, Di Tolla MF, Campana P, Comentale G, Pilato E, et al. Epicardial Adipose Tissue-Derived IL-1β Triggers Postoperative Atrial Fibrillation. Front Cell Dev Biol. 2022;10:893729. doi: 10.3389/fcell.2022.893729 171. Ernault AC, Meijborg VMF, Coronel R. Modulation of Cardiac Arrhythmogenesis by Epicardial Adipose Tissue: JACC State-of-the-Art Review. Journal of the American College of Cardiology. 2021;78:1730-1745. doi: https://doi.org/10.1016/j.jacc.2021.08.037 172. Levelt E, Gulsin G, Neubauer S, McCann GP. MECHANISMS IN ENDOCRINOLOGY: Diabetic cardiomyopathy: pathophysiology and potential metabolic interventions state of the art review. Eur J Endocrinol. 2018;178:R127-r139. doi: 10.1530/eje-17-0724 173. Dillmann WH. Diabetic Cardiomyopathy. Circ Res. 2019;124:1160-1162. doi: 10.1161/circresaha.118.314665 174. Chowdhary A, Thirunavukarasu S, Jex N, Coles L, Bowers C, Sengupta A, Swoboda P, Witte K, Cubbon R, Xue H, et al. Coronary microvascular function and visceral adiposity in patients with normal body weight and type 2 diabetes. Obesity. 2022;30:1079-1090. doi: https://doi.org/10.1002/oby.23413 175. Al-Talabany S, Mordi I, Graeme Houston J, Colhoun HM, Weir-McCall JR, Matthew SZ, Looker HC, Levin D, Belch JJF, Dove F, et al. Epicardial adipose tissue is related to arterial stiffness and inflammation in patients with cardiovascular disease and type 2 diabetes. BMC Cardiovasc Disord. 2018;18:31. doi: 10.1186/s12872-018-0770-z 176. Homsi R, Sprinkart AM, Gieseke J, Meier-Schroers M, Yuecel S, Fischer S, Nadal J, Dabir D, Luetkens JA, Kuetting DL, et al. Cardiac magnetic resonance based evaluation of aortic stiffness and epicardial fat volume in patients with hypertension, diabetes mellitus, and myocardial infarction. Acta Radiol. 2018;59:65-71. doi: 10.1177/0284185117706201 177. Huang S, Li Y, Jiang L, Ren Y, Wang J, Shi K, Yan WF, Qian WL, Yang ZG. Impact of Type 2 Diabetes Mellitus on Epicardial Adipose Tissue and Myocardial Microcirculation by MRI in Postmenopausal Women. J Magn Reson Imaging. 2022;56:1404-1413. doi: 10.1002/jmri.28121 178. Taylor R, Holman RR. Normal weight individuals who develop type 2 diabetes: the personal fat threshold. Clin Sci (Lond). 2015;128:405-410. doi: 10.1042/CS20140553 179. Trayhurn P, Wang B, Wood IS. Hypoxia in adipose tissue: a basis for the dysregulation of tissue function in obesity? British Journal of Nutrition. 2008;100:227-235. doi: 10.1017/s0007114508971282 180. Virtue S, Vidal-Puig A. Adipose tissue expandability, lipotoxicity and the Metabolic Syndrome--an allostatic perspective. Biochim Biophys Acta. 2010;1801:338-349. doi: 10.1016/j.bbalip.2009.12.006 181. Levelt E, Pavlides M, Banerjee R, Mahmod M, Kelly C, Sellwood J, Ariga R, Thomas S, Francis J, Rodgers C, et al. Ectopic and Visceral Fat Deposition in Lean and Obese Patients With Type 2 Diabetes. J Am Coll Cardiol. 2016;68:53-63. doi: 10.1016/j.jacc.2016.03.597 182. Guglielmo M, Lin A, Dey D, Baggiano A, Fusini L, Muscogiuri G, Pontone G. Epicardial fat and coronary artery disease: Role of cardiac imaging. Atherosclerosis. 2021;321:30-38. doi: 10.1016/j.atherosclerosis.2021.02.008 183. Monti CB, Capra D, Zanardo M, Guarnieri G, Schiaffino S, Secchi F, Sardanelli F. CT-derived epicardial adipose tissue density: Systematic review and meta-analysis. Eur J Radiol. 2021;143:109902. doi: 10.1016/j.ejrad.2021.109902 184. Mancio J, Azevedo D, Saraiva F, Azevedo AI, Pires-Morais G, Leite-Moreira A, Falcao-Pires I, Lunet N, Bettencourt N. Epicardial adipose tissue volume assessed by computed tomography and coronary artery disease: a systematic review and meta-analysis. Eur Heart J Cardiovasc Imaging. 2018;19:490-497. doi: 10.1093/ehjci/jex314 185. Machann JR, Thamer C, Schnoedt B, Haap M, Haring H-U, Claussen CD, Stumvoll M, Fritsche A, Schick F. Standardized assessment of whole body adipose tissue topography by MRI. Journal of Magnetic Resonance Imaging. 2005;21:455-462. doi: 10.1002/jmri.20292 186. Leo LA, Paiocchi VL, Schlossbauer SA, Ho SY, Faletra FF. The Intrusive Nature of Epicardial Adipose Tissue as Revealed by Cardiac Magnetic Resonance. J Cardiovasc Echogr. 2019;29:45-51. doi: 10.4103/jcecho.jcecho_22_19 187. Leiner T, Bogaert J, Friedrich MG, Mohiaddin R, Muthurangu V, Myerson S, Powell AJ, Raman SV, Pennell DJ. SCMR Position Paper (2020) on clinical indications for cardiovascular magnetic resonance. Journal of Cardiovascular Magnetic Resonance. 2020;22. doi: 10.1186/s12968-020-00682-4 188. Levelt E, Gulsin G, Neubauer S, McCann GP. MECHANISMS IN ENDOCRINOLOGY: Diabetic cardiomyopathy: pathophysiology and potential metabolic interventions state of the art review. European Journal of Endocrinology. 2018;178:R127-R139. doi: 10.1530/EJE-17-0724 189. Marwick TH, Gimelli A, Plein S, Bax JJ, Charron P, Delgado V, Donal E, Lancellotti P, Levelt E, Maurovich-Horvat P, et al. Multimodality imaging approach to left ventricular dysfunction in diabetes: an expert consensus document from the European Association of Cardiovascular Imaging. European Heart Journal - Cardiovascular Imaging. 2022;23:e62-e84. doi: 10.1093/ehjci/jeab220 190. Salerno M, Sharif B, Arheden H, Kumar A, Axel L, Li D, Neubauer S. Recent Advances in Cardiovascular Magnetic Resonance. Circulation: Cardiovascular Imaging. 2017;10:e003951. doi: 10.1161/circimaging.116.003951 191. Patel AR, Salerno M, Kwong RY, Singh A, Heydari B, Kramer CM. Stress Cardiac Magnetic Resonance Myocardial Perfusion Imaging: JACC Review Topic of the Week. J Am Coll Cardiol. 2021;78:1655-1668. doi: 10.1016/j.jacc.2021.08.022 192. Garcia MJ, Kwong RY, Scherrer-Crosbie M, Taub CC, Blankstein R, Lima J, Bonow RO, Eshtehardi P, Bois JP. State of the Art: Imaging for Myocardial Viability: A Scientific Statement From the American Heart Association. Circulation: Cardiovascular Imaging. 2020;13. doi: 10.1161/hci.0000000000000053 193. Flüchter S, Haghi D, Dinter D, Heberlein W, Kühl HP, Neff W, Sueselbeck T, Borggrefe M, Papavassiliu T. Volumetric Assessment of Epicardial Adipose Tissue With Cardiovascular Magnetic Resonance Imaging*. Obesity. 2007;15:870-878. doi: 10.1038/oby.2007.591 194. Homsi R, Thomas D, Gieseke J, Meier-Schroers M, Dabir D, Kuetting D, Luetkens J, Marx C, Schild H, Sprinkart A. Epicardial Fat Volume and Aortic Stiffness in Healthy Individuals: A Quantitative Cardiac Magnetic Resonance Study. RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren. 2016;188:853-858. doi: 10.1055/s-0042-110098 195. Daudé P, Ancel P, Confort Gouny S, Jacquier A, Kober F, Dutour A, Bernard M, Gaborit B, Rapacchi S. Deep-Learning Segmentation of Epicardial Adipose Tissue Using Four-Chamber Cardiac Magnetic Resonance Imaging. Diagnostics. 2022;12:126. doi: 10.3390/diagnostics12010126 196. Evin M, Broadhouse KM, Callaghan FM, McGrath RT, Glastras S, Kozor R, Hocking SL, Lamy J, Redheuil A, Kachenoura N, et al. Impact of obesity and epicardial fat on early left atrial dysfunction assessed by cardiac MRI strain analysis. Cardiovascular Diabetology. 2016;15. doi: 10.1186/s12933-016-0481-7 197. Cristobal-Huerta A, Torrado-Carvajal A, Malpica N, Luaces M, Hernandez-Tamames JA. Automated quantification of epicardial adipose tissue in cardiac magnetic resonance imaging. Paper/Poster presented 2015, 2015; https://dx.doi.org/10.1109/embc.2015.7320079 [link]. 198. He F, Chen W, Xu W, Liu D, Xiao Z, Tang Y, Lin Z, Liao Y, Bin J, Chen G, Chen Y. Safety and efficacy of liraglutide on reducing visceral and ectopic fat in adults with or without type 2 diabetes mellitus: A systematic review and meta‐analysis. Diabetes, Obesity and Metabolism. 2023;25:664-674. doi: 10.1111/dom.14908 199. Launbo N, Zobel EH, Scholten BJ, Færch K, Jørgensen PG, Christensen RH. Targeting epicardial adipose tissue with exercise, diet, bariatric surgery or pharmaceutical interventions: A systematic review and meta‐analysis. Obesity Reviews. 2021;22. doi: 10.1111/obr.13136 200. Berg G, Barchuk M, Lobo M, Nogueira JP. Effect of glucagon-like peptide-1 (GLP-1) analogues on epicardial adipose tissue: A meta-analysis. Diabetes Metab Syndr. 2022;16:102562. doi: 10.1016/j.dsx.2022.102562 201. Li Y, Liu B, Li Y, Jing X, Deng S, Yan Y, She Q. Epicardial fat tissue in patients with diabetes mellitus: a systematic review and meta-analysis. Cardiovascular Diabetology. 2019;18. doi: 10.1186/s12933-019-0807-3 202. Nerlekar N, Muthalaly RG, Wong N, Thakur U, Wong DTL, Brown AJ, Marwick TH. Association of Volumetric Epicardial Adipose Tissue Quantification and Cardiac Structure and Function. Journal of the American Heart Association. 2018;7. doi: 10.1161/jaha.118.009975 203. Gaborit B, Kober F, Jacquier A, Moro PJ, Cuisset T, Boullu S, Dadoun F, Alessi MC, Morange P, Clément K, et al. Assessment of epicardial fat volume and myocardial triglyceride content in severely obese subjects: relationship to metabolic profile, cardiac function and visceral fat. International Journal of Obesity. 2012;36:422-430. doi: 10.1038/ijo.2011.117 204. Kim HM, Kim KJ, Lee HJ, Yu HT, Moon JH, Kang ES, Cha BS, Lee HC, Lee BW, Kim YJ. Epicardial adipose tissue thickness is an indicator for coronary artery stenosis in asymptomatic type 2 diabetic patients: its assessment by cardiac magnetic resonance. Cardiovasc Diabetol. 2012;11:83. doi: 10.1186/1475-2840-11-83 205. Edin C, Ekstedt M, Scheffel T, Karlsson M, Swahn E, Östgren CJ, Engvall J, Ebbers T, Leinhard OD, Lundberg P, Carlhäll CJ. Ectopic fat is associated with cardiac remodeling-A comprehensive assessment of regional fat depots in type 2 diabetes using multi-parametric MRI. Front Cardiovasc Med. 2022;9:813427. doi: 10.3389/fcvm.2022.813427 206. Rado SD, Lorbeer R, Gatidis S, Machann J, Storz C, Nikolaou K, Rathmann W, Hoffmann U, Peters A, Bamberg F, Schlett CL. MRI-based assessment and characterization of epicardial and paracardial fat depots in the context of impaired glucose metabolism and subclinical left-ventricular alterations. The British Journal of Radiology. 2019;92:20180562. doi: 10.1259/bjr.20180562 207. Haberka M, Machnik G, Kowalowka A, Biedron M, Skudrzyk E, Regulska-Ilow B, Gajos G, Manka R, Deja M, Okopien B, Gasior Z. Epicardial, paracardial, and perivascular fat quantity, gene expressions, and serum cytokines in patients with coronary artery disease and diabetes. Pol Arch Intern Med. 2019;129:738-746. doi: 10.20452/pamw.14961 208. Zhu J, Li W, Xie Z, Zhuo K. Relationship Between Epicardial Adipose Tissue and Biventricular Longitudinal Strain and Strain Rate in Patients with Type 2 Diabetes Mellitus. Acad Radiol. 2023;30:833-840. doi: 10.1016/j.acra.2022.08.019 209. Huang S, Li Y, Jiang L, Ren Y, Wang J, Shi K, Yan WF, Qian WL, Yang ZG. Impact of Type 2 Diabetes Mellitus on Epicardial Adipose Tissue and Myocardial Microcirculation by <scp>MRI</scp> in Postmenopausal Women. Journal of Magnetic Resonance Imaging. 2022;56:1404-1413. doi: 10.1002/jmri.28121 210. Kim H, Kim K, Lee H-J, Yu H, Moon J, Kang E, Cha B, Lee H, Lee B-W, Kim Y. Epicardial adipose tissue thickness is an indicator for coronary artery stenosis in asymptomatic type 2 diabetic patients: its assessment by cardiac magnetic resonance. Cardiovascular Diabetology. 2012;11:83. doi: 10.1186/1475-2840-11-83 211. Gaborit B, Ancel P, Abdullah AE, Maurice F, Abdesselam I, Calen A, Soghomonian A, Houssays M, Varlet I, Eisinger M, et al. Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study. Cardiovasc Diabetol. 2021;20:57. doi: 10.1186/s12933-021-01237-2 212. Bouchi R, Terashima M, Sasahara Y, Asakawa M, Fukuda T, Takeuchi T, Nakano Y, Murakami M, Minami I, Izumiyama H, et al. Luseogliflozin reduces epicardial fat accumulation in patients with type 2 diabetes: a pilot study. Cardiovasc Diabetol. 2017;16:32. doi: 10.1186/s12933-017-0516-8 213. Fukuda T, Bouchi R, Terashima M, Sasahara Y, Asakawa M, Takeuchi T, Nakano Y, Murakami M, Minami I, Izumiyama H, et al. Ipragliflozin Reduces Epicardial Fat Accumulation in Non-Obese Type 2 Diabetic Patients with Visceral Obesity: A Pilot Study. Diabetes Therapy. 2017;8:851-861. doi: 10.1007/s13300-017-0279-y 214. Dutour A, Abdesselam I, Ancel P, Kober F, Mrad G, Darmon P, Ronsin O, Pradel V, Lesavre N, Martin JC, et al. Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy. Diabetes Obes Metab. 2016;18:882-891. doi: 10.1111/dom.12680 215. van Eyk HJ, Paiman EHM, Bizino MB, de Heer P, Geelhoed-Duijvestijn PH, Kharagjitsingh AV, Smit JWA, Lamb HJ, Rensen PCN, Jazet IM. A double-blind, placebo-controlled, randomised trial to assess the effect of liraglutide on ectopic fat accumulation in South Asian type 2 diabetes patients. Cardiovasc Diabetol. 2019;18:87. doi: 10.1186/s12933-019-0890-5 216. Bizino MB, Jazet IM, de Heer P, van Eyk HJ, Dekkers IA, Rensen PCN, Paiman EHM, Lamb HJ, Smit JW. Placebo-controlled randomised trial with liraglutide on magnetic resonance endpoints in individuals with type 2 diabetes: a pre-specified secondary study on ectopic fat accumulation. Diabetologia. 2020;63:65-74. doi: 10.1007/s00125-019-05021-6 217. Zhao N, Wang X, Wang Y, Yao J, Shi C, Du J, Bai R. The Effect of Liraglutide on Epicardial Adipose Tissue in Type 2 Diabetes. J Diabetes Res. 2021;2021:5578216. doi: 10.1155/2021/5578216 218. Moody AJ, Molina-Wilkins M, Clarke GD, Merovci A, Solis-Herrera C, Cersosimo E, Chilton RJ, Iozzo P, Gastaldelli A, Abdul-Ghani M, DeFronzo RA. Pioglitazone reduces epicardial fat and improves diastolic function in patients with type 2 diabetes. Diabetes Obes Metab. 2022. doi: 10.1111/dom.14885 219. Fiore D, Gianfrilli D, Giannetta E, Galea N, Panio G, di Dato C, Pofi R, Pozza C, Sbardella E, Carbone I, et al. PDE5 Inhibition Ameliorates Visceral Adiposity Targeting the miR-22/SIRT1 Pathway: Evidence From the CECSID Trial. J Clin Endocrinol Metab. 2016;101:1525-1534. doi: 10.1210/jc.2015-4252 220. Zhao N, Wang X, Wang Y, Yao J, Shi C, Du J, Bai R. The Effect of Liraglutide on Epicardial Adipose Tissue in Type 2 Diabetes. Journal of Diabetes Research. 2021;2021:1-6. doi: 10.1155/2021/5578216 221. Gaborit B, Ancel P, Abdullah AE, Maurice F, Abdesselam I, Calen A, Soghomonian A, Houssays M, Varlet I, Eisinger M, et al. Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study. Cardiovascular Diabetology. 2021;20. doi: 10.1186/s12933-021-01237-2 222. Van Eyk HJ, Paiman EHM, Bizino MB, De Heer P, Geelhoed-Duijvestijn PH, Kharagjitsingh AV, Smit JWA, Lamb HJ, Rensen PCN, Jazet IM. A double-blind, placebo-controlled, randomised trial to assess the effect of liraglutide on ectopic fat accumulation in South Asian type 2 diabetes patients. Cardiovascular Diabetology. 2019;18. doi: 10.1186/s12933-019-0890-5 223. Dutour A, Abdesselam I, Ancel P, Kober F, Mrad G, Darmon P, Ronsin O, Pradel V, Lesavre N, Martin JC, et al. Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy. Diabetes, Obesity and Metabolism. 2016;18:882-891. doi: 10.1111/dom.12680 224. van Schinkel LD, Sleddering MA, Lips MA, Jonker JT, de Roos A, Lamb HJ, Jazet IM, Pijl H, Smit JW. Effects of bariatric surgery on pericardial ectopic fat depositions and cardiovascular function. Clin Endocrinol (Oxf). 2014;81:689-695. doi: 10.1111/cen.12402 225. Jonker JT, de Mol P, de Vries ST, Widya RL, Hammer S, van Schinkel LD, van der Meer RW, Gans RO, Webb AG, Kan HE, et al. Exercise and type 2 diabetes mellitus: changes in tissue-specific fat distribution and cardiac function. Radiology. 2013;269:434-442. doi: 10.1148/radiol.13121631 226. Ardissino M, McCracken C, Bard A, Antoniades C, Neubauer S, Harvey NC, Petersen SE, Raisi-Estabragh Z. Pericardial adiposity is independently linked to adverse cardiovascular phenotypes: a CMR study of 42 598 UK Biobank participants. Eur Heart J Cardiovasc Imaging. 2022;23:1471-1481. doi: 10.1093/ehjci/jeac101 227. Thirunavukarasu S, Ansari F, Cubbon R, Forbes K, Bucciarelli-Ducci C, Newby DE, Dweck MR, Rider OJ, Valkovič L, Rodgers CT, et al. Maternal Cardiac Changes in Women With Obesity and Gestational Diabetes Mellitus. Diabetes Care. 2022;45:3007-3015. doi: 10.2337/dc22-0401 228. Pennell DJ, Sechtem UP, Higgins CB, Manning WJ, Pohost GM, Rademakers FE, van Rossum AC, Shaw LJ, Yucel EK. Clinical indications for cardiovascular magnetic resonance (CMR): Consensus Panel report. J Cardiovasc Magn Reson. 2004;6:727-765. 229. Wei L, Dong JX, Jin LX, He J, Zhao CX, Kong LC, An DA, Ding S, Yang F, Yang YN, et al. Peak early diastolic strain rate improves prediction of adverse cardiovascular outcomes in patients with ST-elevation myocardial infarction. Radiol Med. 2023;128:1372-1385. doi: 10.1007/s11547-023-01700-y 230. Nazir SA, Shetye AM, Khan JN, Singh A, Arnold JR, Squire I, McCann GP. Inter-study repeatability of circumferential strain and diastolic strain rate by CMR tagging, feature tracking and tissue tracking in ST-segment elevation myocardial infarction. Int J Cardiovasc Imaging. 2020;36:1133-1146. doi: 10.1007/s10554-020-01806-8 231. American Heart Association Writing Group on Myocardial S, Registration for Cardiac I, Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK, Pennell DJ, Rumberger JA, et al. Standardized Myocardial Segmentation and Nomenclature for Tomographic Imaging of the Heart. Circulation. 2002;105:539-542. doi: 10.1161/hc0402.102975 232. Xue H, Artico J, Fontana M, Moon JC, Davies RH, Kellman P. Landmark Detection in Cardiac MRI Using a Convolutional Neural Network. Radiology: Artificial Intelligence. 2021:e200197. doi: 10.1148/ryai.2021200197 233. Xue H, Artico J, Fontana M, Moon JC, Davies RH, Kellman P. Landmark Detection in Cardiac MRI by Using a Convolutional Neural Network. Radiol Artif Intell. 2021;3:e200197. doi: 10.1148/ryai.2021200197 234. Kellman Peter, Hernando D, Shah S, Liang Z-P, Bluemke DA, AE A. Rapid, multi-slice fat water separated imaging for mapping body fat. In: ISMRM. Stockholm, Sweden; 2010. 235. Kellman P, Hernanado, D., Shah, S.,Liang, Z-P., Bluemke, DA., Arai, AE. Rapid, multi‐slice fat water separated imaging for mapping body fat. In: Annual Meeting of the International Society for Magnetic Resonance Medicine. Stockholm; 2010. 236. Jerosch-Herold M, Sheridan DC, Kushner JD, Nauman D, Burgess D, Dutton D, Alharethi R, Li D, Hershberger RE. Cardiac magnetic resonance imaging of myocardial contrast uptake and blood flow in patients affected with idiopathic or familial dilated cardiomyopathy. Am J Physiol Heart Circ Physiol. 2008;295:H1234-h1242. doi: 10.1152/ajpheart.00429.2008 237. Park YJ, Park SJ, Kim EK, Park KM, Lee SC, On YK, Kim JS. Semi-quantitative versus quantitative assessments of late gadolinium enhancement extent for predicting spontaneous ventricular tachyarrhythmia events in patients with hypertrophic cardiomyopathy. Sci Rep. 2020;10:2920. doi: 10.1038/s41598-020-59804-8 238. Kellman P, Hansen MS, Nielles-Vallespin S, Nickander J, Themudo R, Ugander M, Xue H. Myocardial perfusion cardiovascular magnetic resonance: optimized dual sequence and reconstruction for quantification. Journal of Cardiovascular Magnetic Resonance. 2016;19:43. doi: https://doi.org/10.1186/s12968-017-0355-5 239. Kramer CM, Barkhausen J, Flamm SD, Kim RJ, Nagel E. Standardized cardiovascular magnetic resonance (CMR) protocols 2013 update. Journal of Cardiovascular Magnetic Resonance. 2013;15:91. doi: 10.1186/1532-429x-15-91 240. Chong C-R, Clarke K, Levelt E. Metabolic remodelling in diabetic cardiomyopathy. Cardiovascular Research. 2017;113:422-430. doi: 10.1093/cvr/cvx018 241. Hudsmith LE, Petersen SE, Tyler DJ, Francis JM, Cheng AS, Clarke K, Selvanayagam JB, Robson MD, Neubauer S. Determination of cardiac volumes and mass with FLASH and SSFP cine sequences at 1.5 vs. 3 Tesla: a validation study. J Magn Reson Imaging. 2006;24:312-318. doi: 10.1002/jmri.20638 242. Ferreira VM, Piechnik SK. CMR Parametric Mapping as a Tool for Myocardial Tissue Characterization. Korean Circ J. 2020;50:658-676. 243. Greenwood JP, Maredia N, Younger JF, Brown JM, Nixon J, Everett CC, Bijsterveld P, Ridgway JP, Radjenovic A, Dickinson CJ, et al. Cardiovascular magnetic resonance and single-photon emission computed tomography for diagnosis of coronary heart disease (CE-MARC): a prospective trial. Lancet. 2012;379:453-460. doi: 10.1016/s0140-6736(11)61335-4 244. Neumann F-J, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, Byrne RA, Collet J-P, Falk V, Head SJ, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. European Heart Journal. 2018;40:87-165. doi: 10.1093/eurheartj/ehy394 245. Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, Capodanno D, Conradi L, De Bonis M, De Paulis R, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease: Developed by the Task Force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal. 2022;43:561-632. doi: 10.1093/eurheartj/ehab395 246. Jex N, Greenwood JP, Cubbon RM, Rider OJ, Chowdhary A, Thirunavukarasu S, Kotha S, Giannoudi M, McGrane A, Maccannell A, et al. Association Between Type 2 Diabetes and Changes in Myocardial Structure, Contractile Function, Energetics, and Blood Flow Before and After Aortic Valve Replacement in Patients With Severe Aortic Stenosis. Circulation. 2023;148:1138-1153. doi: 10.1161/CIRCULATIONAHA.122.063444 247. Haywood NJ, Luk C, Bridge KI, Drozd M, Makava N, Skromna A, Maccannell A, Ozber CH, Warmke N, Wilkinson CG, et al. Endothelial IGF‐1 receptor mediates crosstalk with the gut wall to regulate microbiota in obesity. EMBO reports. 2021;22:e50767. doi: https://doi.org/10.15252/embr.202050767 248. Cinti S, Mitchell G, Barbatelli G, Murano I, Ceresi E, Faloia E, Wang S, Fortier M, Greenberg AS, Obin MS. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. Journal of Lipid Research. 2005;46:2347-2355. doi: 10.1194/jlr.M500294-JLR200 249. Nakamura K, Fuster JJ, Walsh K. Adipokines: A link between obesity and cardiovascular disease. Journal of Cardiology. 2014;63:250-259. doi: https://doi.org/10.1016/j.jjcc.2013.11.006 250. Johansson I, Dahlström U, Edner M, Näsman P, Rydén L, Norhammar A. Prognostic Implications of Type 2 Diabetes Mellitus in Ischemic and Nonischemic Heart Failure. Journal of the American College of Cardiology. 2016;68:1404-1416. doi: https://doi.org/10.1016/j.jacc.2016.06.061 251. Kotha S, Plein S, Greenwood JP, Levelt E. Role of epicardial adipose tissue in diabetic cardiomyopathy through the lens of cardiovascular magnetic resonance imaging - a narrative review. Ther Adv Endocrinol Metab. 2024;15:20420188241229540. doi: 10.1177/20420188241229540 252. Kristiansen OP, Mandrup-Poulsen T. Interleukin-6 and Diabetes: The Good, the Bad, or the Indifferent? Diabetes. 2005;54:S114-S124. doi: 10.2337/diabetes.54.suppl_2.S114 253. Chia YC, Kieneker LM, van Hassel G, Binnenmars SH, Nolte IM, van Zanden JJ, van der Meer P, Navis G, Voors AA, Bakker SJL, et al. Interleukin 6 and Development of Heart Failure With Preserved Ejection Fraction in the General Population. Journal of the American Heart Association. 2021;10:e018549. doi: 10.1161/JAHA.120.018549 254. Ridker PM. From RESCUE to ZEUS: will interleukin-6 inhibition with ziltivekimab prove effective for cardiovascular event reduction? Cardiovasc Res. 2021;117:e138-e140. doi: 10.1093/cvr/cvab231 255. Reilly MP, Iqbal N, Schutta M, Wolfe ML, Scally M, Localio AR, Rader DJ, Kimmel SE. Plasma Leptin Levels Are Associated with Coronary Atherosclerosis in Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism. 2004;89:3872-3878. doi: 10.1210/jc.2003-031676 256. Martin SS, Blaha MJ, Muse ED, Qasim AN, Reilly MP, Blumenthal RS, Nasir K, Criqui MH, McClelland RL, Hughes-Austin JM, Allison MA. Leptin and incident cardiovascular disease: the Multi-ethnic Study of Atherosclerosis (MESA). Atherosclerosis. 2015;239:67-72. doi: 10.1016/j.atherosclerosis.2014.12.033 257. Laurencikiene J, Skurk T, Kulyté A, Hedén P, Åström G, Sjölin E, Rydén M, Hauner H, Arner P. Regulation of Lipolysis in Small and Large Fat Cells of the Same Subject. The Journal of Clinical Endocrinology & Metabolism. 2011;96:E2045-E2049. doi: 10.1210/jc.2011-1702 258. Skurk T, Alberti-Huber C, Herder C, Hauner H. Relationship between Adipocyte Size and Adipokine Expression and Secretion. The Journal of Clinical Endocrinology & Metabolism. 2007;92:1023-1033. doi: 10.1210/jc.2006-1055 259. Ritterhoff J, Tian R. Metabolism in cardiomyopathy: every substrate matters. Cardiovasc Res. 2017;113:411-421. doi: 10.1093/cvr/cvx017 260. Burrage MK, Hundertmark M, Valkovic L, Watson WD, Rayner J, Sabharwal N, Ferreira VM, Neubauer S, Miller JJ, Rider OJ, Lewis AJM. Energetic Basis for Exercise-Induced Pulmonary Congestion in Heart Failure With Preserved Ejection Fraction. Circulation. 2021;144:1664-1678. doi: 10.1161/CIRCULATIONAHA.121.054858 261. Thornton GD, Vassiliou VS, Musa TA, Aziminia N, Craig N, Dattani A, Davies RH, Captur G, Moon JC, Dweck MR, et al. Myocardial Scar and Remodelling Predict Long-Term Mortality in Severe Aortic Stenosis Beyond 10 Years. European Heart Journal. 2024:ehae067. doi: 10.1093/eurheartj/ehae067 262. Halliday BP, Gulati A, Ali A, Guha K, Newsome S, Arzanauskaite M, Vassiliou VS, Lota A, Izgi C, Tayal U, et al. Association Between Midwall Late Gadolinium Enhancement and Sudden Cardiac Death in Patients With Dilated Cardiomyopathy and Mild and Moderate Left Ventricular Systolic Dysfunction. Circulation. 2017;135:2106-2115. doi: 10.1161/circulationaha.116.026910 263. Treibel TA, López B, González A, Menacho K, Schofield RS, Ravassa S, Fontana M, White SK, DiSalvo C, Roberts N, et al. Reappraising myocardial fibrosis in severe aortic stenosis: an invasive and non-invasive study in 133 patients. Eur Heart J. 2018;39:699-709. doi: 10.1093/eurheartj/ehx353 264. Zinman B, Wanner C, Lachin John M, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen Odd E, Woerle Hans J, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine.373:2117-2128. doi: 10.1056/NEJMoa1504720 265. Marso Steven P, Bain Stephen C, Consoli A, Eliaschewitz Freddy G, Jódar E, Leiter Lawrence A, Lingvay I, Rosenstock J, Seufert J, Warren Mark L, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine.375:1834-1844. doi: 10.1056/NEJMoa1607141 266. Chowdhary A, Thirunavukarasu S, Joseph T, Jex N, Kotha S, Giannoudi M, Procter H, Cash L, Akkaya S, Broadbent D, et al. Liraglutide Improves Myocardial Perfusion and Energetics and Exercise Tolerance in Patients With Type 2 Diabetes. Journal of the American College of Cardiology. 2024;84:540-557. doi: 10.1016/j.jacc.2024.04.064 267. Gregg EW, Sattar N, Ali MK. The changing face of diabetes complications. Lancet Diabetes Endocrinol. 2016;4:537-547. doi: 10.1016/s2213-8587(16)30010-9 268. Wong ND, Sattar N. Cardiovascular risk in diabetes mellitus: epidemiology, assessment and prevention. Nature Reviews Cardiology. 2023;20:685-695. doi: 10.1038/s41569-023-00877-z 269. Investigators TBARIB. Comparison of Coronary Bypass Surgery with Angioplasty in Patients with Multivessel Disease. New England Journal of Medicine. 1996;335:217-225. doi: 10.1056/nejm199607253350401 270. Farkouh ME, Domanski M, Sleeper LA, Siami FS, Dangas G, Mack M, Yang M, Cohen DJ, Rosenberg Y, Solomon SD, et al. Strategies for Multivessel Revascularization in Patients with Diabetes. New England Journal of Medicine. 2012;367:2375-2384. doi: doi:10.1056/NEJMoa1211585 271. Ramanathan K, Abel JG, Park JE, Fung A, Mathew V, Taylor CM, Mancini GBJ, Gao M, Ding L, Verma S, et al. Surgical Versus Percutaneous Coronary Revascularization in Patients With Diabetes and Acute Coronary Syndromes. Journal of the American College of Cardiology. 2017;70:2995-3006. doi: https://doi.org/10.1016/j.jacc.2017.10.029 272. Pezeshki PS, Masoudkabir F, Pashang M, Vasheghani-Farahani A, Jalali A, Sadeghian S, Hosseini K, Mansourian S, Momtahan S, Karimi A. 7-year outcomes in diabetic patients after coronary artery bypass graft in a developing country. BMC Cardiovascular Disorders. 2023;23. doi: 10.1186/s12872-023-03279-8 273. Rajakaruna C, Rogers CA, Suranimala C, Angelini GD, Ascione R. The effect of diabetes mellitus on patients undergoing coronary surgery: A risk-adjusted analysis. The Journal of Thoracic and Cardiovascular Surgery. 2006;132:802-810. doi: 10.1016/j.jtcvs.2006.05.056 274. Thourani VH, Weintraub WS, Stein B, Gebhart SSP, Craver JM, Jones EL, Guyton RA. Influence of diabetes mellitus on early and late outcome after coronary artery bypass grafting. The Annals of Thoracic Surgery. 1999;67:1045-1052. doi: 10.1016/s0003-4975(99)00143-5 275. Banning AP, Westaby S, Morice M-C, Kappetein AP, Mohr FW, Berti S, Glauber M, Kellett MA, Kramer RS, Leadley K, et al. Diabetic and Nondiabetic Patients With Left Main and/or 3-Vessel Coronary Artery Disease: Comparison of Outcomes With Cardiac Surgery and Paclitaxel-Eluting Stents. Journal of the American College of Cardiology. 2010;55:1067-1075. doi: https://doi.org/10.1016/j.jacc.2009.09.057 276. Krasivskyi I, Ivanov B, Msallati Z, Großmann C, Gerfer S, Mihaylova M, Eghbalzadeh K, Origel Romero C, Djordjevic I, Wahlers T, et al. Impact of diabetes on short-term outcomes in patients undergoing coronary artery bypass grafting surgery in acute coronary syndrome. Perfusion. 2024:02676591241253461. doi: 10.1177/02676591241253461 277. Seraphim A, Dowsing B, Rathod KS, Shiwani H, Patel K, Knott KD, Zaman S, Johns I, Razvi Y, Patel R, et al. Quantitative Myocardial Perfusion Predicts Outcomes in Patients With Prior Surgical Revascularization. J Am Coll Cardiol. 2022;79:1141-1151. doi: 10.1016/j.jacc.2021.12.037 278. Kinnel M, Sanguineti F, Pezel T, Unterseeh T, Hovasse T, Toupin S, Landon V, Champagne S, Morice MC, Garot P, et al. Prognostic value of vasodilator stress perfusion CMR in patients with previous coronary artery bypass graft. European Heart Journal - Cardiovascular Imaging. 2020;22:1264-1272. doi: 10.1093/ehjci/jeaa316 279. Lawton JS, Tamis-Holland JE, Bangalore S, Bates ER, Beckie TM, Bischoff JM, Bittl JA, Cohen MG, DiMaio JM, Don CW, et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145:e18-e114. doi: doi:10.1161/CIR.0000000000001038 280. Casanova C, Celli BR, Barria P, Casas A, Cote C, Torres JPd, Jardim J, Lopez MV, Marin JM, Oca MMd, et al. The 6-min walk distance in healthy subjects: reference standards from seven countries. European Respiratory Journal. 2011;37:150. doi: 10.1183/09031936.00194909 281. Serruys PW, Morice M-C, Kappetein AP, Colombo A, Holmes DR, Mack MJ, Ståhle E, Feldman TE, Brand Mvd, Bass EJ, et al. Percutaneous Coronary Intervention versus Coronary-Artery Bypass Grafting for Severe Coronary Artery Disease. New England Journal of Medicine. 2009;360:961-972. doi: doi:10.1056/NEJMoa0804626 282. Seraphim A, Knott KD, Beirne AM, Augusto JB, Menacho K, Artico J, Joy G, Hughes R, Bhuva AN, Torii R, et al. Use of quantitative cardiovascular magnetic resonance myocardial perfusion mapping for characterization of ischemia in patients with left internal mammary coronary artery bypass grafts. J Cardiovasc Magn Reson. 2021;23:82. doi: 10.1186/s12968-021-00763-y 283. Kogan A, Ram E, Levin S, Fisman EZ, Tenenbaum A, Raanani E, Sternik L. Impact of type 2 diabetes mellitus on short- and long-term mortality after coronary artery bypass surgery. Cardiovasc Diabetol. 2018;17:151. doi: 10.1186/s12933-018-0796-7 284. Koene RJ, Kealhofer JV, Adabag S, Vakil K, Florea VG. Effect of coronary artery bypass graft surgery on left ventricular systolic function. J Thorac Dis. 2017;9:262-270. doi: 10.21037/jtd.2017.02.09 285. Gozdzik A, Letachowicz K, Grajek BB, Plonek T, Obremska M, Jasinski M, Gozdzik W. Application of strain and other echocardiographic parameters in the evaluation of early and long-term clinical outcomes after cardiac surgery revascularization. BMC Cardiovasc Disord. 2019;19:189. doi: 10.1186/s12872-019-1162-8 286. Aggarwal R, Qi SS, So SW, Swingen C, Reyes CP, Rose R, Wright C, Hocum Stone LL, Nixon JP, McFalls EO, et al. Persistent diastolic dysfunction in chronically ischemic hearts following coronary artery bypass graft. J Thorac Cardiovasc Surg. 2023;165:e269-e279. doi: 10.1016/j.jtcvs.2022.08.010 287. Paterek A, Załęska-Kocięcka M, Wojdyńska Z, Kalisz M, Litwiniuk A, Leszek P, Mączewski M. Epicardial fat in heart failure—Friend, foe, or bystander. Obesity Reviews.n/a:e13820. doi: https://doi.org/10.1111/obr.13820 288. Nakamura M. Lipotoxicity as a therapeutic target in obesity and diabetic cardiomyopathy. J Pharm Pharm Sci. 2024;27:12568. doi: 10.3389/jpps.2024.12568 289. Christensen RH, Hansen CS, Scholten BJ, Jensen MT, Pedersen BK, Schnohr P, Vilsbøll T, Rossing P, Jørgensen PG. Epicardial and pericardial adipose tissues are associated with reduced diastolic and systolic function in type 2 diabetes. Diabetes, Obesity and Metabolism. 2019;21:2006-2011. doi: 10.1111/dom.13758 290. Neubauer S. The Failing Heart — An Engine Out of Fuel. New England Journal of Medicine.356:1140-1151. doi: 10.1056/NEJMra063052 291. Bedi KC, Snyder NW, Brandimarto J, Aziz M, Mesaros C, Worth AJ, Wang LL, Javaheri A, Blair IA, Margulies KB, Rame JE. Evidence for Intramyocardial Disruption of Lipid Metabolism and Increased Myocardial Ketone Utilization in Advanced Human Heart Failure. Circulation. 2016;133:706-716. doi: 10.1161/CIRCULATIONAHA.115.017545 292. Kramer CM, Barkhausen J, Bucciarelli-Ducci C, Flamm SD, Kim RJ, Nagel E. Standardized cardiovascular magnetic resonance imaging (CMR) protocols: 2020 update. Journal of Cardiovascular Magnetic Resonance. 2020;22:17. doi: 10.1186/s12968-020-00607-1 293. Kellman P, Hansen MS, Nielles-Vallespin S, Nickander J, Themudo R, Ugander M, Xue H. Myocardial perfusion cardiovascular magnetic resonance: optimized dual sequence and reconstruction for quantification. Journal of Cardiovascular Magnetic Resonance. 2017;19:43. doi: 10.1186/s12968-017-0355-5 294. Clarke K, Tchabanenko K, Pawlosky R, Carter E, Todd King M, Musa-Veloso K, Ho M, Roberts A, Robertson J, Vanitallie TB, Veech RL. Kinetics, safety and tolerability of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate in healthy adult subjects. Regul Toxicol Pharmacol. 2012;63:401-408. doi: 10.1016/j.yrtph.2012.04.008 295. Flood D, Brant LCC, Sussman JB. The triglyceride glucose index and cardiovascular disease outcomes. The Lancet Healthy Longevity. 2023;4:e2-e3. doi: 10.1016/s2666-7568(22)00269-0 296. Lopez-Jaramillo P, Gomez-Arbelaez D, Martinez-Bello D, Abat MEM, Alhabib KF, Avezum Á, Barbarash O, Chifamba J, Diaz ML, Gulec S, et al. Association of the triglyceride glucose index as a measure of insulin resistance with mortality and cardiovascular disease in populations from five continents (PURE study): a prospective cohort study. The Lancet Healthy Longevity. 2023;4:e23-e33. doi: 10.1016/S2666-7568(22)00247-1 297. Purvis LAB, Clarke WT, Biasiolli L, Valkovič L, Robson MD, Rodgers CT. OXSA: An open-source magnetic resonance spectroscopy analysis toolbox in MATLAB. PLOS ONE. 2017;12:e0185356. doi: 10.1371/journal.pone.0185356 298. Xue H, Artico J, Davies RH, Adam R, Shetye A, Augusto JB, Bhuva A, Fröjdh F, Wong TC, Fukui M, et al. Automated In-Line Artificial Intelligence Measured Global Longitudinal Shortening and Mitral Annular Plane Systolic Excursion: Reproducibility and Prognostic Significance. J Am Heart Assoc. 2022;11:e023849. doi: 10.1161/jaha.121.023849 299. Mogensen M, Sahlin K, Fernström M, Glintborg D, Vind BF, Beck-Nielsen H, Højlund K. Mitochondrial Respiration Is Decreased in Skeletal Muscle of Patients With Type 2 Diabetes. Diabetes. 2007;56:1592. 300. Mazumder PK, O’Neill BT, Roberts MW, Buchanan J, Yun UJ, Cooksey RC, Boudina S, Abel ED. Impaired Cardiac Efficiency and Increased Fatty Acid Oxidation in Insulin-Resistant ob/ob Mouse Hearts. Diabetes. 2004;53:2366-2374. 301. Nielsen R, Møller N, Gormsen LC, Tolbod LP, Hansson NH, Sorensen J, Harms HJ, Frøkiær J, Eiskjaer H, Jespersen NR, et al. Cardiovascular Effects of Treatment With the Ketone Body 3-Hydroxybutyrate in Chronic Heart Failure Patients. Circulation. 2019;139:2129-2141. doi: doi:10.1161/CIRCULATIONAHA.118.036459 302. Berg-Hansen K, Gopalasingam N, Christensen KH, Ladefoged B, Andersen MJ, Poulsen SH, Borlaug BA, Nielsen R, Møller N, Wiggers H. Cardiovascular Effects of Oral Ketone Ester Treatment in Patients With Heart Failure With Reduced Ejection Fraction: A Randomized, Controlled, Double-Blind Trial. Circulation. 2024;149:1474-1489. doi: 10.1161/circulationaha.123.067971 303. Cameron D, Soto-Mota A, Willis DR, Ellis J, Procter NEK, Greenwood R, Saunders N, Schulte RF, Vassiliou VS, Tyler DJ, et al. Evaluation of Acute Supplementation With the Ketone Ester (R)-3-Hydroxybutyl-(R)-3-Hydroxybutyrate (deltaG) in Healthy Volunteers by Cardiac and Skeletal Muscle (31)P Magnetic Resonance Spectroscopy. Front Physiol. 2022;13:793987. doi: 10.3389/fphys.2022.793987 304. Oneglia AP, Young BE, Cipher DJ, Zaha V, Nelson MD. Acute effects of β-hydroxybutyrate on left ventricular function in young, healthy adults. Journal of Applied Physiology. 2023;135:1440-1445. doi: 10.1152/japplphysiol.00630.2023 305. Selvaraj S, Hu R, Vidula MK, Dugyala S, Tierney A, Ky B, Margulies KB, Shah SH, Kelly DP, Bravo PE. Acute Echocardiographic Effects of Exogenous Ketone Administration in Healthy Participants. Journal of the American Society of Echocardiography. 2022;35:305-311. doi: https://doi.org/10.1016/j.echo.2021.10.017 306. Gormsen LC, Svart M, Thomsen HH, Søndergaard E, Vendelbo MH, Christensen N, Tolbod LP, Harms HJ, Nielsen R, Wiggers H, et al. Ketone Body Infusion With 3-Hydroxybutyrate Reduces Myocardial Glucose Uptake and Increases Blood Flow in Humans: A Positron Emission Tomography Study. J Am Heart Assoc. 2017;6. doi: 10.1161/jaha.116.005066 307. Homilius C, Seefeldt JM, Axelsen JS, Pedersen TM, Sørensen TM, Nielsen R, Wiggers H, Hansen J, Matchkov VV, Bøtker HE, Boedtkjer E. Ketone body 3-hydroxybutyrate elevates cardiac output through peripheral vasorelaxation and enhanced cardiac contractility. Basic Research in Cardiology. 2023;118:37. doi: 10.1007/s00395-023-01008-y 308. Neudorf H, Little JP. Impact of fasting & ketogenic interventions on the NLRP3 inflammasome: A narrative review. Biomed J. 2024;47:100677. doi: 10.1016/j.bj.2023.100677 309. Falkenhain K, Daraei A, Forbes SC, Little JP. Effects of Exogenous Ketone Supplementation on Blood Glucose: A Systematic Review and Meta-analysis. Adv Nutr. 2022;13:1697-1714. doi: 10.1093/advances/nmac036 310. Falkenhain K, Oliveira BF, Islam H, Neudorf H, Cen HH, Johnson JD, Madden K, Singer J, Walsh JJ, Little JP. The effect of acute and 14-day exogenous ketone supplementation on glycemic control in adults with type 2 diabetes: two randomized controlled trials. American Journal of Physiology-Endocrinology and Metabolism. 2024;326:E61-E72. doi: 10.1152/ajpendo.00332.2023 311. Monteyne AJ, Falkenhain K, Whelehan G, Neudorf H, Abdelrahman DR, Murton AJ, Wall BT, Stephens FB, Little JP. A ketone monoester drink reduces postprandial blood glucose concentrations in adults with type 2 diabetes: a randomised controlled trial. Diabetologia. 2024;67:1107-1113. doi: 10.1007/s00125-024-06122-7 312. Tahara A, Kurosaki E, Yokono M, Yamajuku D, Kihara R, Hayashizaki Y, Takasu T, Imamura M, Li Q, Tomiyama H, et al. Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats. J Pharm Pharmacol. 2014;66:975-987. doi: 10.1111/jphp.12223 313. Iacobellis G, Bianco AC. Epicardial adipose tissue: emerging physiological, pathophysiological and clinical features. Trends Endocrinol Metab. 2011;22:450-457. doi: 10.1016/j.tem.2011.07.003 314. Malavazos AE, Di Leo G, Secchi F, Lupo EN, Dogliotti G, Coman C, Morricone L, Corsi MM, Sardanelli F, Iacobellis G. Relation of Echocardiographic Epicardial Fat Thickness and Myocardial Fat. American Journal of Cardiology. 2010;105:1831-1835. doi: 10.1016/j.amjcard.2010.01.368 315. Kankaanpää M, Lehto H-R, Pärkkä JP, Komu M, Viljanen A, Ferrannini E, Knuuti J, Nuutila P, Parkkola R, Iozzo P. Myocardial Triglyceride Content and Epicardial Fat Mass in Human Obesity: Relationship to Left Ventricular Function and Serum Free Fatty Acid Levels. The Journal of Clinical Endocrinology & Metabolism. 2006;91:4689-4695. doi: 10.1210/jc.2006-0584 316. Sacks HS, Fain JN. Human epicardial adipose tissue: A review. American Heart Journal. 2007;153:907-917. doi: https://doi.org/10.1016/j.ahj.2007.03.019 317. Ding B, Peterzan M, Mózes FE, Rider OJ, Valkovič L, Rodgers CT. Water-suppression cycling 3-T cardiac (1) H-MRS detects altered creatine and choline in patients with aortic or mitral stenosis. NMR Biomed. 2021;34:e4513. doi: 10.1002/nbm.4513 318. Sharma S, Adrogue JV, Golfman L, Uray I, Lemm J, Youker K, Noon GP, Frazier OH, Taegtmeyer H. Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. Faseb j. 2004;18:1692-1700. doi: 10.1096/fj.04-2263com 319. Ugurbil K, Petein M, Maidan R, Michurski S, Cohn JN, From AH. High resolution proton NMR studies of perfused rat hearts. FEBS Letters. 1984;167:73-78. doi: https://doi.org/10.1016/0014-5793(84)80835-2 320. Faller KME, Lygate CA, Neubauer S, Schneider JE. 1H-MR spectroscopy for analysis of cardiac lipid and creatine metabolism. Heart Failure Reviews. 2013;18:657-668. doi: 10.1007/s10741-012-9341-z 321. Esmaeili M, Vettukattil R. In Vivo Magnetic Resonance Spectroscopy Methods for Investigating Cardiac Metabolism. Metabolites. 2022;12. doi: 10.3390/metabo12020189 322. de Heer P, Bizino MB, Lamb HJ, Webb AG. Parameter optimization for reproducible cardiac 1H-MR spectroscopy at 3 Tesla. Journal of Magnetic Resonance Imaging. 2016;44:1151-1158. doi: https://doi.org/10.1002/jmri.25254 323. Rial B, Robson MD, Neubauer S, Schneider JE. Rapid quantification of myocardial lipid content in humans using single breath-hold 1H MRS at 3 Tesla. Magn Reson Med. 2011;66:619-624. doi: 10.1002/mrm.23011 324. Bakermans AJ, Boekholdt SM, de Vries DK, Reckman YJ, Farag ES, de Heer P, Uthman L, Denis SW, Zuurbier CJ, Houtkooper RH, et al. Quantification of Myocardial Creatine and Triglyceride Content in the Human Heart: Precision and Accuracy of in vivo Proton Magnetic Resonance Spectroscopy. J Magn Reson Imaging. 2021;54:411-420. doi: 10.1002/jmri.27531 325. Ith M, Stettler C, Xu J, Boesch C, Kreis R. Cardiac lipid levels show diurnal changes and long-term variations in healthy human subjects. NMR in Biomedicine. 2014;27:1285-1292. doi: https://doi.org/10.1002/nbm.3186 326. Weiss K, Summermatter S, Stoeck CT, Kozerke S. Compensation of signal loss due to cardiac motion in point-resolved spectroscopy of the heart. Magn Reson Med. 2014;72:1201-1207. doi: 10.1002/mrm.25028 327. Gastl M, Peereboom SM, Fuetterer M, Boenner F, Kelm M, Manka R, Kozerke S. Retrospective phase-based gating for cardiac proton spectroscopy with fixed scan time. Journal of Magnetic Resonance Imaging. 2019;50:1973-1981. doi: https://doi.org/10.1002/jmri.26802 328. Gastl M, Peereboom SM, Fuetterer M, Boenner F, Kelm M, Manka R, Kozerke S. Cardiac- versus diaphragm-based respiratory navigation for proton spectroscopy of the heart. Magma. 2019;32:259-268. doi: 10.1007/s10334-018-0711-y 329. Lopaschuk GD, Karwi QG, Tian R, Wende AR, Abel ED. Cardiac Energy Metabolism in Heart Failure. Circulation Research. 2021;128:1487-1513. doi: 10.1161/circresaha.121.318241 330. Zlobine I, Gopal K, Ussher JR. Lipotoxicity in obesity and diabetes-related cardiac dysfunction. Biochim Biophys Acta. 2016;1861:1555-1568. doi: 10.1016/j.bbalip.2016.02.011 331. Rijzewijk LJ, van der Meer RW, Lamb HJ, de Jong HWAM, Lubberink M, Romijn JA, Bax JJ, de Roos A, Twisk JW, Heine RJ, et al. Altered Myocardial Substrate Metabolism and Decreased Diastolic Function in Nonischemic Human Diabetic Cardiomyopathy: Studies With Cardiac Positron Emission Tomography and Magnetic Resonance Imaging. Journal of the American College of Cardiology. 2009;54:1524-1532. doi: https://doi.org/10.1016/j.jacc.2009.04.074 332. Buchanan J, Mazumder PK, Hu P, Chakrabarti G, Roberts MW, Yun UJ, Cooksey RC, Litwin SE, Abel ED. Reduced Cardiac Efficiency and Altered Substrate Metabolism Precedes the Onset of Hyperglycemia and Contractile Dysfunction in Two Mouse Models of Insulin Resistance and Obesity. Endocrinology. 2005;146:5341-5349. doi: 10.1210/en.2005-0938 333. Stanley WC, Recchia FA, Lopaschuk GD. Myocardial Substrate Metabolism in the Normal and Failing Heart. Physiological Reviews. 2005;85:1093-1129. doi: 10.1152/physrev.00006.2004 334. Unger RH. Lipotoxicity in the Pathogenesis of Obesity-Dependent NIDDM: Genetic and Clinical Implications. Diabetes. 1995;44:863-870. doi: 10.2337/diab.44.8.863 335. van de Weijer T, Schrauwen-Hinderling VB, Schrauwen P. Lipotoxicity in type 2 diabetic cardiomyopathy. Cardiovasc Res. 2011;92:10-18. doi: 10.1093/cvr/cvr212 336. Rijzewijk LJ, van der Meer RW, Smit JW, Diamant M, Bax JJ, Hammer S, Romijn JA, de Roos A, Lamb HJ. Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. J Am Coll Cardiol. 2008;52:1793-1799. doi: 10.1016/j.jacc.2008.07.062 337. Saddik M, Lopaschuk GD. Triacylglycerol turnover in isolated working hearts of acutely diabetic rats. Canadian Journal of Physiology and Pharmacology. 1994;72:1110-1119. doi: 10.1139/y94-157 %M 7882174 338. Chang KF, Lin G, Huang PC, Juan YH, Wang CH, Tsai SY, Lin YC, Wu MT, Liao PA, Yang LY, et al. Left Ventricular Function and Myocardial Triglyceride Content on 3T Cardiac MR Predict Major Cardiovascular Adverse Events and Readmission in Patients Hospitalized with Acute Heart Failure. J Clin Med. 2020;9. doi: 10.3390/jcm9010169 339. Wende AR, Abel ED. Lipotoxicity in the heart. Biochim Biophys Acta. 2010;1801:311-319. doi: 10.1016/j.bbalip.2009.09.023 340. Nakae I, Mitsunami K, Yoshino T, Omura T, Tsutamoto T, Matsumoto T, Morikawa S, Inubushi T, Horie M. Clinical features of myocardial triglyceride in different types of cardiomyopathy assessed by proton magnetic resonance spectroscopy: comparison with myocardial creatine. J Card Fail. 2010;16:812-822. doi: 10.1016/j.cardfail.2010.05.006 341. Hannukainen JC, Lautamäki R, Mari A, Pärkkä JP, Bucci M, Guzzardi MA, Kajander S, Tuokkola T, Knuuti J, Iozzo P. Elevated Glucose Oxidation, Reduced Insulin Secretion, and a Fatty Heart May Be Protective Adaptions in Ischemic CAD. J Clin Endocrinol Metab. 2016;101:2701-2710. doi: 10.1210/jc.2015-4091 342. Mahmod M, Bull S, Suttie JJ, Pal N, Holloway C, Dass S, Myerson SG, Schneider JE, De Silva R, Petrou M, et al. Myocardial Steatosis and Left Ventricular Contractile Dysfunction in Patients With Severe Aortic Stenosis. Circulation: Cardiovascular Imaging. 2013;6:808-816. doi: 10.1161/CIRCIMAGING.113.000559 343. Sharma S, Adrogue JV, Golfman L, Uray I, Lemm J, Youker K, Noon GP, Frazier OH, Taegtmeyer H. Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. The FASEB Journal. 2004;18:1692-1700. doi: https://doi.org/10.1096/fj.04-2263com 344. O'Donnell JM, Fields AD, Sorokina N, Lewandowski ED. The absence of endogenous lipid oxidation in early stage heart failure exposes limits in lipid storage and turnover. Journal of Molecular and Cellular Cardiology. 2008;44:315-322. doi: https://doi.org/10.1016/j.yjmcc.2007.11.006 345. Nakae I, Mitsunami K, Yoshino T, Omura T, Tsutamoto T, Matsumoto T, Morikawa S, Inubushi T, Horie M. Clinical Features of Myocardial Triglyceride in Different Types of Cardiomyopathy Assessed by Proton Magnetic Resonance Spectroscopy: Comparison With Myocardial Creatine. Journal of Cardiac Failure. 2010;16:812-822. doi: https://doi.org/10.1016/j.cardfail.2010.05.006 346. Iacobellis G, Barbaro G. Epicardial adipose tissue feeding and overfeeding the heart. Nutrition. 2019;59:1-6. doi: https://doi.org/10.1016/j.nut.2018.07.002"],"dcterms:accessrights":["public"],"dc:title":["Epicardial adipose tissue remodelling in type 2 diabetes and the potential therapeutic role of ketosis in diabetic heart disease"],"dc:type":["Thesis"],"dc:type.qualificationlevel":["doctoral"],"dc:type.qualificationname":["Ph.D"],"person:identifier.orcid":["0000000168533231"]},"updated_at":"2026-11-18T23:29:21Z"}